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Abstract 
 
In recent years, the amino acid neurotransmitter γ-aminobutyric acid (GABA) has been 
widely studied for its significant inhibitory action in the central nervous system. Two 
polymorphs of GABA with different crystal systems have been reported in literature. A 
novel GABA solvate has been crystallized as thin needle-like single crystals. Through X-
ray single crystal diffraction analysis, this solvate was found to have a hexagonal crystal 
system and contain disordered solvent molecules in the asymmetric unit, which are found 
in channels created by the GABA molecules. 1H NMR allowed for the solvent to be 
identified as ethanol. This hexagonal GABA solvate is unique in that it is the first single 
amino acid to be crystallized in this form, where it has hexagonal channels which contain 
solvent molecules.  
 
Gabapentin (1-(aminomethyl)cycloheaxaneacetic acid) is a drug compound which is 
structurally related to GABA. It has been extensively studied due to interest in possible 
polymorphs and gabapentin analogues. Gabapentin exists as a zwitterion in the solid 
state. The crystal structures and bonding networks of two new monoclinic polymorphs 
(β- and γ-gabapentin) were studied using x-ray powder and single crystal diffraction. 
These polymorphs were compared with a previously reported gabapentin polymorph (α-
gabapentin). All three polymorphs have extensive hydrogen bonding between the NH3
+ 
and COO- groups of neighbouring molecules, with the β-gabapentin polymorph 
containing an additional weak intramoleular hydrogen bond.  
 
There have also been a number of reported studies on the co-crystallization of amino 
acids with various carboxylic acids. A significant feature in the co-crystallization of 
amino-carboxylic acid complexes includes the ionization states of the individual 
compounds used. The co-crystallization of neurotransmitter amino acids and their 
analogues with oxalic acid were carried out. Co-crystals of GABA-oxalic acid, 
gabapentin-oxalic acid and β-alanine-oxalic acid-water were formed at specific pH 
values. The crystal structures and hydrogen bonding networks of the co-crystals were 
analysed using X-ray diffraction techniques.     
  iii 
 
Thermal analysis was carried out on all the structures as a means of comparing the 
melting points of different polymorphs and examining the possibility of phase transitions 
for each structure.  
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  1 
Chapter 1 
 Introduction 
 
1.1 Amino Acids 
Amino acids are a class of small biomolecules which are characterised by the presence of 
amine and carboxyl groups. This class of molecules can be divided into various 
categories, according to their function, availability, properties and uses. One vital 
category is the α-amino acids in which the amine group is found on a carbon atom 
adjacent to the carboxylic acid group. They have the alpha carbon in the centre and differ 
with respect to the -R side chain. The properties of these amino acids are generally 
attributed to the composition of their side chains, which can cause them to behave as 
weak acids or bases, as well as making them hydrophilic or hydrophobic (Brown et al., 
2003, 9th ed.). The general structure of these α-amino acids is presented in figure 1.1. 
 
 
 
Figure 1.1 General structure of α-amino acids. 
Within this group, there exist twenty standard amino acids which are used by the cells in 
the synthesis of proteins. Ten of these amino acids can be synthesized within the body 
and are referred to as non-essential amino acids; however the other ten, known as 
essential amino acids, must be taken in as part of the human diet as the body is unable to 
synthesize them. Some examples of standard amino acids include glycine, glutamic acid, 
aspartic acid, alanine, leucine and serine (Clugston et al., 2002, 1st ed.). 
Apart from glycine, the remaining nineteen standard amino acids are optically active and 
can exist as both D and L stereoisomers. In general, the naturally occurring amino acids 
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found in proteins, most often take on the levorotatory isomer form 
(www.micro.magnet.fsu.edu, 31/10/2007). 
Apart from the standard amino acids, there are a number of other non-standard amino 
acids which can often be formed by modifying the standard amino acids. Both standard 
and non-standard amino acids can often function in non-protein roles in the cells, for 
example, as neurotransmitters and chemical messengers. 
1.2 Neurotransmitters 
Neurotransmitters are chemicals used in the body in order to relay, amplify and modulate 
signals between neurons and other cells. They are generally classified as either amino 
acids, peptides or monoamines. Neurotransmitters are used throughout the central 
nervous system and in the case of the various amino acid types; they act as either 
inhibitory or excitatory neurotransmitters. Some examples of monoamine 
neurotransmitters include serotonin, dopamine and melatonin. There are also over fifty 
peptide neurotransmitters including insulin and neurotensin. Four amino acids function as 
neurotransmitters, including glycine, γ-aminobutyric acid (GABA), glutamic acid and 
aspartic acid (www.web.indstate.edu, 31/10/2007). 
Apart from these neurotransmitters, there exist a large number of neurotransmitter 
analogues which are structurally related to the neurotransmitters. An example of such an 
amino acid is β-alanine which is closely related in structure to glycine but contains one 
additional carbon in the backbone (figure 1.2). 
 
 
 
                                            (a)                                                                           (b) 
Figure 1.2 Structures of (a) glycine and (b) β-alanine. 
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β-alanine is the only naturally occurring β-amino acid in the brain and acts as a glycine 
receptor agonist which binds to the glycine receptor and triggers a response in the cell 
(Mori et al., 2002). 
Further neurotransmitter analogues often come in the form of amino acid drug 
compounds.  Examples of these include gabapentin (Ibers, 2001), pregabalin (Venu et al., 
2007) and phenibut (Lapin, 2001), all of which have structural similarities to GABA. 
These three analogues also operate within the central nervous system. 
1.3 Zwitterionic Form 
For most amino acids, at a certain pH called the isoelectric point, the carboxyl group 
becomes deprotonated and the amine group, protonated.  This is known as the 
zwitterionic form and the molecule has no net charge. Each amino acid will exist as a 
zwitterion at different specific pH values depending on the properties of the molecule. 
The zwitterionic form is shown in figure 1.3. 
 
 
 
Figure 1.3 Amino acid zwitterion. 
These protonated amino acid forms can generally be obtained from amino acid solutions, 
acidified with strong acids such as HCl (Mukhopadhyay et al., 2004). 
1.4 Hydrogen Bonding 
In both the non-protonated and protonated forms of amino acid structures, there exists 
extensive hydrogen bonding due to the presence of the carboxyl and amine groups in 
each molecule.  
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The hydrogen bonding networks present for protonated amino acids are generally more 
complex and can often consist of mono-, bi- or trifurcated intermolecular C-COO----
+H3N-C hydrogen bonds. These refer to bonds in which for example, a hydrogen atom 
interacts with two other atoms, thus creating two hydrogen bonds with a single hydrogen 
atom(bifurcated) (www.cmt.dur.ac.uk, 15/06/2007). Another type of hydrogen bond 
which could exist for protonated amino acids is intramolecular hydrogen bonding which 
occurs between the N-H and O atoms of the same molecule. There is also weaker 
hydrogen bonding interactions which take place between C-H---N and C-H---O groups.  
An effective method of examining hydrogen bonding networks is by using a graph set 
method (Etter et al., 1990) to find the similarities and differences in various hydrogen 
bonding networks. This divides the hydrogen bonding network up according to the 
patterns of hydrogen bonding present. The patterns can include intramolecular bonds(S), 
chains(C), rings(R) and finite hydrogen bond sets(D). The graph set symbol also 
describes the number of hydrogen bonding donors and acceptors which are present for a 
particular pattern. An example of a graph set symbol is )5(22D , where D indicates a finite 
hydrogen bond set, the superscripted ‘2’ refers to the number of hydrogen bond acceptors 
in the motif, the subscripted ‘2’ refers to the number of hydrogen bond donors in the 
motif and the (5) indicates the number of atoms which make up the graph set motif 
(Bernstein, 2002). 
1.5 Polymorphism 
Amino acids can often exist as polymorphs, which is a characteristic of particular interest 
to the pharmaceutical industry. Polymorphism can occur as a result of a compound 
crystallizing into more than one structure. The chemical composition of the structures are 
the same, however, they have different crystal lattices. Each polymorph often has very 
different properties such as varying energies, thermal and chemical stabilities, and 
solubilities. This is particularly significant for polymorphs of drug compounds when 
examining the way in which each polymorph interacts with the body (Bernstein, 1993). 
Different polymorphs are generally obtained when altering the experimental conditions 
under which crystallization takes place. Some factors which can have an effect are 
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temperature, atmospheric changes, the use of different solvents and the rate and 
conditions of evaporation. An example of using different evaporation conditions is the 
case of using contact line crystallization in order to grow metastable polymorphs. This 
was carried out on the drug paracetamol where it was found that the more stable form 
crystallizes at the centre of the crystallization set-up whereas the metastable form grew in 
contact with the solution surface. The crystal nucleation of this form occurred at the edge 
of the meniscus and the crystals then grew in contact with the solution surface as 
evaporation occurred (Capes et al., 2007). 
 
In the case of temperature, it is often found that different polymorphs exist in different 
temperature ranges and some are more thermodynamically favoured while others are 
more kinetically favoured. The solvent used in crystallizations can play a vital role in 
forming a particular polymorph.  An example which has been extensively studied in the 
past is the crystallization of α, β and γ forms of glycine. A mixture of ethanol or methanol 
and water as the solvent causes the formation of the least stable β-glycine form. When 
water is used as the solvent, α- and γ-glycine forms are produced (Weissbuch et al., 
2005).  
Another factor which has been examined in controlling crystal polymorphism is the use 
of additives to stabilize the formation of one form over another 
(www.xtal.gws.uky.edu/info_polymorph.htm l, 05/11/2007). An additive can have the 
effect of retarding the growth of one phase and allowing the nuclei of another phase to 
develop and form macroscopic crystals. Thus, the use of specific additives can allow for 
the growth of a less thermodynamically stable polymorph over a more stable one. 
Additives are able to effect the nucleation, growth, habit and texture of the crystals which 
are formed. The ability of amino acids to act as stereospecific nucleation inhibitors has 
been studied, again using glycine. It is shown that in the presence of certain amino acids, 
changes are obtained in the form of glycine which is crystallized. As mentioned in the 
paragraph above, α- and γ-glycine forms are produced when using an aqueous solution. 
In order to isolate the growth of γ-glycine, racemic hexafluorovaline can be added 
(Weissbuch et al., 2003). The concentration of the amino acids also has an effect on 
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which form is crystallized (Torbeev et al., 2005). Additives are also able to affect the face 
growth rates of crystals. An example of this can be found in the case of γ-aminobutyric 
(GABA) acid where the effects of adding various additive types were studied. The 
different additives resulted in varying morphologies and growth rates of the crystal faces. 
One study carried out involved the addition of the ion Cr3+, in the form of hydrated 
chromium nitrate to an aqueous solution containing GABA. When crystals were formed, 
the usual prism shaped GABA crystals were flattened due to the slowing down of the 
progression of one face (Lin et al., 1996). 
Another possible type of polymorphism is pseudo polymorphism or solvates in which the 
solvent used becomes incorporated into the crystals.  An example of this is the 
monoclinic nanoporous crystal structure of L-valyl-L-alanine acetonitrile solvate 
(Görbitz, 2007). These crystals contain pores or channels in which solvent molecules are 
found. Figure 1.4 shows the channel in which the solvent molecules are found. 
 
 
 
 
 
Figure 1.4 Channel in which the solvent molecules are found in L-valyl-L-alanine crystals (Görbitz, 2007).  
If the crystals are dried out, they undergo a change in space group for this substance. 
Crystals of an L-valyl-L-serine trifluoroethanol solvate have also been produced. 
However in this case the solvent was more difficult to remove and its final removal did 
not result in a change in space group (Görbitz, 2005).  
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1.6 Co-crystals 
A further aspect of interest in the pharmaceutical industry is the formation of co-crystals.  
These can be described as a homogenous crystalline material which contains two or more 
molecular species that are present in definite stoichiometric amounts (Aakeröy et al., 
2005). As is the case with different polymorphs, the co-crystallization of a drug 
compound with another substance will greatly affect the physical and chemical properties 
of the compound (Vishweshwar et al., 2006). This is significant as the co-crystallization 
may allow for improved therapeutic utility and could also be useful in possibly reducing 
side effects (Wenger et al., 2006). 
There are a number of cases in which co-crystallizations of two amino acids, as well as an 
amino acid with a carboxylic acid, have been performed. There are also a number of 
factors that need to be considered when attempting to design a co-crystal. One aspect 
which has been considered in the design of co-crystals is the examination of structural 
motifs and patterns, particularly within a hydrogen bonding network. Very often, there 
are specific hydrogen bonding motifs which are present for a group of co-crystals like 
amino acid/carboxylic acid co-crystals. When forming a co-crystal, the two or more 
components have intermolecular interactions which are similar to a known pattern in 
other co-crystals (Wenger et al., 2006). Another important aspect in co-crystallization is 
the combination of functional groups which are chosen. From the Cambridge Structural 
Database (CSD) it is evident that the most widely used synthons for the formation of co-
crystals are species which contain a carboxylic acid on one component and a nitrogen 
group on the other. The presence of these groups allows for strong hydrogen bonding 
interactions and a preference of the different species to interact and bind heteromerically 
to each other (Aakeröy et al., 2005). 
 
A further attribute of co-crystallizing agents is the ability of the involved species to 
exhibit a degree of structural flexibility. A study performed by Aakröy et al. has indicated 
that polymorphic compounds are more likely to produce co-crystals than compounds 
which are not polymorphic. It has also been discovered that the co-crystals which do 
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form, all have the same primary hydrogen bonding motifs and can be described by a 
number of the same graph sets (Aakeröy et al., 2005). 
 
The pH of the solution also plays a role in the formation of co-crystals, particularly in the 
case of amino acids and carboxylic acids where the pH will determine the protonation of 
the amine and carboxyl groups (Wenger et al., 2006).  Therefore, it can be seen that the 
structural motifs and patterns related to hydrogen bonding, the functional groups present, 
the degree of flexibility of the individual species and the pH of the solution all play a vital 
role in determining whether co-crystals will form. 
 
In this project, we focus on the neurotransmitter amino acids. In particular, we consider 
the structural analysis of the neurotransmitter, GABA, as well as the neurotransmitter 
analogue, gabapentin and co-crystals of these analogues with carboxylic acids. 
 
1.7 Aims of this Project 
 
In recent years, there has been intense interest in the structures of γ-aminobutyric acid 
(GABA) and the related drug compound gabapentin. The co-crystallization of amino 
acids has also been of interest. In light of this, the aims of this project can be summarized 
as follows: 
 
 To make use of commercially available gabapentin in order to investigate the 
possibility of the existence of different polymorphs for this drug compound by 
attempting to grow crystals using various methods. 
 To crystallize GABA under a variety of conditions, in order to explore the effect 
on crystal growth, habits and possible polymorphs. 
 To attempt the co-crystallization of selected amino acids. 
 To predict potential co-crystallization pairs and hence attempt the co-
crystallization of amino acids, in particular neurotransmitter analogues with 
GRAS (generally regarded as safe) (www.cfsan.fda.gov/~rdb/opagras1.html, 
9/01/2008) carboxylic acids. 
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 To fully characterise and compare the experimental methods, crystal structures, 
hydrogen bonding patterns, thermal behaviour and stability of the possible 
polymorphs of GABA and gabapentin. 
 To fully characterise all co-crystals in terms of their crystal structures, hydrogen 
bonding patterns, thermal properties and possible phase transitions. 
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Chapter 2 
Experimental Techniques 
 
2.1 Introduction 
 
In this project, it was necessary to use various crystallization techniques. This is due to 
the fact that there is difficulty in producing single crystals of specific polymorphs. The 
quantities of crystals produced using the various techniques are also very small. X-ray 
powder and single crystal diffraction was used in the characterisation of the crystals and 
powders obtained. In addition to this, spectroscopic techniques were necessary to fully 
characterise certain compounds. In order to examine and compare the properties of the 
polymorphs obtained, different methods of thermal analysis were carried out.   
 
2.2 Crystallization Techniques 
 
The crystallization methods that were used involved open air evaporation and also a 
vapour diffusion method. Both methods involve dissolving a solid compound in the 
desired solvent. The main objective of this study, was to obtain polymorphs and co-
crystals for various compounds, therefore, in the case of open air evaporation, the 
crystallization environment was varied extensively. The rate of solvent evaporation was 
changed by making use of different crystallization vessels. The temperatures of the 
solutions were varied and a number of the solutions were placed under reflux for different 
lengths of time. The solubility of the compounds in different solvents also had an effect 
on the type of solvent which was chosen. 
 
The method of vapour diffusion involved placing the solution into a small vial and 
wrapping cotton wool around the vial. This small vial was then placed into a larger vial 
containing a small amount of solvent. The solvent used in the larger vial was one in 
which the compound is not soluble. The large vial was sealed and this allowed the vapour 
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from the outer solvent to move slowly through the cotton wool and settle on the inner 
solution, thus decreasing the rate at which the inner solvent evaporates (figure 2.1). 
 
                                                                                            Inner solution                   
 
                                                
                                                                                         Cotton Wool 
 
                                                                                            Outer solvent 
 
Figure 2.1 Vapour diffusion method set-up. 
 
2.3 X-ray Diffraction 
 
Since the discovery of X-rays in 1895, the development of X-ray diffraction techniques, 
has allowed for the examination of crystalline materials at the atomic level. There are two 
main uses of X-ray diffraction. Firstly, to find the unique characteristic X-ray powder 
pattern for a specific crystalline solid by making use of X-ray powder diffraction and 
secondly to determine the crystal structure of the material using X-ray single crystal 
diffraction (Atkins, 1998, ed. 6, www.materials.binghamton.edu.html).  
 
2.3.1 X-ray Powder Diffraction 
 
Historically, the greatest use for X-ray powder diffraction is to identify crystalline 
compounds by their unique diffraction patterns. The method was developed by Debye 
and Scherrer in 1916 and involves the use of monochromatic radiation and a powdered 
sample containing crystallites. The powdered sample is ground and then placed on a flat 
plate holder and leveled out. If there is only a very small amount of sample available, a 
zero background holder is used. Once placed on the holder, some of the crystallites in the 
sample will be orientated so as to satisfy Bragg’s conditions. The sample can then be 
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placed onto a powder diffractometer where the diffraction pattern and the intensities of 
the reflections are electronically monitored (Atkins, 1998, ed. 6).  
 
X-ray powder diffraction was particularly useful in this project as it allowed for the 
different polymorphs of the drug compounds to be clearly distinguished. Each polymorph 
has its own characteristic peaks due to possible differences in crystal systems, space 
groups and cell dimensions. It was also very useful when analyzing the samples in which 
crystals could not be grown, as in the case of a number of co-crystal attempts. The 
possible formation of new substances could be examined from the powder patterns. 
 
Powder diffraction patterns were collected on a Bruker D8 AXS powder diffractometer 
employing copper radiation for the range 5 to 90° 2θ with a step size of 0.02° and a total 
run time of 10 minutes. A zero background holder was used due to the small amount of 
product obtained. 
 
2.3.2 X-ray Single Crystal Diffraction 
 
X-ray single crystal diffraction makes use of a monochromatic beam of X-rays in which a 
single crystal is rotated in the beam. The angles as well as intensities of the reflections for 
specific orientations are recorded. From the diffraction pattern obtained, all information 
about the atomic structure of a compound can be found including aspects such as bond 
lengths, angles,  torsions, molecular conformation, unit cell dimensions, space group and 
the packing within the unit cell (Atkins, 1998, ed. 6). 
 
This technique was used extensively in this project as it allowed for the structures of the 
polymorphs to be determined and hence compared in terms of conformation. It also 
allowed for the structures of the co-crystals to be determined. Phase transitions could also 
be examined, by determining the unit cell dimensions at increasing temperatures.  
 
One disadvantage of this method is the need to obtain crystals which are sufficiently 
large, pure in composition and regular in structure. Large imperfections and cracks result 
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in difficulties in structural data collection. This method obviously cannot be used if good 
quality crystals are not obtained.  
 
For this project, two different X-ray single crystal diffractometers were used in order to 
collect data. Room temperature collections were performed on a Bruker SMART 1K 
CCD area detector with graphite monochromated Mo Kα radiation (40kV, 40mA). The 
collection method involved ω-scans of width 0.3°. Data reduction was carried out using 
the program SAINT+ (Bruker, 1999a) and face indexed absorption corrections were made 
using the program XPREP (Bruker, 1999a). 
 
All low temperature and high temperature collections were performed on the Bruker 
APEX II CCD area detector diffractometer with graphite monochromated Mo Kα 
radiation (50kV, 30mA) using the APEX 2 (Bruker, 2005a) data collection software. The 
collection method involved ω-scans of width 0.5° and 512 x 512 bit data frames. Data 
reduction was carried out using the program SAINT+ (Bruker, 2005b) and face indexed 
absorption corrections were made using the program XPREP (Bruker, 2005b). 
 
The crystal structures were solved by direct methods using SHELX97 (Sheldrick, 1997). 
Non-hydrogen atoms were first refined isotropically followed by anisotropic refinement 
by full matrix least-squares calculations based on F2 using SHELX97. Hydrogen atoms 
were positioned geometrically and allowed to ride on their respective parent atoms.  
Diagrams and publication material were generated using WinGX (Farrugia, 1999), 
SHELX97 (Sheldrick, 1997), PLATON (Spek, 2003), ORTEP-3 (Farrugia, 1997) and 
Mercury (Macrae et al., 2006). 
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2.4 Thermal Analysis 
 
2.4.1 Hot Stage Microscopy 
 
Hot stage microscopy makes use of a polarizing microscope which contains a stage that is 
temperature controlled. A recording device is attached to the microscope. The sample is 
placed on a microscope slide which is positioned so that a video camera can focus on the 
sample and capture the image on a computer screen. The sample can then be heated at an 
appropriate rate. This thermal analytical technique allows for the melting points of 
samples to be determined. It also allows for the possible visualization of phase 
transitions.  
 
In this project, the melting points of the samples were determined by hot stage 
microscopy using a Micro Met Scientific microscope and Kohler hot stage. The melting 
points were then compared with the values obtained from differential scanning 
calorimetry. Attempts were also made to observe possible phase transitions. 
 
2.4.2 Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry is an analytical technique which measures the 
difference in the amount of heat required to increase the temperature of a sample and an 
inert reference material. The sample and reference are maintained at the same 
temperature throughout, but when the sample melts or undergoes a phase transition; 
either more heat or less heat is received by the sample, depending upon whether an 
exothermic or endothermic change takes place.  The curve produced by the calorimeter is 
a measure of the heat flow (mW) as the temperature (°C) increases.  
 
The differential scanning calorimeter which was used produces curves in which peaks 
pointing downwards are endothermic and peaks pointing upwards are exothermic. 
Integration over the area of a peak allows for the measurement of the enthalpy associated 
with the particular transition.  
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There are a number of factors which can affect the appearance of a DSC curve. The 
heating rate and mass of sample used can have a significant effect upon the resolution of 
the thermal change. They may result in changes in the peak temperature. Slower heating 
rates and smaller masses allow for better resolution of the peaks. When making 
comparisons between samples eg. polymorphs, the mass of the samples used should be 
similar (Giron, 1995).  
 
The differential scanning calorimeter used for measurements in this project was a Mettler 
Toledo DSC 822 instrument.  Aluminum, 40 µl sample pans were used in which a hole 
was punched into the lid of the pans prior to sealing. The reference pan was left empty 
and simply sealed with a punctured lid. For each scan, a heating rate of 5°C per minute 
was used and the temperatures ranged from 25°C to approximately forty degrees above 
the melting points determined by hot stage microscopy. The computer package used to 
analyze the DSC curve was the Stare software. 
 
Although it would have been informative to use thermo gravimetric analysis (TGA) and 
other spectroscopic techniques, such as infrared and Raman spectroscopy, this proved to 
be unfeasible due to the minute amounts of pure crystalline material available for most of 
the compounds, often only a few milligrams. 
 
2.5 1H Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
Proton nuclear magnetic resonance involves the recording of spectra in which specific 
chemical shifts and spin-spin coupling between protons of a substance are recorded. This 
technique is useful in allowing for the structure of an unknown organic substance to be 
determined. It provides information regarding the number of different types of hydrogen 
atoms which are present in the molecule. It also indicates the number of hydrogen atoms 
on a neighboring group as well as the electronic environment of the different hydrogen 
atoms. An integration curve for each set of peaks can be plotted and this allows for the 
abundance of the individual protons to be determined. 
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The instrument used for 1H Nuclear Magnetic Resonance (NMR) spectroscopy in this 
project was the Bruker Avance 300 which operated at a 1H frequency of 300.1318534 
MHz. 1H NMR spectroscopy was used specifically in order to identify the solvent present 
in solvate crystals. The crystals were dissolved in deuterated water (D2O). 
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Chapter 3  
γ- Aminobutyric acid 
 
 
3.1 Introduction and related work 
 
As discussed in chapter 1, γ-aminobutyric acid (GABA) is an inhibitory neurotransmitter. 
The structure of GABA has been widely studied for its significant inhibitory action in the 
central nervous system where it operates in the brain and allows for a decrease in the 
firing of neurons, resulting in minimized chances of seizures (www.health.enotes.com, 
9/11/2007). In this chapter, the structures of GABA which have been previously reported 
will be discussed and compared with the results of this research project.  
GABA appears as a white crystalline solid with the molecular formula C4H9NO2 and 
molecular weight 103.12 g/mol. The structural formula for GABA in its zwitterionic form is 
shown in figure 3.1. 
NH
3
+-OOC
 
Figure 3.1 Structural formula of GABA. 
Two structures as well as one chloride salt of GABA have been previously published. 
The first GABA structure has a monoclinic crystal system with the space group P21/c 
(Tomita et al., 1973), while the second structure has a tetragonal crystal system with a 
space group of I41cd (Dobson
 
et al., 1996). These two structures are polymorphs. They 
exhibit distinct conformational differences and a number of intermolecular and hydrogen 
bonding variations, as will be discussed later in the chapter. 
The chloride salt of GABA (C4 H10 N O2 
+, Cl -) has a monoclinic crystal system and the 
space group P21 (Steward et al., 1973). This is the only salt of GABA which has thus far 
been reported. 
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In this project we have obtained a new unpublished solvate crystal structure of GABA. 
The structure of this pseudo polymorph is related in terms of its crystal system, to a range 
of dipeptides such as L-valyl-L-alanine (Görbitz et al., 1996) and L-leucyl-L-serine 
(Görbitz et al., 2005) which form structures with hexagonally symmetric pores. These 
dipeptide crystals contain channels which run along the hexagonal axes and these 
channels contain solvent molecules, for example acetonitrile. The acetonitrile can also be 
substituted by another substance such as iodine, by placing the crystals in an iodine 
saturated solution of toluene (Görbitz et al., 2005). 
3.2 Hexagonal GABA and published polymorphs 
3.2.1 Experimental 
In attempts to co-crystallize GABA and the neurotransmitter analogue gabapentin, 
equimolar amounts of Sigma Aldrich GABA and gabapentin were dissolved in 96% 
ethanol at room temperature.  The solution was then placed into a vial and set up under 
vapour diffusion. Hexane was used as the initial external solvent due to its relatively high 
vapour pressure. The setup was then placed into a water bath maintained at 18 ± 1°C. 
After approximately 2 weeks, long, thin needle shaped crystals formed accompanied by 
the formation of block shaped monoclinic α-gabapentin (Ibers, 2001) and tetragonal 
GABA (Dobson et al., 1996) crystals within the same vial. The needle shaped crystals 
grew either upwards or downwards from the contact line of the solution. In subsequent 
crystallization attempts, gabapentin was removed and only GABA was dissolved in 96% 
ethanol under the same conditions. This resulted in the formation of two different thin 
needle shaped crystal types, where the slightly thicker needle shaped crystals were 
monoclinic GABA (Tomita et al., 1973). 
The solvents were also varied in terms of using water, absolute ethanol, varying 
percentages of water in absolute ethanol, methanol, 2-propanol and 2-butanol. The same 
conditions were adopted and it was found that the thin needle shaped crystals only 
formed when 96% ethanol or 2–butanol were used.  
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The external solvent was also varied by trying acetonitrile, 2-propanol and methanol 
while keeping the initial conditions. As was the case with the hexane, acetonitrile as the 
external solvent also allowed for the formation of the thin needle shaped crystals. The 
other external solvents did not have this effect. 
3.2.2 Visual Comparison of GABA Forms 
The different crystal forms of GABA could firstly be examined by taking snapshot 
images using a Micro Met Scientific microscope at a 45x magnification. This allows for 
the various forms to be examined in terms of visual differences, including differences in 
the crystal habit of the crystalline forms. Images of the two previously published forms 
and the newly formed pseudo polymorph were recorded (see figure 3.2). 
   
 
 
  
                        (a)                                                     (b)                                                      (c) 
Figure 3.2 Optical microscope (Micro Met Scientific, 45x magnification) images of different crystalline 
forms of GABA. (a) GABA Monoclinic (exists as blocks and needles) (b) GABA tetragonal (c) New thin 
needle shaped crystals (GABA solvate). 
It was observed that there are significant differences in the morphologies of the three 
crystal types. However, different morphologies of crystals, does not imply different 
structural forms. Further characterisation was needed in order to fully characterise these 
different forms.              
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3.2.3 X-ray Powder Diffraction 
A method which can be used to indicate the presence of different structures is X-ray 
powder diffraction, therefore, diffraction patterns were obtained for all three samples and 
superimposed using Winplotr (Roisnel et al., 2000) in order to compare the patterns. The 
comparison is shown in figure 3.3.  
Figure 3.3 X-ray powder diffraction pattern comparison of the three forms of GABA. 
Figure 3.3 clearly indicates that there is very little overlapping of the three diffraction 
patterns. The patterns are very different and this is proof that the crystalline phases are 
different. A full examination of the structures of these three crystalline GABA forms can 
only be done using X-ray single crystal diffraction. 
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3.2.4 X-ray Single Crystal Diffraction 
Using X-ray single crystal diffraction, the two forms, (a) GABA monoclinic and (b) 
GABA tetragonal in figure 3.2 were identified as the previously reported monoclinic 
(Tomita et al., 1973) and tetragonal (Dobson et al., 1996) forms of GABA. 
The thin needle shaped crystals of the third form, (c) in Figure 3.2 were examined by X-
ray single crystal diffraction at -100°C on the Bruker, APEX II diffractometer and found 
to be a new hexagonal solvate of GABA. The data presented in table 3.1 below lists the 
parameters for this form and gives a comparison with the two previously reported GABA 
polymorphs. 
Table 3.1: Crystallographic data of the new GABA solvate compared with data from 
two existing polymorphs. 
 GABA Solvate GABA Monoclinic 
(Tomita et al., 1973) 
GABA Tetragonal 
(Dobson et al.,1996) 
Empirical Formula 2(C4 H9 N O2) 
Disordered solvent 
C4 H9 N O2 C4 H9 N O2 
Formula Weight 220.90g/mol 103.12g/mol 103.12g/mol 
Temperature 173(2)K 138K 296K 
Crystal System Hexagonal Monoclinic Tetragonal 
Space Group P62 P21/a I41cd 
Description Colourless, needles Colourless, blocks Colourless, blocks 
Unit cell dimensions a=15.9164 (4) Å a=8.214(2) Å a=11.963(1) Å 
 b= 15.9164(4) Å b= 10.000(2) Å b= 11.963(1) Å 
 c=  7.8769(4) Å c=  7.208(2) Å c=  15.282(2) Å 
 α = 90° α = 90° α = 90° 
 β = 90° β = 110.59(2)° β = 90° 
 γ = 120° γ = 90° γ = 90° 
Volume V=1728.13(1)A3 V= 2187.0(6)A3 V= 2187.0(6)A3 
Z 12 4 16 
Density 1.29g/cm-3 1.20g/cm-3 1.25g/cm-3 
Absorption coefficient 0.101mm-1 0.095mm-1 0.093mm-1 
Θ range for data col. 1.5-27.1° 2.5 -28.1° 3.4 -28.3° 
Reflections collected 15552 2816 1440 
Independent reflect. 1367 1686 767 
Final R indices 0.0475 0.044 0.033 
Note: Disordered solvent: 0.36(C1X), 0.12(C2X), 0.34(C3X), 0.28(C5X), 0.1(O) where the numbers 
represent the site occupancy factors for each atom.  
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The above crystallographic data indicates significant differences in all the parameters for 
the three structures. It is evident that the newly formed GABA structure is a pseudo 
polymorph of the two previously published forms. Further comparison of the three 
structures can be done by examining the molecular conformations which are obtained 
from x-ray single crystal diffraction.  
The molecular conformation of the two molecules in the asymmetric unit of the 
hexagonal GABA polymorph is shown in figure 3.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 An Ortep diagram of the two independent GABA molecules in the asymmetric unit with 
disordered solvate molecules. The non-hydrogen atoms of the two GABA molecules have the displacement 
ellipsoids drawn at 50% probability. 
This hexagonal GABA solvate has two GABA molecules and disordered solvent 
molecules in the asymmetric unit. The disordered solvent molecules could not be 
GABA Molecule 1 
GABA Molecule 2 
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resolved. As is shown in figure 3.4, the two GABA molecules are similarly orientated. 
However, there are slight conformational differences which can be seen by a comparison 
of the torsion angles.  
Figure 3.5 below indicates three different torsion angles which can be compared in order 
to examine the differences between the two molecules. 
 
 
Figure 3.5 The three torsion angles to be compared on the GABA molecules where α = O1-C4-C3-C2 and 
O4-C8-C7-C6; β = C4-C3-C2-C1 and C8-C7-C6-C5; γ = C3-C2-C1-N1 and C7-C6-C5-N2 for GABA  
molecules 1 and 2 respectively. 
Table 3.2 below gives an indication of the differences. 
Table 3.2: Comparison of the torsion angles of the two GABA molecules within the 
hexagonal GABA asymmetric unit. 
 
 
 
Table 3.2 shows that there are only minor differences between the two GABA molecules. 
The differences range between approximately 7- 10°. This shows that the two molecules 
in the same asymmetric unit for hexagonal GABA have similar conformations. The 
conformations however are not exactly the same; otherwise the space group in which they 
exist would have been different. A higher symmetry space group such as P61 would have 
been present. In this structure, the lowering of the symmetry can also be as a result of the 
presence of the solvent molecules.  
Torsion Angle  Molecule 1(°) Molecule 2(°) 
α 172.4(3) 162.5(3) 
β -178.7(3) 175.2(3) 
γ 177.7(3) 171.1(3) 
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The molecular conformation of the hexagonal GABA molecules can also be compared to 
the conformations of the monoclinic and tetragonal GABA polymorphs together with the 
GABA molecule in the chloride GABA salt. 
                             
 
 
 
                                    (a)                                                                  (b) 
 
 
 
 
(c) 
Figure 3.6 Molecular conformations of GABA in (a) Monoclinic GABA, (b) Tetragonal GABA and (c) 
GABA chloride salt where the formula is HOOCCH2CH2CH2NH3
+, Cl-. 
The three conformations in figure 3.6 are significantly different. A comparison of the 
hexagonal GABA molecular conformations with the monoclinic and tetragonal GABA 
conformations indicates that they are significantly different. There are however, 
similarities between the hexagonal GABA molecular conformations and the conformation 
of the GABA molecule in the chloride salt compound. Table 3.3 gives a comparison of 
the torsion angles for these structures.   
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Table 3.3: Comparison of the torsion angles of the hexagonal GABA molecules with 
the GABA molecule in the chloride salt compound. 
 
 
 
The values in table 3.3 indicate that the torsion angles of the two hexagonal GABA 
molecules are similar to the torsion angles for the GABA molecule in the chloride salt 
compound. GABA adopts the ‘trans-trans’ conformation in both the chloride salt and 
hexagonal GABA compounds.   
3.2.5 Hydrogen Bonding 
As mentioned in chapter 1, the possible hydrogen bonding for zwitterionic amino acids is 
extensive due to the presence of the COO- and NH3
+ groups.  The hydrogen bonding 
network for hexagonal GABA as viewed down the c-axis is shown in figure 3.7. 
 
 
 
 
 
 
 
 
Figure 3.7 A view of the hexagonal GABA solvate unit cell down the c-axis, showing the hydrogen 
bonding network. 
Torsion Angle Hexagonal GABA GABA Chloride Salt(°) 
 Molecule 1(°) Molecule 2(°)  
α 172.4(3) 162.5(3) 180.00(3) 
β -178.7(3) 175.2(3) 180.00(3) 
γ 177.7(3) 171.1(3) 180.00(3) 
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The hydrogen bonding network in figure 3.7 indicates the presence of a 62 axis, three fold 
screw axis and a two fold rotation axis. This is in line with the symmetry operators within 
the P62 space group. The disordered solvent molecules lie along the c-axis of the unit cell. 
The GABA molecules are arranged around the disordered solvent molecules to form a 
channel which would contain the solvent molecules. Apart from the hydrogen bonding 
indicated in figure 3.7, there also exists short contact interactions between the GABA 
molecules and the solvent within the channels, which are smaller than the sum of the Van 
der Waals radii. The lengths of these contacts are approximately 3.1Å. No distances 
compatible with hydrogen bonding interactions could be found between the GABA and 
disordered solvent molecules, although the disorder could not be resolved as stated 
above. 
The space-filled model shown in figure 3.8 gives a better indication of the arrangement of 
the solvent molecules within a channel of GABA molecules, where the GABA molecules 
are all orientated in the same direction. When the c-axis is viewed from the one end, the 
NH3
+ groups are visible as indicated in figure 3.8, but when viewed from the opposite 
end, the COO- groups will be visible. This is a consequence of the fact that P62 is a polar 
space group. The diameter of each channel is approximately 4.8Å and therefore, only 
solvent molecules of diameter smaller than this can be included in the channel. The 
solvent molecules occur in two different sites in the asymmetric unit. The site occupancy 
factor is 10.2 % for the four atoms which are attached and 0.17% for the other single 
atom. This indicates that within the channel, the disordered solvent molecules occupy 
approximately 10% of the space and the remainder of the channel is empty.  
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Figure 3.8 Space-filling model of the unit cell of the hexagonal GABA solvate viewed down the c-axis. 
A closer look at the hydrogen bonding between the GABA molecules, as presented in 
figure 3.9, indicates that one of the hydrogen atoms from the NH3
+ group on a molecule 1 
GABA acts as a bifurcated hydrogen bond donor and forms hydrogen bonds with the two 
oxygen atoms of a neighbouring molecule 1 GABA. This results in a chain of molecule 1 
GABA being formed in the c-direction. The N-H---O bond lengths are 3.091(4)Å and 
2.878(3) Å for N1-H3---O1 and N1-H3---O2 respectively. A chain of molecule 2 GABA 
is also formed in the c-direction in a similar manner, with the hydrogen bond lengths 
being 2.840(4)Å and 3.197(4)Å for the bonds N2-H10---O3 and N2-H10---O4 
respectively. Therefore, the average N-H---O lengths of the hydrogen bonds forming the 
two different GABA chains within the network are 2.985 and 3.019Å for the chains made 
up of molecule 1 and molecule 2 GABA respectively.  The three dimensional hydrogen 
bonding network is then formed by the cross-linking of the two different chain types. 
Each chain type contains hydrogen bonding which links it to a chain of both molecule 1 
and molecule 2 GABA in the a-direction. Within the hydrogen bonding network, 
molecule 1 GABA forms the six membered ring channels and molecule 2 GABA forms 
the 3-fold axis chains which coincide with the 3-fold screw axis. 
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                                                                                               Molecule 2 chain type 
                                                                                                           
                                                                                                                                   Molecule 1 chain type 
                                                                                                              Molecule 1 chain type    
                                                                                                                                       Molecule 2 chain type 
                                                                                                                        
                                                                                                        Molecule 2 chain type 
Figure 3.9 View of the linking of the two different types of GABA chains present in the hydrogen bonding 
network. 
A comparison of this hydrogen bonding network with those presented in the papers by 
Tomita et al., (1973) and Dobson et al., (1996) for each GABA polymorph, indicates that 
due to the differences in the molecular conformations and crystal systems of these GABA 
polymorphs, there exist very different hydrogen bonding networks for the three 
structures. 
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3.2.6 Thermal Analysis 
In order to determine the melting point of hexagonal GABA, hot stage microscopy was 
used and the value was verified by means of differential scanning calorimetry (DSC). 
Through hot stage microscopy, the melting point was found to be approximately 206°C. 
The DSC curve of hexagonal GABA was then obtained. The curve is presented in figure 
3.10. 
Figure 3.10 DSC curve of heat flow (mW) vs. temperature (°C) for the hexagonal GABA solvate grown in 
the presence of gabapentin. 
The first peak obtained at 154.1°C corresponds to the melting point of gabapentin, which 
could not be separated from the hexagonal GABA crystals. The second peak corresponds 
to the melting of the hexagonal GABA crystals. This shows that the melting point is 
205.9°C which is close to the melting point obtained using hot stage microscopy. The 
DSC plot further allows for the enthalpy of fusion to be determined.  
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Integral = 436.38mJ 
 
Number of moles of GABA: n = m/M = 2.05mg/ 103.12 
                                                  = 1.988 x 10-5 mol 
 
Enthalpy = 436.38mJ/1.988 x 10-5 mol 
Enthalpy = 21.95kJ/mol 
This value is positive, indicating that it is endothermic as expected. 
The melting points of the monoclinic and tetragonal GABA forms, which were also 
determined from DSC plots, were found to be 207.3°C and 203.9°C respectively (see 
Appendix 1.1.1 and 1.1.2). The enthalpy values for these two polymorphs are 
65.56kJ/mol and 65.88kJ/mol. These enthalpy values are much greater than the enthalpy 
of hexagonal GABA (21.95kJ/mol), thus indicating that the monoclinic and tetragonal 
forms are thermodynamically more stable. The greater stability of the monoclinic and 
tetragonal GABA polymorphs can also be seen by the fact that crystals of these 
polymorphs are more easily grown. In the case of the hexagonal GABA solvate, very 
specific conditions are required in order to produce crystals.   
3.3 Further characterisation of the GABA solvate 
3.3.1 Hot Stage Microscopy 
X-ray single crystal diffraction allowed for the structure of hexagonal GABA to be 
determined and indicated that there are two GABA molecules and a disordered solvent 
molecule within the asymmetric unit. Hot stage microscopy was used in order to examine 
the presence of the solvent within the crystal. The crystals were placed on a microscope 
slide and covered with paraffin oil. They were then mounted on a modified Kohler hot 
stage and heated.  
At approximately 190°C, the solvate bubbles started to be emitted from the needle-like 
crystal, down the centre channel of the needle. Figure 3.11 indicates the release of solvate 
bubbles and other gases as the temperature increases from 190°C to the melting point at 
206°C. 
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Figure 3.11 Optical microscope images of the release of solvate bubbles from the hexagonal GABA 
solvate crystals as the temperature is increased from 190 to 206°C. 
3.3.2 Nuclear Magnetic Resonance (1H NMR) Spectroscopy 
Due to the disorder of the solvent molecules, it was not possible to determine what 
solvent is present in the crystals from the crystal structure alone. A thermo gravimetric 
analysis was carried out; however, the curve produced could not be interpreted. 
Therefore, 1H nuclear magnetic resonance was used in order to determine the nature of 
the solvent. It could not be assumed that the solvent present in the crystals was ethanol 
due to the fact that 96% ethanol was used. In addition to this, experiments that were 
carried out using absolute ethanol did not produce hexagonal GABA crystals. Therefore 
there was the possibility of H2O, ethanol or some impurity being present within the 
crystals.  In order to examine the nature of the solvent, the hexagonal GABA crystals 
were dried by placing them in an oven at 120°C in order to remove the external ethanol 
solvent. The crystals were then dissolved in deuterated water (D2O) and a proton NMR 
was run. The 1H NMR spectrum is shown in figure 3.12 with the assigned functional 
groups given in table 3.4. 
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Figure 3.12 1H NMR spectrum of the hexagonal GABA solvate (excluding D2O solvent peak at 
4.780ppm). 
 Table 3.4: 1H NMR chemical shifts and assigned functional groups. 
 
 
  
 
 
 
 
 
 
Chemical Shift(ppm) Multiplicity Functional Group 
1.1258     
1.1495    Triplet CH3(ethanol) 
1.1731     
1.8181     
1.8429     
1.8678    Pentet OOC-CH2(GABA) 
1.8928     
1.9176     
2.1978    Singlet Acetone 
2.2392     
2.2637    Triplet Central CH2 group (GABA) 
2.2881     
2.9533     
2.9790   Triplet N-CH2(GABA) 
3.0036     
3.5856     
3.6092   Quartet HO-CH2(ethanol)  
3.6329     
3.6564     
4.7800 Singlet D2O(solvent) 
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From table 3.4, it is evident that the solvent present within the GABA channels is ethanol. 
Due to proton exchange, the amine and carboxyl groups form ND3 and COOD when the 
crystals are dissolved in deuterated water, therefore, only the three CH2 groups of the 
GABA molecule are represented in the NMR spectrum. The relative intensities of the 
peaks allow for the determination of the ratio of GABA molecules to ethanol molecules 
present within the crystal. 
When the heights of the integration curves are measured for the ethanol peaks, it is found 
that the ratio of the number of ethanol solvent molecules to the number of GABA 
molecules present is 1:10. The refined site occupancy factors for ethanol (as indicated in 
section 3.2.5) agree with the NMR results. Therefore, within the channels there are large 
vacancies and only about 10% of the space is occupied.  
3.4 Further Experimentation 
Further experimentation was done in order to test whether the ethanol within the crystals 
could be replaced by a different substance, as was carried out by Görbitz et al., (2005) in 
the replacement of acetonitrile by iodine in dipeptide crystals. The crystal system of the 
dipeptides is closely related to this hexagonal GABA solvate and the diameter of the 
channels are also comparable. Therefore, a similar method was used to that of Görbitz et 
al. (2005), where a saturated solution of iodine in toluene was made and this was then 
placed drop wise onto single hexagonal GABA solvate crystals under a microscope. 
Figure 3.13, gives an indication of the effect that the solvent had on the GABA crystals. 
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Figure 3.13 Visual indication of the effect of iodine saturated toluene on the hexagonal GABA solvate 
crystals. 
The images in figure 3.13 indicate that the hexagonal GABA solvate crystals start to react 
with the solution and initially form diamond shapes at the end of the thin, needle shaped 
crystals. As the reaction proceeds, the entire crystal reacts and the diamond shaped 
fragments start to break away from the rest of the crystal. Some smaller crystals did 
remain needle shaped and changed to a brown colour, however, these were not suitable 
for X-ray single crystal diffraction.  Although it appears that iodine is absorbed by the 
hexagonal GABA crystals, it is evident that this method is not suitable to exchange 
ethanol with iodine while still maintaining the structure of these crystals. Alternate 
methods need to be examined in order to test whether solvent exchange is possible for 
these hexagonal GABA solvate crystals. 
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3.5 Discussion and Conclusion 
It is evident from the above X-ray diffraction as well as thermal and spectroscopic 
techniques, that a new, unpublished GABA solvate structure has been obtained. This 
structure is a pseudo polymorph of the previously published GABA structures. The 
conditions under which the new hexagonal GABA crystals form are by the diffusion of 
either hexane or acetonitrile into a saturated ethanol or 2-butanol solution maintained at 
18±1°C. The inability of these crystals to grow in the presence of 2-propanol and 2-
butanol could be due to the fact that GABA is more readily soluble in the alcohols when 
compared to the hexane and acetonitrile external solvents. The purpose of using the 
vapour diffusion method was in order for the external solvent to decrease the rate of 
evaporation of the ethanol. This method would therefore not be as effective with the 
alcohol solvents as they could become miscible with the ethanol and affect the crystal 
growth. The hexane and acetonitrile would simply form a thin layer on top of the ethanol 
and slow down the evaporation rate, thus allowing for the hexagonal GABA solvate 
crystals to form. 
Hexagonal GABA solvate crystals were also formed by using 2-butanol as the internal 
solvent, however this was not the case when methanol, 2-propanol and absolute ethanol 
were used. In these solvents, the more stable polymorphs were formed. This could be due 
to the fact that the crystal growth depends on the initial solubility of GABA in the 
solvents. GABA dissolves in methanol and 2-propanol more readily than in ethanol and 
2-butanol, therefore the increased solubility in these solvents could have the effect of 
causing the more stable polymorphs to form and not allowing the hexagonal GABA 
polymorph to grow. 
As was the case with paracetamol (Capes et al., 2007), mentioned in the introduction, the 
hexagonal GABA solvate crystals also grew from the contact line of the solution. 
However, in this case, the nucleation occurred at the contact line of the meniscus and then 
grew either upwards or downwards as evaporation occurred. As was the case with the 
paracetamol example, this hexagonal GABA polymorph is also the least stable of the 
polymorphs.  
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For GABA, the visual differences between the three crystal types were an indication, in 
this case of the presence of three different structures. The technique of x-ray single 
crystal diffraction was effective in allowing for the crystal structure to be obtained. The 
two GABA molecules within the hexagonal GABA asymmetric unit had minor 
differences, but their conformations were significantly different from the conformations 
of the other polymorphs. Therefore, each GABA polymorph, salt and solvate has distinct 
thermal properties, morphologies, conformations and hydrogen bonding networks. 
A factor which is significant for the GABA hexagonal structure is the presence of the 
short Van der Waals interactions between the GABA molecules which form the channel 
and the disordered ethanol molecules within the channel. There is no indication of any 
hydrogen bonds present. Nevertheless, the ethanol molecules remain in the channels until 
the crystals are heated to a temperature of 190°C. This temperature is approximately 
112°C higher than the regular boiling point of ethanol. This could be due to a high 
stability of the hexagonal channels, where the ethanol and other gases are only released 
when the hexagonal channels collapse, close to the melting point.   
The new hexagonal GABA structure is also unique in that it is the first single amino acid 
to be crystallized in this form, where it has hexagonal channels which contain solvent 
molecules. Further studies will need to be done in the future in order to examine the 
potential of these crystals as microporous organic crystals where the ethanol can be 
removed from the crystals and replaced by another appropriate solvent.  
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Chapter 4  
Gabapentin 
 
4.1 Introduction and related work 
 
As discussed in chapter 1, gabapentin (1-(aminomethyl)cyclohexaneacetic acid)  is a 
neurotransmitter analogue and amino acid drug compound. It was first developed in 1994 
by the pharmaceutical company Pfizer under the commercial name Neurontin® and was 
originally approved as an antiepileptic drug. Its applications have recently been extended 
to the treatment of neuropathic pain (Magnus, 1999).  
 
Gabapentin was originally synthesized to mimic the structure of the neurotransmitter γ-
aminobutyric acid (GABA).  It is structurally similar to GABA and simply contains an 
additional cyclohexane ring attached to the GABA fragment. As is the case with GABA, 
gabapentin also operates within the central nervous system; however it does not act on 
the same brain receptors (www.health.enotes.com, 10/10/2006). 
 
Gabapentin has the molecular formula C9H17NO2 and a molecular weight of 171.24g/mol. 
It is a white crystalline solid which is extremely soluble in water and mildly soluble in a 
number of acidic and basic aqueous solutions. The structural formula is shown in figure 
4.1. 
 
 
 
Figure 4.1 Structural formula of gabapentin. 
In recent years, there has been intense interest in the polymorphs of gabapentin and the 
synthesis of gabapentin analogues. One form of anhydrous gabapentin has been published 
(α-gabapentin). It exists as a zwitterion and crystallizes with a monoclinic crystal system 
NH
2
COOH
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in the space group P21/c (Ibers, 2001). This form corresponds to Form II in US Patent 
6521787 (Lladó et al., 2003) and to the form of gabapentin found in the commercially 
available Pfizer pharmaceutical, Neurontin®. It contains an extensive hydrogen bonding 
network due to the presence of the NH3
+ and COO- groups. 
 
The structure of a gabapentin monohydrate has also been published and, as is the case 
with the anhydrous structure, it crystallizes in a monoclinic crystal system with a P21/c 
space group. The molecules in this crystal form are involved in additional hydrogen 
bonding due to the presence of the water molecule (Ibers, 2001). 
 
Several gabapentin derivatives have also been synthesized including gabapentin HCl, 
gabapentin lactam, t-butyloxycarbonyl-gabapentin-OH, pivaloyl-gabapentin-OH, tosyl-
gabapentin-OH, t-butyloxycarbonyl-gabapentin-N-hydroxysuccinimide ester and t-
butyloxycarbonyl-gabapentin-NHMe. In some of the structures, the aminomethyl group 
lies in an axial position while others have the carboxymethyl group lying axially. The 
paper published by Ananda et al., (2003) discusses these different structures, their 
orientations and their individual crystal and diffraction parameters. 
 
Structures of peptides incorporating gabapentin have also been studied where the 
conformation of gabapentin is stereochemically constrained in order to adopt folded 
conformations, resulting in the formation of intramolecular hydrogen bonded structures. 
A paper published by Vasudev et al., (2007) discusses examples of 7, 9, 12 and 13 atom 
hydrogen bonded rings which form in these peptide structures containing the gabapentin 
residue. 
 
In addition to these derivatives, a 1-(aminomethyl)- drug compound, pregabalin, has also 
been reported. This compound is both structurally and functionally related to gabapentin 
and has been designed to be more medicinally potent than gabapentin in the treatment of 
seizures and neuropathic pain (Venu, 2007). 
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In this chapter, the structure of α-gabapentin which has previously been reported will be 
compared with the results obtained in this research project, namely, the structures of two 
unreported gabapentin polymorphs, β-gabapentin and γ-gabapentin. 
 
4.2 Gabapentin polymorphs 
 
4.2.1 Experimental  
 
Using x-ray powder diffraction, it was found that the gabapentin available from Sigma 
Aldrich corresponds to α-gabapentin. The gabapentin found in Neurontin® capsules also 
corresponds to α-gabapentin. This gabapentin was extracted from the Neurontin® 
capsules by dissolving the contents of 300mg capsules in 96% ethanol and then filtering 
the solution using 0.45µm hydrophilic microporous filters in order to remove the inactive 
materials in the capsule. The filtered solution was then left under open-air evaporation in 
order to crystallize. β-gabapentin was prepared by dissolving commercially available 
gabapentin (Sigma Aldrich) in 96% ethanol at ambient temperature until the solution was 
saturated. The solution was then placed into a vial and heated in an oil bath at 60°C for 
48 hours. Needle-like crystals of β-gabapentin were grown from the solution. 
 
In the preparation of γ-gabapentin, commercially available gabapentin (Sigma Aldrich) 
was dissolved in 96% ethanol at 60°C. The solution was then cooled to room 
temperature. Plate-like diamond shaped crystals of γ-gabapentin formed after 3 days of 
slow open-air evaporation. 
 
4.2.2 Visual comparison of gabapentin structures 
 
As was the case with GABA, an initial comparison could be done by examining the 
visual differences and crystal habit of the three different crystal types. Again, images 
were taken using a Micro Met Scientific microscope at a 45x magnification (see figure 
4.2). 
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                          (a)                                                    (b)                                                     (c) 
Figure 4.2 Optical microscope (Micro Met Scientific, 45x magnification) images of three different 
crystalline forms of gabapentin, (a) α-gabapentin, (b) β-gabapentin, (c) γ-gabapentin.       
                 
Therefore, it can be observed from figure 4.2 that there exist significant differences in the 
morphologies of the three gabapentin forms. However, further characterisation needed to 
be performed in order to verify that these crystals are in fact different polymorphs.  
 
4.2.3 X-ray Powder Diffraction 
 
The X-ray powder diffraction patterns of β-gabapentin and γ-gabapentin were recorded 
and compared with the diffraction pattern of α-gabapentin. The patterns were 
superimposed using Winplotr (Roisnel et al., 2000). Figure 4.3 shows the comparison. 
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Figure 4.3 X-ray powder diffraction pattern comparison of α-, β- and γ-gabapentin.  
 
It is clear from figure 4.3, that the diffraction pattern of α-gabapentin is very different 
from the patterns of the other two forms, as there is very little peak overlapping. In the 
case of the β- and γ-gabapentin diffraction patterns, the first peak for each pattern appears 
to be overlapping. However, there is a slight difference, where the 2θ values are 6.08° 
and 6.30° for β- and γ-gabapentin respectively. The second peak in each of these patterns 
also shows a difference of approximately 0.5°. A comparison of the remainder of the 
peaks for these two forms indicates very little peak overlap. Therefore, it is evident that 
the powder diffraction patterns of the three structures are different, proving that different 
crystalline phases are present. 
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The X-ray powder diffraction pattern of β-gabapentin was also compared with the pattern 
found in US Patent 6255526 (Pesachovich et al., 2001) and it was found that β-
gabapentin corresponds to Form III in this US patent. The X-ray powder diffraction 
pattern of γ-gabapentin was compared with the pattern found in patent WO/2004/110342 
and it was found that γ-gabapentin corresponds to Form IV in this patent (Satyanarayana 
et al., 2004). The crystal structures of these forms have not been reported. 
 
4.2.4 X-ray Single Crystal Diffraction  
 
X-ray single crystal diffraction was used in order to examine the molecular 
conformations and fully characterise β- and γ-gabapentin. A crystal was mounted and 
examined at -100°C on the Bruker, APEX II diffractometer. The data presented in table 
4.1 below gives an indication of the parameters of β- and γ-gabapentin as well as a 
comparison between the three structures. 
 
Table 4.1: Crystallographic data of the gabapentin crystalline forms. 
 
Empirical Formula 
Formula Weight 
Temperature 
Crystal System 
Space Group 
Description 
Unit cell dimensions 
 
 
 
 
 
Volume 
Z 
Packing efficiency 
Density(calculated) 
Absorption coefficient 
Θ range for data collection 
Reflections collected 
Independent reflections 
Final R indices 
α-gabapentin 
C9H17NO2 
171.24g/mol 
153(2)K 
Monoclinic 
P21/c 
Block, colourless 
a = 5.8759 (6) Å 
b = 6.9198 (7) Å 
c = 22.262 (2) Å 
α = 90° 
β = 90.08° 
γ = 90° 
V = 905.18 (16) Å3 
4 
71.3% 
1.26g/cm-3 
0.088mm-1 
1.83 - 28.40° 
7951 
2147 
0.042 
β-gabapentin 
C9H17NO2 
171.24g/mol 
173(2)K 
Monoclinic 
P21/c 
Needle, colourless 
a=14.5376(16) Å 
b= 6.6329(6)Å 
c=  9.8343(9)Å 
α = 90° 
β = 105.922(5)° 
γ = 90° 
V=911.91(15)  Å 3 
4 
70.5% 
1.25g.cm-3 
0.087mm-1 
1.46 - 27.99° 
5118 
2195 
0.046 
γ-gabapentin 
C9H17NO2 
171.24g/mol 
173(2)K 
Monoclinic 
C2/c 
Plate, colourless 
a=30.5452(11) Å 
b= 5.9268(2)Å 
c=  10.8841(4)Å 
α = 90° 
β = 108.316(2)° 
γ = 90° 
V=1870.58(12) Å 3 
8 
68.7% 
1.22g.cm-3 
0.085mm-1 
1.40 - 26.99° 
7746 
2042 
0.046 
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The above crystallographic data indicates clear differences for the three structures. The α- 
and β-gabapentin both have the same crystal system and space group; however, the unit 
cell parameters are very different. γ-gabapentin has a space group of C2/c which is also 
different from the other two forms. A comparison of the densities and packing 
efficiencies for the three structures shows that the molecules are most efficiently packed 
in α-gabapentin and this could indicate that it is the most thermodynamically stable form.  
 
The structures can be further compared and characterised by examining the molecular 
conformations obtained by X-ray single crystal diffraction. The conformations are 
presented in figure 4.4. 
 
 
 
 
 
 
 
 
 
                        (a)                                                              (b)                                              (c) 
Figure 4.4 Ortep diagrams of (a) α-gabapentin, (b) β-gabapentin and (c) γ-gabapentin with the 
displacement ellipsoids drawn at the 50% probability level. 
 
The conformational diagrams in figure 4.4 clearly indicate differences in the structures in 
terms of the positioning of the NH3
+ and COO- groups. β-gabapentin contains the NH3
+ 
group in an equatorial position and the COO- group in an axial position, however, in α- 
and γ-gabapentin these groups are in the opposite positions. This difference is further 
indicated by the torsion C3-C1-C5-C7 = -166.22°, -65.44°, -168.7° for α, β- and γ-
gabapentin respectively, where the β-gabapentin value is significantly different from the 
other forms.  
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The differences in the torsion angles O1-C2-C3-C1= -161.36°, 95.97°, 151.56°, C2-C3-
C1-C4 = 51.21°, -46.4°, 63.47° and C3-C1-C4-N1= 60.07°, -52.5°, 47.74° for the α-, β- 
and γ-gabapentin respectively, indicate the different angles and directions at which the 
NH3
+ and COO- groups are twisted. The above torsion angles indicate that the largest 
conformational difference which occurs is due to the twisting of the COO- group. The 
centrosymmetric hydrogen bonded dimers of the three structures are presented in figure 
4.5 and further indicate these differences.  
 
 
 
 
 
 
                                                                      (a) 
 
 
 
 
 
 
                                                            
                       (b) 
 
 
 
 
 
 
 
                                                                                   (c) 
Figure 4.5 Centrosymmetric dimers of (a) α-gabapentin, (b) β-gabapentin and (c) γ-gabapentin indicating 
the )14(22C graph set in each case. 
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Further torsion angles which indicate the differences in the three gabapentin polymorphs 
are listed in table 4.2. 
 
Table 4.2: Selected torsion angle parameters of the gabapentin polymorphs (°). 
 
Torsion Angle α β γ 
C2-C3-C1-C5 -68.63(14) -168.37(14) -56.38(18) 
C2-C3-C1-C6 172.52(11) 71.87(18) -174.14(14) 
N1-C4-C1-C6 -58.28(14) -173.57(14) -72.56(17) 
N1-C4-C1-C5 -178.71(10) 69.42(18) 168.72(13) 
 
Comparing the polymorphs, it is seen that the cyclohexane rings all have the chair 
configuration, however, the aminomethyl and carboxyl groups are oriented in different 
positions. Therefore, the above torsion angles and diagrams clearly show that the three 
gabapentin polymorphs are structurally very different.  
 
4.2.5 Hydrogen bonding 
 
In all three polymorphs there exists extensive hydrogen bonding due to the presence of 
the NH3
+ and COO- groups. In each case, the NH3
+ group on the gabapentin molecules, 
hydrogen bonds to three COO- groups, each from a different neighbouring molecule. 
Table 4.3 gives an indication of the differences in the hydrogen bonding in each of the 
polymorphs. 
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Table 4.3: Hydrogen bonding parameters of the gabapentin polymorphs (Å,°). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symmetry Codes: 
a. (i) -x+1, -y+1, -z+1; (ii) -x, -y+1, -z+1; (iii) x, y+1, z;                                                                   
b. (i) -x, -y, -z+1; (ii) x, y-1, z; (iii) -x, y-1/2, -z+1/2;                                                                         
c. (i) -x+1/2, -y+1/2, -z+1; (ii) x, -y+1, z+1/2; (iii) x, -y, z+1/2. 
 
There is a significant difference in the hydrogen bonding networks of α- and β-
gabapentin which is primarily due to the presence of an intramolecular hydrogen bond in 
β-gabapentin [N1-H15---O1 = 2.940(19)Å ]. Atom O1 acts as a trifurcated hydrogen 
bond acceptor in β-gabapentin compared to the bifurcated acceptor in α-gabapentin. This 
results in the lengthening of the N1-H15---O1 bond between two neighbouring 
molecules, i.e. N1-H15---O1 = 2.783(16)Å and 3.024(18)Å for α- and β-gabapentin 
respectively. 
 
D-H---A D-H H---A D---A D-H---A 
α-gabapentin (Ibers, 2001)     
N1-H15—O1i,a, 0.92 1.91 2.7827 (16) 158 
N1-H16—O2ii,a 0.92 1.85 2.7525 (16) 165 
N1-H17—O1iii,a 0.96 1.81 2.7547 (18) 166 
β-gabapentin     
N1-H15—O1 0.91 2.19 2.9398 (19) 139 
N1-H15—O1i,b 0.91 2.42 3.0242 (18) 124 
N1-H16—O2ii,b 0.91 1.86 2.7230 (2) 157 
N1-H17—O1iii,b 0.91 1.81 2.7174 (19) 176 
γ-gabapentin     
N1-H15—O1i,c 0.91 1.93 2.7980 (16) 159 
N1-H16—O2ii,c 0.91 1.85 2.7324 (17) 161 
N1-H17—O1iii,c 0.91 1.91 2.7851 (18) 161 
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As is the case with α-gabapentin, there is no intramolecular hydrogen bond in γ-
gabapentin. The N-H---O hydrogen bond distances are very similar to those in α-
gabapentin [average N1-H-O = 2.763Å and 2.771Å for α- and γ-gabapentin respectively]. 
The α- and γ-gabapentin polymorphs also both have the O1 atom acting as a bifurcated 
hydrogen bond acceptor. Figure 4.6 indicates the differences in the hydrogen bonding 
networks for the three structures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                          (a)                                                           (b)                                                                  (c) 
Figure 4.6 Hydrogen bonding networks of (a) α-gabapentin, (b) β-gabapentin and (c) γ-gabapentin where 
the α-form is viewed down the a-axis and the β- and γ-forms are viewed down the b-axis. 
 
There are clear differences in the packing of gabapentin in the three polymorphs. The 
hydrogen bonding networks can further be compared by the use of graph sets. Some first 
and second level hydrogen bond motifs which are present for the hydrogen bonding 
networks of the three structures were determined by RPLUTO (Motherwell et al., 1999). 
A summary of the main graph sets is shown in matrix form in table 4.4 which 
corresponds to figure 4.7. 
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Table 4.4: Matrix of selected graph sets for the hydrogen bonding of the gabapentin 
polymorphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            (a)                                                (b)                                                    (c) 
Figure 4.7 Diagram representing the possible hydrogen bonds present for each structure (a) α-gabapentin, 
(b) β-gabapentin and (c) γ-gabapentin where the bold letters each represent a different individual hydrogen 
bond in each structure. Some of the first and second level graph set motifs, resulting from these bonds, are 
indicated in table 4.4 for α-gabapentin, β-gabapentin and γ-gabapentin. The single red dots refer to the 
oxygen atoms where the remainder of the molecule has been deleted for visual clarity.  
α-gabapentin 
 a b c  
a )6(
2
2C  - -  
b )14(
2
2C  )14(
2
2R  -  
c )28(
4
4R  )28(
4
4R  )7(
1
1C   
β-gabapentin 
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1
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2
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2
2R  - - 
c - )28(
4
4R  )6(
2
2C  - 
d - - )14(
2
2C  )7(
1
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a )14(
2
2R  - -  
b )6(
2
2C  )7(
1
1C  -  
c )14(
2
2C  )14(
2
2C  )7(
1
1C   
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There are four graph sets common to each polymorph including the unitary level )7(11C  
and )14(22R , and secondary level )14(
2
2C  and )6(
2
2C  sets. The common )14(
2
2R graph set 
was shown in the centrosymmetric dimers presented in figure 4.5. The β polymorph is the 
only form which contains the unitary level )7(11S  graph set for the intramolecular 
interaction. 
 
4.3 Thermal Analysis 
 
The melting points of the gabapentin polymorphs were initially determined by hot stage 
microscopy and again these values were verified using differential scanning calorimetry. 
The melting point of α-gabapentin was measured to be 160°C. A DSC scan was run and 
the melting point was found to be over the range 155-166°C with the peak position at 
160.9°C (please see Appendix 1.2.1). The enthalpy, as calculated by the standard method 
shown in section 3.2.6, was found to be 40.52 kJ/mol. 
 
The melting point of β-gabapentin was measured to be 166°C. The DSC scan is shown in 
figure 4.8. 
Figure 4.8 DSC curve of heat flow (mW) vs. temperature (°C) for β-gabapentin over the range 25- 220°C. 
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The DSC curve indicates that the melting point occurs over the range 155 – 168°C with 
the peak position at 166.1°C. This is close to the value obtained using hot stage 
microscopy. From the integral, the enthalpy was calculated to be 35.99 kJ/mol. The curve 
also indicates that there is a small endothermic peak present at approximately 87.5°C 
with an enthalpy of approximately 0.054 kJ/mol. This peak could relate to a possible 
phase transition. In order to examine this possible transition, parameters of a single 
crystal of β-gabapentin were measured at increasing temperatures in order to test whether 
a change occurs. Table 4.5 and figure 4.9 below indicate the changes in the unit cell 
parameters. 
 
Table 4.5: Changes in the unit cell parameters of β-gabapentin with temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Plot of points obtained for the change in volume (Å3) against the change in temperature (°C) for 
β-gabapentin. 
Temperature(°C) a(Å) b(Å) c(Å) α(°) β(°) γ(°) Volume(Å3) 
25 9.89 6.66 14.71 90 106.37 90 929 
50 9.93 6.66 14.77 90 106.49 90 937 
70 9.97 6.67 14.86 90 106.65 90 946 
75 9.90 6.64 14.77 90 106.68 90 930 
80 9.97 6.69 14.87 90 106.68 90 950 
85 9.91 6.65 14.78 90 106.77 90 932 
90 9.86 6.63 14.78 90 106.54 90 926 
95 9.91 6.63 14.80 90 106.95 90 930 
100 9.91 6.62 14.77 90 106.99 90 927 
105 9.86 6.54 14.77 90 107.10 90 910 
110 9.89 6.54 14.82 90 106.92 90 924 
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This plot indicates that there is a drop in volume after 80°C. This could correspond with 
the change observed on the DSC curve. The other unit cell parameters remained fairly 
similar, with only slight increases in the unit cell lengths due to heating. Data collections 
were carried out at 70°C and at 100°C in order to examine possible differences. A 
comparison of the corresponding hydrogen bonding and selected geometric parameters is 
presented in tables 4.6 and 4.7. 
 
Table 4.6: Comparison of the hydrogen bonding parameters of β-gabapentin at 
different temperatures (Å, °). 
 
D-H---A D-H H---A D---A D-H--A 
β-gabapentin(-100°C)     
N1-H15---O1(intra) 0.91 2.19 2.940(19) 139 
N1-H15---O1 0.91 2.42 3.024(18) 124 
N1-H16---O2 0.91 1.86 2.7230(2) 157 
N1-H17---O1 0.91 1.81 2.717(19) 176 
β-gabapentin(70°C)     
N1-H15---O1(intra) 0.89 2.21 2.936(2) 139 
N1-H15---O1 0.89 2.48 3.065(2) 124 
N1-H16---O2 0.89 1.88 2.713(2) 156 
N1-H17---O1 0.89 1.84 2.722(2) 174 
β-gabapentin(100°C)     
N1-H15---O1(intra) 0.89 2.21 2.933(3) 139 
N1-H15---O1 0.89 2.49 3.084(3) 124 
N1-H16---O2 0.89 1.88 2.718(3) 156 
N1-H17---O1 0.89 1.83 2.720(3) 175 
 
The above table indicates that there are only minor differences in the hydrogen bonding 
parameters of the three structures. 
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Table 4.7: Comparison of the torsion angles of β-gabapentin at different 
temperatures (°). 
 
The comparison of the torsion angles indicates only very small differences. Therefore, the 
endothermic peak which appears at approximately 87.5°C is not as a result of a 
significant change in the structure or a change in the hydrogen bonding of β-gabapentin. 
It is possible that the structure could change at that specific temperature and then revert 
back to the original structure during the data collection. The packing for the structures at 
the three temperatures is very similar.  
 
The melting point of the γ-gabapentin was found to be 164°C. The DSC scan was 
recorded and figure 4.10 shows the curve obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 DSC curve of heat flow (mW) vs. temperature (°C) for γ-gabapentin over the range 25- 200°C.  
Torsion β-gabapentin(-100°C) β-gabapentin(70°C) β-gabapentin(100°C) 
C3-C1-C5-C7 -65.44(18) -67.10(2) -66.50(3) 
O1-C2-C3-C1 95.97(18) 94.50(2) 93.70(3) 
C2-C3-C1-C4 -46.40(2) -46.90(2) -46.10(3) 
C3-C1-C4-N1 -52.50(2) -52.20(2) -52.90(3) 
C2-C3-C1-C5 -168.37(14) -168.54(17) -168.6(2) 
C2-C3-C1-C6 71.87(18) 71.4(2) 71.90(3) 
N1-C4-C1-C6 -173.57(14) -173.38(16) -173.4(2) 
N1-C4-C1-C5 69.42(18) 69.10(2) 69.60(3) 
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The scan in figure 4.10 shows the melting point to be over the range 150 – 168°C and the 
peak position at 163.4°C which is very close to the value obtained using hot stage 
microscopy. The enthalpy value for this melting point is 43.97 kJ/mol. For this curve, 
there is also a small exothermic peak present at approximately 89°C with an enthalpy of 
approximately 1.5 kJ/mol. This could also indicate the presence of a phase change at this 
point. As was the case with β-gabapentin, the unit cell parameters were measured at 
various temperatures. In this case however, a plot of Volume (Å3) vs. Temperature (°C) 
did not show a clear trend. Again, data was collected at 70°C and 100°C in order to 
examine whether any structural changes occur. 
 
A comparison of the corresponding hydrogen bonding is given in table 4.8. 
 
Table 4.8: Comparison of the  hydrogen bonding parameters of γ-gabapentin at 
different temperatures(Å,°). 
 
D-H---A D-H H---A D---A D-H--A 
γ-gabapentin(-100°C)     
N1-H15---O1 0.91 1.929 2.798(16) 159 
N1-H16---O2 0.91 1.854 2.732(17) 162 
N1-H17---O1 0.91 1.908 2.785(18) 161 
γ-gabapentin(70°C)     
N1-H15---O1 0.89 2.056 2.795(18) 140 
N1-H16---O2 0.89 1.961 2.734(19) 144 
N1-H17---O1 0.89 1.995 2.785(19) 147 
N1-H16---O1 0.89 2.680 3.344(19) 132 
γ-gabapentin(100°C)     
N1-H15---O1 0.89 2.090 2.830(15) 140 
N1-H16---O2 0.89 1.962 2.759(19) 147 
N1-H17---O1 0.89 2.041 2.815(15) 151 
N1-H16---O1 0.89 2.686 3.343(19) 132 
 
This comparison indicates that there are differences between the hydrogen bonding 
distances in the -100°C structure when compared to the 70°C and 100°C structures.  The 
hydrogen bond lengths are shorter and hence stronger in the -100°C structure than the 
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other structures. There are also smaller differences between the 70°C and 100°C 
structures. In the two high temperature structures, there is also the presence of an 
additional weak hydrogen bonding interaction which results in H16 acting as a bifurcated 
hydrogen bond donor.  
 
This can be seen in figure 4.11 below, which shows the hydrogen bonding contacts for 
each molecule.  
 
 
 
 
 
 
 
 
                         (a)                                                     (b)                                                   (c) 
Figure 4.11 Hydrogen bonding contacts for γ-gabapentin at (a) -100°C, (b) 70°C and (c) 100°C 
respectively. 
 
A comparison of selected torsion angles is presented in table 4.9. 
 
Table 4.9: Comparison of the torsion angles of γ-gabapentin at different 
temperatures(°). 
Torsion γ -gabapentin(-100°C) γ -gabapentin(70°C) γ -gabapentin(100°C) 
C3-C1-C5-C7 -168.79(15) -168.7(15) -168.4(15) 
O1-C2-C3-C1 151.56(14) 151.7(15) 142.6(14) 
C2-C3-C1-C4 63.47(18) 63.30(19) 63.00(18) 
C3-C1-C4-N1 47.74(17) 48.21(19) 55.40(19) 
C2-C3-C1-C5 -56.38(18) -56.31(19) -55.01(18) 
C2-C3-C1-C6 -174.14(14) -173.99(15) -179.8(14) 
N1-C4-C1-C6 -72.56(17) -72.22(18) -70.70(17) 
N1-C4-C1-C5 168.72(13) 168.94(14) 172.4(14) 
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The above table (Table 4.9) indicates that the three structures only have small differences 
in their torsion angles. The small exotherm could be an indication of energy given off, 
when the conformation of the structure is slightly altered. The packing for the structures 
at the three temperatures is very similar. 
 
4.4 Molecular Modeling 
 
Attempts were made at modeling the possible lowest energy conformations of isolated 
molecules of gabapentin, in order to determine whether the modeled structures would 
match those of the three gabapentin polymorphs. In Hyperchem Professional, a geometry 
optimisation was carried out with the charges set to zero. This file was then exported as a 
PDB file and opened in Gaussian. In order to assign accurate charges, a single point 
calculation was carried out using density functional theory with the BZLYP hybrid 
functional and the 3-21G* basis set. Density functional theory is an approach which 
makes use of electronic density as the basic quantity. It is a simple quantity to use when 
compared with other electronic wavefunction approaches as it is a function of only three 
variables. Charges were fitted to the electrostatic potential at points selected according to 
the Merz-Singh-Kollman scheme in which atomic charges are fitted to reproduce the 
molecular electrostatic potential at various points around the molecule. (Besler et al., 
1990; Singh et al., 1984; www.physics.ohio-state.edu.html). 
 
The charged gabapentin structure was then opened in Hyperchem and conformational 
searches with different constraints were carried out. The Generalised AMBER force field 
was used. The AMBER forcefield has often been used in the modeling of proteins and 
nucleic acids, however, it has limited parameters for organic molecules. The Generalised 
AMBER forcefield has been developed to accommodate most pharmaceutical molecules 
and was therefore chosen for this project (www.amber.scripps.edu.html). The lowest 
energy conformations which were found did not resemble the conformations of the three 
gabapentin polymorphs described above. Subsequent correspondence with Professor 
Graeme Day from the Cambridge Pfizer institute revealed that work is being done on the 
molecular modeling of gabapentin and thus far the crystal structures of α- and β-
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gabapentin have been modeled. The complications in the modeling of this compound lie 
in the choice of force field to be used.  
  
4.5 Discussion and Conclusion 
 
Through an initial visual comparison and the analysis of the X-ray powder diffraction 
patterns of the three gabapentin forms, it was evident that different crystalline phases had 
been obtained. Further characterisation of the crystals through X-ray single crystal 
diffraction and the examination of the parameters, molecular conformations and hydrogen 
bonding networks, clearly indicated the presence of three different gabapentin 
polymorphs.  
 
α-gabapentin has been published (Ibers, 2001), and this could be compared with the two 
unreported crystal structures of gabapentin. All three of the structures are monoclinic. 
However, the α-gabapentin and β-gabapentin have P21/c space groups while γ-gabapentin 
has a C2/c space group. The molecular conformations of the three structures are also 
clearly different in terms of having the NH3
+ and COO- groups positioned very differently 
relative to the cyclohexane ring. All three structures have extensive hydrogen bonding 
due to the presence of the NH3
+ and COO- groups. Significant differences can be seen in 
the hydrogen bonding networks and a comparison can be made by examining the graph 
sets present. The three structures have two unitary and two secondary level graph sets in 
common, however the remainder are all different. β-gabapentin is the only structure 
which contains an additional intramoleular hydrogen bond. 
 
The thermal analysis of the three structures indicates that the melting points differ by 
approximately 2-4°C. The DSC scans for the β-and γ-gabapentin indicate the presence of 
possible phase transitions. For β-gabapentin, only small changes occur in the structure 
and hydrogen bonding distances at the higher temperatures of 70°C and 100°C. In the 
case of γ-gabapentin, at the higher temperatures of 70°C and 100°C, an additional 
hydrogen bonding interaction is formed. However, the structures at the three different 
temperatures only have small differences. The small endothermic and exothermic peaks 
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which are present for β-and γ-gabapentin respectively, may be due to slight changes in 
the structures as the temperature increases. It is also possible that the structures change at 
the peak positions and then revert back to the original structures after that point.  The 
possible phase transitions could indicate that the melting point measured in each case 
refers only to the melting point of one thermodynamically stable polymorph.   
 
The relative stabilities of the polymorphs are also seen from the degree of ease with 
which crystals are formed. α-gabapentin is the polymorph which can most easily be 
obtained at room temperature while γ-gabapentin is much less stable and more difficult to 
obtain. Crystals of β-gabapentin can only be obtained at higher temperatures and have a 
lower enthalpy value than the other two forms.  
   
Therefore, it is evident that the structures of two unreported gabapentin polymorphs have 
been obtained. A fourth polymorph has been reported in patent literature as Form I (US 
Patent 6521787, Lladó et al., 2003). However, single crystals of this polymorph have not 
yet been isolated.  
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Chapter 5 
 Co-crystals 
 
5.1 Introduction and related work 
 
As discussed in chapter 1, the study of co-crystals has become very significant in the 
pharmaceutical industry as there is a continuous search for drug compounds which 
exhibit the best possible properties for therapeutic use and manufacturability. Factors 
which affect the value of these compounds include the stability, hygroscopicity, 
dissolution rate, solubility and bioavailability.  
 
The possibility of forming co-crystals is often considered when the properties of the most 
thermodynamically stable form of a substance are not acceptable. In the past, the 
development of co-crystal forms for drug compounds had not been extensively 
researched, however, in recent years there has been growing interest in co-crystals as a 
means of improving the properties of drugs, while leaving the active pharmaceutical 
ingredients unaltered (Thayer, 2007). 
 
There has been much debate regarding the definition of a co-crystal. Some suggestions in 
terms of designating co-crystals have been to define co-crystals according to the state of 
their components under standard conditions, for example the suggestion by Aakeröy et 
al., (2005) that co-crystals should only be composed of components that are solids at 
ambient temperature as opposed to suggestions by Dunitz, (2003) that co-crystals 
encompass molecular compounds, molecular complexes, solvates, inclusion compounds, 
channel compounds and clathrates. It has thus been suggested that the components must 
individually be solids under ambient conditions, but it is not essential that they retain 
their individual identity within the co-crystal (Bond, 2007).The generally accepted 
definition of a co-crystal, is a crystalline solid containing multiple components, where the 
two or more components are associated through intermolecular interactions.  
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A method which has been used as a means to distinguish between co-crystals and salts 
has been based upon whether a proton transfer occurs from an acid to a base. This is 
largely dependant upon the strengths of the acids and bases as well as the crystalline 
environment (Childs et al., 2007). 
 
It has been found that in general, a reaction of an acid with a base is expected to produce 
a salt when the ∆pKa value is greater than 2 or 3. It has also been found that for ∆pKa 
values less than 0, co-crystal formation is the most likely. These rules however, do not 
apply in every situation and it has been difficult to predict the formation of either co-
crystals or salts in the region of ∆pKa 1 to 3 (Childs et al., 2007). 
 
It has been found through the examination of proton transfer, that when a solution 
contains an organic acid and organic base, if the proton is present on the base, then proton 
transfer has occurred and the crystalline acid-base complex would be classed as a salt. 
However, if the proton remains on the acid, then proton transfer has not occurred and the 
crystalline complex would be a co-crystal.  The relation of the pKa values for the acid and 
base in solution as well as the difference between these values allows for the extent of 
proton transfer to be determined in a solution. When examining the crystalline structures 
ie. the solid state,  the extent of proton transfer can be determined by making use of 
various techniques such as X-ray single crystal diffraction, neutron diffraction or infrared 
spectroscopy in order to locate the protons or determine the bond lengths and angles. 
There are however cases in which there is disorder that can lead to multiple protonation 
states with partial occupancy. In such cases, it is not possible to distinguish between co-
crystals and salts (Childs et al., 2007). Therefore, co-crystals and salts can be considered 
as species which exist at either end of a continuum of multicomponent crystal structures 
(Stahly, 2007). 
 
An area of research which has found particular interest, has been the co-crystallization of 
amino acid compounds with carboxylic acids, where drug company researchers have 
made use of carboxylic acids which are on the FDA’s  Generally Recognized as 
Safe(GRAS) list (www.cfsan.fda.gov/~rdb/opagras1.html, 9/01/2008). Some examples of 
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acids which have been used include oxalic acid, benzoic acid, tartaric acid, formic acid, 
acetic acid and maleic acid.  In the case of the amino acids L- and DL-arganine, lysine 
and histidine, these have been co-crystallized with a number of carboxylic acids including 
tartaric acid (Selvaraj et al., 2007),  formic acid (Suresh et al., 1995), dicarboxylic oxalic 
acid (Chandra et al., 1998) and malonic acid (Saraswathi et al., 2002). Other examples 
include the co-crystallization of L-leucine (Rajagopal et al., 2003) and bis-(DL-aspartic 
acid) (Alagar et al., 2003) with oxalic acid. 
 
From the research done on the above co-crystallization examples, it is evident that 
significant features in the co-crystallization of amino-carboxylic acid complexes include 
the ionization states of the individual amino and carboxylic acid compounds, the 
aggregation patterns and the stoichiometry. 
 
When examining the possibility of co-crystallization, it is necessary to examine the 
ionization states which exist at various pH values. In order to do this, the pKa values need 
to be examined, where pKa = -log Ka and Ka is the acid dissociation constant. The pKa 
value is also related to the pH value by pKa = pH – log [A-]/[AH] where AH could 
represent a group of atoms in a molecule (www.web-
books.com/moBio/Free/Ch2A4.html, 09/01/2008).  
 
In the case of amino acids, they can exist in three possible forms as indicated in figure 
5.1.1. 
 
 
 
 
 
 
                          (a)                                               (b)                                                  (c) 
Figure 5.1.1 Three possible ionization states of an amino acid, (a) zwitterionic form, (b) cationic form, (c) 
anionic form. 
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Figure 5.1.1 indicates the presence of the amino acid in a zwitterionic form, in a cationic 
form with the carboxyl group being neutral and the amino group positively charged as 
well as in an anionic form where the amino group is neutral and the carboxyl group is 
negatively charged. Each type of amino acid has pKa values which have been determined 
and are specific to that acid. 
 
In the case of carboxylic acids, they can also exist in various forms as shown in figure 
5.1.2. 
 
      
OH
O OH
O
            
O
O O
O
                 
OH
O O
O
                  
                          (a)                                            (b)                                                    (c) 
 
Figure 5.1.2 Three possible forms of a carboxylic acid, (a) neutral form, (b) carboxylate dianion, (c) semi-
carboxylate anion. 
 
Figure 5.1.2 indicates that the carboxylic acid can be neutral or exist as a carboxylate 
dianion or semi-carboxylate anion.  
 
The various forms of the amino acids and carboxylic acids are obtained by adjusting the 
pH of the solution in which the acids are dissolved. It is therefore possible to obtain a 
range of different combinations of the above forms. 
 
In this project, the possible co-crystallization of the neurotransmitter and neurotransmitter 
analogues, GABA, Gabapentin, glycine and β-alanine with oxalic acid (HO2CCO2H) 
were studied by varying the pH of equimolar, aqueous solutions of the amino acids and 
oxalic acid. Oxalic acid was chosen due to the success with which it has been co-
crystallized with amino acids as discussed above. 
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5.2 Co-crystals of Glycine and Oxalic acid 
 
5.2.1 Introduction 
 
Glycine is an amino acid which operates as an inhibitory neurotransmitter in the central 
nervous system. It functions particularly in the spinal cord, retina and brainstem. When 
the glycine receptors are activated, they cause chloride to enter the neurons via receptors, 
which causes an inhibitory postsynaptic potential (www.britannica.com, 15/06/2007). 
Three different polymorphs of glycine have been reported, namely the α form (Jonsson et 
al., 1972), β form (Drebushchak et al., 2002) and γ form (Iitaka, 1958). The protonation 
constants of glycine are approximately 2.34 and 9.6 
(www.research.chem.psu.edu/brpgroup/pka_compilation.pdf, 07/10/2007) and it can 
therefore exist in three different ionization states. A plot of the calculated molar fractions 
of glycine (determined from the protonation constants) against the pH, gives an indication 
of the regions in which each different ionization state occurs (figure 5.2.1). 
 
Figure 5.2.1 Speciation diagram of glycine. 
Oxalic acid has pKa values of approximately 1.25 and 4.14 
(www.research.chem.psu.edu/brpgroup/pka_compilation.pdf, 07/10/2007) and it can also 
exist in three different ionization states. Again, a plot of the calculated molar fraction 
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against pH indicates the regions in which the different forms of oxalic acid exist (figure 
5.2.2).   
Figure 5.2.2 Speciation diagram of oxalic acid. 
 
The curve in figure 5.2.2 indicates that oxalic acid is primarily found in its neutral state 
below a pH of 1.25, its semi-carboxylate state between 1.25 and 4.14 and as a carboxylate 
dianion above 4.14. 
 
Therefore, in the different pH ranges, different combinations of the two compounds 
would be present. At a pH of approximately 3, glycine can exist as a mixture of the 
zwitterionic and protonated forms and oxalic acid exists as the semi-carboxylate anion. 
For a pH of 6, glycine is still in the zwitterionic form; however oxalic acid exists as the 
carboxylate dianion.  Finally, at a pH of 12, glycine exists as an anion and oxalic acid 
exists as the carboxylate dianion. 
 
5.2.2 Experimental 
 
Equimolar amounts of glycine (Sigma Aldrich) and oxalic acid were dissolved in 
deionised water at room temperature. The solution was then adjusted to the desired pH 
using 1M hydrochloric acid and 2M sodium hydroxide solutions. Solutions of the 
compounds were adjusted to pH 3, 6 and 12. The pH values were estimated using 
indicator paper. The solutions were then placed into vials and left in a fume hood in order 
for open-air evaporation to take place.  
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5.2.3 X-ray Powder Diffraction 
 
The products which formed from open-air evaporation were ground up and tested using 
X-ray powder diffraction.  The powder diffraction patterns obtained for pH 3, 6 and 12 
were compared with diffraction patterns of the original glycine and oxalic acid materials 
(figure 5.2.3). 
 
Figure 5.2.3 X-ray powder diffraction patterns of glycine-oxalic acid at pH 3, 6 and 12 compared with 
patterns of the starting materials. 
 
The above comparison indicates that there are differences between the glycine-oxalic acid 
patterns and the patterns of the starting materials. This indicates that the substances 
formed at the various pH values have different crystalline phases, however, they cannot 
be fully characterised as only pH 6 yielded single crystals. Therefore, they could be 
polymorphs, solvates, salts, co-crystals or hydrates. Through a comparison of the reduced 
unit cell parameters, the single crystals obtained at pH 6 were found to be sodium oxalate 
crystals.  
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5.2.4 Discussion and Conclusion 
 
Although single crystals could not be obtained, it was evident from a comparison of the 
powder diffraction patterns, that different crystalline phases were formed. The structures 
of glycinium oxalate (Nandhini et al., 2001) and bis-glycinium oxalate (Chitra et al., 
2007) co-crystals have been reported. The reported method used for the formation of the 
glycinium oxalate crystals is very similar to the method attempted; however a comparison 
of the patterns obtained for pH 3, 6 and 12 with the calculated patterns for the reported 
structures, showed a number of differences. Therefore, the forms obtained are most likely 
not the co-crystal, but rather other possible forms of glycine or oxalic acid.  
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5.3 Co-crystals of GABA and Oxalic acid 
 
5.3.1 Introduction 
 
The protonation constants of the inhibitory neurotransmitter GABA are 4.23 and 10.43 
(www.research.chem.psu.edu/brpgroup/pka_compilation.pdf, 07/10/2007) and it can 
therefore also exist in three different ionization states. A plot of the calculated molar 
fractions versus the pH for GABA gives an indication of the pH regions in which the 
different forms exist (figure 5.3.1). 
 
Figure 5.3.1 Speciation diagram of GABA. 
 
At a pH of approximately 4, GABA exists as a mixture of the zwitterionic and protonated 
forms, while oxalic acid exists in the semi-carboxylate anion form. For a pH of 6, GABA 
is in the zwitterionic form and oxalic acid exists as the carboxylate dianion. Finally, at a 
pH of 10 GABA exists as a mixture of zwitterions and anions, while oxalic acid exists as 
the carboxylate dianion. 
 
 
 
  72 
5.3.2 Experimental 
 
Equimolar amounts of GABA (Sigma Aldrich) and oxalic acid were dissolved in 
deionised water at room temperature. The solution was then adjusted to the desired pH 
using 1M hydrochloric acid and 2M sodium hydroxide solutions. Solutions of the 
compounds were adjusted to pH values of approximately 4, 6 and 10. The pH values were 
estimated using indicator paper. The solutions were then placed into vials and left in a 
fume hood in order for open-air evaporation to take place. For the solutions of pH 4 and 
10, no suitable crystals were formed. In the pH 6 solution, large crystals of oxalic acid 
were initially produced, however, when these crystals were removed, crystals of a 
different morphology began to form in the vial. 
 
5.3.3 Microscopic analysis of crystals formed 
 
The crystals which formed after the removal of the large oxalic acid crystals were 
examined and images were taken using an optical Micro Met Scientific microscope with 
a magnification of 45x. This allowed for the morphology of the crystals to be examined. 
Figure 5.3.2 shows the images of the crystals.  
 
Figure 5.3.2 Optical microscope images of crystals formed from a pH 6 solution at 45x magnification. 
 
As indicated from the images in figure 5.3.2, the crystals are very small (0.30 x 0.24 x 
0.20mm), however, suitable crystals could be isolated for analysis.  
  73 
5.3.4 X-ray Powder diffraction 
 
X-ray powder diffraction patterns were recorded for the substances obtained at pH 4, 6 
and 10. These were compared with the patterns of the original starting materials as well 
as an additional pattern of a tetragonal GABA polymorph (Dobson et al., 1996). Figure 
5.3.3 shows the overlapping of the patterns. 
Figure 5.3.3 X-ray powder diffraction patterns of the products obtained at pH 4, 6 and 10, compared with 
the patterns of the starting materials and an additional known GABA polymorph. 
 
The above comparison indicates that the powder patterns of crystals grown at pH 4 and 6 
are very similar; however they do not correspond to any of the patterns for the pure 
starting materials. The pattern for pH 10 appears to be very different from the other 
patterns. Therefore, it is evident that different crystalline forms have been produced. At 
pH 6, single crystals were obtained and could be further characterised.  
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5.3.5 X-ray Single Crystal Diffraction 
The block shaped crystals which were formed at pH 6, were examined by X-ray single 
crystal diffraction at 25°C on the Bruker, SMART 1K CCD area detector diffractometer. 
The crystallographic data is presented in table 5.3.1 below. 
Table 5.3.1: Crystallographic data for GABA-oxalic acid crystals. 
Formula (C4 H10 N O2), (C2 O4) 
Formula Weight 200.14g/mol 
Temperature 298(2)K 
Crystal System Monoclinic 
Space Group P21/C 
Description Colourless, blocks 
Unit cell dimensions a = 7.4755(9)Å 
 b = 10.2973(13)Å 
 c = 9.8115(12)Å 
 α = 90° 
 β =108.477(3)° 
 γ = 90° 
Volume V = 716.33(15)Å3 
Z 4 
Density 1.374g/cm-3 
Absorption coefficient 0.119mm-1 
Θ range for data col. 2.9-28.0° 
Reflections collected 4705 
Independent reflect. 1722 
Final R indices 0.0388 
The molecular conformational diagram obtained through X-ray single crystal diffraction 
and the numbering scheme for the GABA-oxalic acid conformation is shown in figure 
5.3.4. 
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Figure 5.3.4 Ortep diagram of the molecular conformation of the GABA-oxalic acid co-crystal, with the 
displacement ellipsoids at a 50% probability level. 
The single crystal structure analysis shows that the crystals obtained at a pH of 6 are in 
fact the co-crystal of GABA and oxalic acid. A visual comparison of the molecular 
conformation of the GABA molecule within this co-crystal and the GABA molecules 
discussed in chapter 3, shows that there are significant differences. Structurally, the most 
closely related GABA molecule is the monoclinic GABA; however, the presence of the 
oxalic acid molecule has a large effect on altering the conformation of the GABA 
molecule within the co-crystal. The GABA molecule in this case is also protonated as 
opposed to being a zwitterion or anion. The oxalic acid appears as a dianion species and 
has a slightly elongated C-C bond length of 1.56Å. 
The unit cell of this co-crystal is shown in figure 5.3.5. 
  76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.5 Unit cell of the GABA-oxalic acid co-crystal. 
 
There are 4 GABA molecules and 0.25 x 8 = 2 oxalate dianions within the unit cell. 
Therefore this is a 2:1 GABA-oxalic acid co-crystal with the formula 2(C4 H10 N O2), (C2 
O4).  
 
5.3.6 Hydrogen bonding 
 
The co-crystal of GABA-oxalic acid has an extensive hydrogen bonding network due to 
the presence of the NH3
+ and COOH groups on the GABA molecules and the COO- 
groups of the oxalate dianion. The numbering scheme of the hydrogen atoms present on 
the GABA molecule is given in figure 5.3.6.  
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Figure 5.3.6 Diagram indicating the numbering scheme of the hydrogen atoms present on the GABA 
molecule. 
 
Each NH3
+ group is involved in five hydrogen bonding interactions, where four of the 
interactions are with neighbouring oxalate dianion molecules and one of the interactions 
is with a neighbouring GABA molecule. Atom H1 acts as a bifurcated hydrogen bond 
donor and interacts with both the O3 and O4 atoms on a single neighbouring oxalate 
dianion ie. H1---O4 = 1.94Å and H1---O3 = 2.63Å. These lengths show that the H1---O4 
interaction is a relatively strong interaction, whereas the H1---O3 bond would be a very 
weak hydrogen bonding interaction. Atom H2 acts as a single hydrogen bond donor and 
interacts with an O3 atom on a different neighbouring oxalate dianion to the one with 
which H1 interacted. The hydrogen bond length for the interaction is H2---O3 = 1.94Å.  
Atom H3 also acts as a bifurcated hydrogen bond donor and interacts with O3 on the 
same oxalate dianion as mentioned for the H1 interactions. It also interacts with O2 on a 
neighbouring GABA molecule. The hydrogen bond lengths are H3---O2 = 2.05Å and H3-
--O3 = 2.68Å. Again, there is a strong interaction with O2 on a neighbouring GABA 
molecule, but the interaction with O3 on the oxalate dianion molecule is very weak.  
 
Atom H10 which is part of the OH group of the GABA molecule is a single hydrogen 
bond donor which also interacts with an O4 atom on a different oxalate dianion. The 
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hydrogen bond length is H10---O4 = 1.73Å. When compared with the other hydrogen 
bonding interactions, this is a very strong interaction.  
 
A summary of the hydrogen bonding is presented in table 5.3.2. 
 
Table 5.3.2: Hydrogen bonding parameters for the GABA-oxalic acid co-crystal(Å, °). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The bond length H3---O3 = 2.68Å from N1-H3---O3 is regarded as being too long to be a hydrogen 
bond. It can only be classed as a weak hydrogen interaction.  
 
Each GABA molecule interacts with three different oxalate dianion molecules and two 
different neighbouring GABA molecules as shown in figure 5.3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
D-H---A D-H H---A D---A D-H---A 
N1-H1---O4 0.89 1.94 2.8250(17) 171 
N1-H1---O3 0.89 2.63 3.0592(16) 111 
N1-H2---O3 0.89 1.94 2.8096(16 164 
N1-H3---O2 0.89 2.05 2.8961(17) 158 
O1-H10---O4 0.89 1.73 2.5474(14) 175 
N1-H3---O3 0.89 2.68 3.0592(16) 107 
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Figure 5.3.7 Hydrogen bonding interactions between GABA and oxalic acid. 
 
In the hydrogen bonding network, the GABA molecules interact with each other to form 
a chain along the b-axis, as indicated in figure 5.3.8.  
 
Figure 5.3.8 Hydrogen bonds linking the GABA molecules along the b-axis in the hydrogen bonding 
network. 
 
These chains are then linked through various hydrogen bonding interactions with the 
oxalate dianion molecules.  
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The hydrogen bonding network can be further characterised by examining the graph sets 
present in the network. The first and second level hydrogen bond motifs which are 
present for the four strong hydrogen bonds were determined by RPLUTO (Motherwell et 
al., 1999). A summary of the main graph sets is shown in matrix form in table 5.3.3 
which corresponds to figure 5.3.9. 
 
Table 5.3.3: Matrix of selected graph sets for the hydrogen bonding of the GABA-
oxalic acid co-crystal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.9 The letters a - d refer to the four strongest individual hydrogen bonds which are present, 
where some of the first and second level graph set motifs resulting from these bonds are indicated in table 
5.3.3 above. The single red dots refer to the oxygen atoms where the remainder of the molecule has been 
deleted for visual clarity.                                                       
 a b c d 
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2D  - - - 
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2C  )6(
2
2D  - - 
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1
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Figure 5.3.9 shows the strongest hydrogen bonds present for the GABA-oxalic acid 
structure. The figure also shows the different ways in which the GABA molecules are 
linked to each other and to the oxalic acid molecules. There are two weaker hydrogen 
bonding interactions (N1-H3-O3 and N1-H1-O3) which do not appear in figure 5.3.9, but 
are listed in table 5.3.2. These additional hydrogen bonds would cause the hydrogen 
bonding network to be more extensive and therefore, the large number and variety of 
graph sets for this 2:1 GABA-oxalic acid co-crystal would have the effect of greatly 
increasing the stability of the compound.  
 
5.3.7 Thermal Analysis 
 
The melting point of the GABA-oxalic acid co-crystal was initially determined by hot 
stage microscopy and this value was verified by running a DSC scan on a ground up 
sample of the co-crystal formed at pH 6. From microscopy, the melting point was 
determined to be approximately 159ºC.  The DSC curve of the 2:1 GABA-oxalic acid co-
crystals is shown in figure 5.3.10. 
Figure 5.3.10 DSC plot of heat flow (mW) vs. temperature (°C) for the 2:1 GABA-oxalic acid co-crystals 
over the range of 25 - 350°C. 
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This curve indicates that the 2:1 co-crystal of GABA-oxalic acid melts at 159.3°C. This 
value is very close to the melting point obtained by hot stage microscopy.  The melting 
points of the starting materials, GABA and oxalic acid are approximately 206°C and 
101°C respectively.  Therefore, the melting point of this co-crystal is significantly 
different from that of the starting materials, indicating that it is a completely different 
crystalline phase. The DSC plot also indicates that no additional phase changes take place 
for these crystals. 
 
5.3.8 Discussion and Conclusion 
 
The X-ray powder and single crystal diffraction as well as thermal analysis, clearly 
indicate that a co-crystal of GABA and oxalic acid has been formed. The co-crystals were 
formed at a pH of approximately 6. The conformational diagram shows that within the 
co-crystal, GABA is protonated and oxalic acid exists as a carboxylate dianion. The 
morphology, powder pattern, melting point and the molecular conformation show that 
this crystalline material is significantly different from the starting materials.  
 
The unit cell representation indicates the presence of four GABA molecules and two 
oxalic acid dianion molecules and therefore, a 2:1 co-crystal of GABA-oxalic acid has 
formed. The presence of the oxalate dianion clearly has an effect on the conformation of 
the GABA molecule as it is oriented differently from all other GABA polymorphs and 
salts. The hydrogen bonding network for this structure is extensive and is made up of 
GABA chains linked together in different ways by the oxalic acid molecules. 
 
An extensive search of the Cambridge Structural Database was carried out by using the 
fragments present in this structure, in order to determine whether the structure has been 
reported. It was found that it is not present in the database. The structure has however, 
been reported in the Angewandte Chemie International journal by M. Wenger and J. 
Bernstein (Wenger et al., 2006). A comparison of the structure presented here and the 
reported structure (CIF file was received directly from the authors) indicates that the 
structures have very similar unit cell parameters, molecular conformations and hydrogen 
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bonding networks. Therefore, this structure is the same as the published structure for this 
2:1 co-crystal of GABA-oxalic acid. 
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Chapter 5.4 Co-crystals of Gabapentin and Oxalic Acid 
 
 
5.4.1 Introduction 
 
The neurotransmitter analogue and drug compound, gabapentin has protonation constants 
of 3.7 and 10.7 (www.drugs.com/mmx/gabapentin.html, 07/10/2007) and it can therefore 
exist in three different ionization states. A plot of the calculated molar fractions versus 
the pH for gabapentin, gives an indication of the pH regions in which the different forms 
exist (figure 5.4.1). 
Figure 5.4.1 Speciation diagram for gabapentin. 
 
At a pH of 4, gabapentin exists as a mixture of zwitterionic and protonated species, while 
oxalic acid exists in the semi-carboxylate anion form. At a pH of 6 it exists in the 
zwitterionic form and oxalic acid exists as the carboxylate dianion. Finally, at pH 12 
gabapentin is found as an anion and oxalic acid exists as a carboxylate dianion. 
 
5.4.2 Experimental 
 
Equimolar amounts of gabapentin (Sigma Aldrich) and oxalic acid were dissolved in 
deionised water at room temperature. The solution was then adjusted to the desired pH 
using 1M hydrochloric acid and 2M sodium hydroxide solutions. Solutions of the 
compounds were adjusted to pH values of approximately 4, 6 and 12. The pH values were 
estimated using indicator paper. The solutions were then placed into vials and left in a 
fume hood in order for open-air evaporation to take place. For the solutions of pH 6 and 
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12, no suitable crystals were formed and a tacky, colourless layer was produced in each 
case. In the pH 4 solution, block shaped crystals were obtained. 
 
5.4.3 Microscopic analysis of the crystals formed 
 
The crystals which were formed at pH 4 were visually analyzed by capturing images 
using an optical Micro Met Scientific microscope at a 45x magnification. The images are 
shown in figure 5.4.2. 
Figure 5.4.2 Optical microscope images of the crystals formed at pH4 using a 45x magnification. 
 
These images indicate that the crystals grow outwards from a central point. Individual 
crystals, suitable for further analysis could be separated. 
 
5.4.4 X-ray Powder Diffraction 
 
Powder diffraction patterns could not be obtained for the products formed at pH 6 and 10, 
as these formed tacky substances which could not be dried out. An X-ray powder 
diffraction pattern was run on the substance formed at pH 4 as an initial test to determine 
whether a new crystalline phase had been produced. A comparison of the substance 
formed at pH 4, with the three gabapentin polymorphs mentioned in chapter 4(α-
gabapentin was the starting material) as well as oxalic acid was made. Figure 5.4.3 shows 
that overlapping of the patterns. 
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Figure 5.4.3 X-ray powder diffraction pattern comparison of the crystals obtained at pH 4 with the patterns 
of known polymorphs of gabapentin and the oxalic acid starting material. 
 
It is evident from this powder diffraction pattern comparison that the pattern for the 
substance formed at pH 4 is very different from the powder patterns of the starting 
materials and other possible polymorphs. Due to the presence of suitable crystals, further 
characterisation could be done.   
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5.4.5 X-ray Single Crystal Diffraction 
The block shaped crystals formed at pH 4, were examined by X-ray single crystal 
diffraction at -100°C on the Bruker, APEX II diffractometer. The crystallographic data is 
presented in table 5.4.1. 
Table 5.4.1: Crystallographic data for gabapentin-oxalic acid crystals. 
Formula (C9 H18 N O2), (C2 O4) 
Formula Weight 260.25g/mol 
Temperature 173(2)K 
Crystal System Monoclinic 
Space Group P21/n 
Description Colourless, blocks 
Unit cell dimensions a= 6.0941(4) 
 b = 8.1995(6) 
 c = 21.3933(15) 
 α = 90 
 β =94.2940(10) 
 γ = 90 
Volume V = 1065.99(13)A3 
Z 4 
Density 1.347g/cm-3 
Absorption coefficient 0.104mm-1 
Θ range for data col. 1.9-28.3° 
Reflections collected 8942 
Independent reflect. 2643 
Final R indices 0.039 
 
The molecular conformational diagram obtained through X-ray single crystal diffraction 
as well as the numbering scheme of the structure, is presented in figure 5.4.4. 
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Figure 5.4.4 Ortep diagram of the molecular conformation of the gabapentin-oxalic acid structure with 
displacement ellipsoids at a 50% probability level. 
The above molecular conformational diagram indicates that the crystals obtained at a pH 
of 4 are co-crystals of gabapentin and oxalic acid.  
 
 A comparison of the molecular conformation of the gabapentin molecule within this co-
crystal and the gabapentin molecules discussed in chapter 4 show that there are 
significant torsion angle differences. Table 5.4.2 indicates the differences in selected 
torsion angles. 
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Table 5.4.2: Selected torsion angles of gabapentin from the co-crystal compared 
with other gabapentin polymorphs. 
 
Torsion 
Gabapentin-oxalic 
acid co-crystal 
αa -gabapentin(°) β-gabapentin(°) γ-gabapentin(°) 
C3-C1-C5-C7 -177.67(8) -166.22(11) -65.44(18) -168.79(15) 
O1-C2-C3-C1 65.25(14) -161.36(11) 95.97(18) 151.56(14) 
C2-C3-C1-C4 174.41(8) 51.21(15) -46.40(2) 63.47(18) 
C3-C1-C4-N1 61.25(10) 60.07(14) -52.50(2) 47.74(17) 
C2-C3-C1-C5 58.24(11) -68.63(14) -168.37(14) -56.38(18) 
C2-C3-C1-C6 -62.50(12) 172.52(11) 71.87(18) -174.14(14) 
N1-C4-C1-C6 -62.02(10) -58.28(14) -173.57(14) -72.56(17) 
N1-C4-C1-C5 178.88(8) -178.71(10) 69.42(18) 168.72(13) 
 
Note: a.) Parameters taken from Ibers, (2001). 
 
Table 5.4.2 indicates that the conformation of the gabapentin molecule within this co-
crystal is different from its conformation for the three polymorphs discussed in chapter 4, 
particularly the torsions related to the positions of the NH3
+ and COOH groups.  The 
differences would be largely due to the presence of the oxalate dianion as a result of the 
interactions between these molecules. The cyclohexane ring is oriented in the chair 
conformation with the GABA fragment of the gabapentin, oriented in a trans-like 
configuration. The gabapentin molecule is also protonated in this co-crystal with the 
oxalic acid being in a dianion form. The oxalic acid in this co-crystal also has a slightly 
elongated C-C bond length of 1.56Å. 
 
The unit cell of the gabapentin-oxalic acid co-crystal is shown in figure 5.4.5. 
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Figure 5.4.5 Unit cell of the gabapentin-oxalic acid co-crystal. 
 
There are 4 gabapentin molecules and ((0.25 x 4) + (0.5 x 2)) = 2 oxalate dianion 
molecules. Therefore, this is a 2:1 gabapentin-oxalic acid co-crystal with the formula 
2(C9 H18 N O2), (C2 O4). 
 
5.4.6 Hydrogen Bonding 
 
The co-crystal of gabapentin-oxalic acid has an extensive hydrogen bonding network 
again due to the presence of the NH3
+ and COOH groups on the GABA molecules and 
the COO- groups of the oxalate dianion. The numbering scheme of the hydrogen atoms 
present on the gabapentin molecule is given in figure 5.4.6. 
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Figure 5.4.6 Numbering scheme for the hydrogen atoms present on the gabapentin molecule. 
 
Each NH3
+ group on the gabapentin molecule has six hydrogen bonding interactions 
where four interactions are with neighbouring oxalate dianion molecules and the other 
two are with neighbouring gabapentin molecules. Atom H16 acts as a bifurcated 
hydrogen donor and interacts with both the O3 and O4 atoms on a single neighbouring 
oxalate dianion ie. H16---O3 = 2.40Å and H16---O4 = 1.88Å. Therefore, the H16---O4 
interaction is the stronger of the interactions. Atom H17 interacts with an O1 and O2 
atom on different gabapentin molecules. The interaction of H17 with O1 has a hydrogen 
bond length of H17---O1= 2.34Å. The other interaction that the H17 atom has is with the 
O2 atom of the OH group. This is a very weak interaction and has the hydrogen bond 
length H17---O2 = 2.63Å.  Atom H18 also acts as a bifurcated hydrogen bond donor and 
interacts with two different O3 atoms on different oxalate dianion molecules. The one 
hydrogen bonding interaction H18---O3 = 1.90Å is a strong hydrogen bond, however, the 
interaction of H18 with the other O3 atom (the same atom with which H16 interacts) is 
very weak and the hydrogen bond length of H18---O3 = 2.690Å is too long to be 
classified as a typical hydrogen bond. It is rather a weak hydrogen interaction.  
 
Atom H1 which is part of the OH group of gabapentin is a single hydrogen bond donor. It 
forms a hydrogen bond with an O4 atom on a neighbouring oxalate dianion.  The 
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hydrogen bond length is H1---O4 = 1.74Å. This is the strongest hydrogen bonding 
interaction present within the network. 
 
A summary of the hydrogen bonding is presented in table 5.4.3. 
 
Table 5.4.3: Hydrogen bonding parameters of the gabapentin-oxalic acid co-crystal 
(Å, °). 
 
 
 
 
 
 
 
   
 
Each gabapentin molecule interacts with three different oxalate dianion molecules and 
four different neighbouring gabapentin molecules as shown in figure 5.4.7 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.7 Hydrogen bonding interactions between gabapentin and oxalic acid. 
D-H---A D-H H---A D---A D-H---A 
N1-H16-O4 0.91 1.88 2.767(11) 164 
N1-H16-O3 0.91 2.40 2.890(11) 114 
N1-H17-O1 0.91 2.34 3.039(11) 134 
N1-H17-O2 0.91 2.63 3.136(11) 116 
N1-H18-O3 0.91 1.90 2.781(10) 161 
O2-H1-O4 0.84 1.74 2.553(10) 164 
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In the hydrogen bonding network, the gabapentin molecules interact with each other to 
form a chain along the b-axis. This is indicated in figure 5.4.8.  
 
 
 
Figure 5.4.8 Hydrogen bonds linking the gabapentin molecules along the b-axis in the hydrogen bonding 
network. 
 
These chains are then linked through various hydrogen bonding interactions with the 
oxalate dianion molecules.  
 
The hydrogen bonding network can further be characterised by examining the graph sets 
present in the network. The first and second level hydrogen bond motifs which are 
present for the five strong hydrogen bonds were determined by RPLUTO (Motherwell et 
al., 1999). A summary of the main graph sets is shown in matrix form in table 5.4.4 
which corresponds to figure 5.4.9.  
 
Table 5.4.4: Matrix of selected graph sets for the hydrogen bonding of the 
gabapentin-oxalic acid co-crystal. 
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Figure 5.4.9 The letters a - e refer to five individual hydrogen bonds which are present, where some of the 
first and second level graph set motifs resulting from these bonds are indicated in table 5.4.4. The single red 
dots refer to the oxygen atoms where the remainder of the molecule has been deleted for visual clarity. 
Only a portion of the )7(11C  chain motif is present. 
 
Figure 5.4.9 shows the extensive hydrogen bonding present for the gabapentin-oxalic acid 
structure. The figure also shows the different ways in which the gabapentin molecules are 
linked to each other and to the oxalic acid molecules. The large number and variety of 
graph sets for this 2:1 gabapentin-oxalic acid co-crystal would have the effect of greatly 
increasing the stability of the compound.  
 
5.4.7 Thermal Analysis 
 
   
The melting point of the 2:1 gabapentin-oxalic acid co-crystal was initially determined by 
hot stage microscopy and this value verified by running a DSC scan. The melting point 
was determined to be approximately 157.5ºC from hot stage microscopy.  The DSC of the 
2:1 gabapentin-oxalic acid co-crystals produced the curve shown in figure 5.4.10. 
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Figure 5.4.10 DSC curve of heat flow (mW) vs. temperature (°C) for the 2:1 gabapentin-oxalic acid co-
crystals over the range of 25-200°C. 
 
This curve shows a melting point of 158.2°C which is close to the value obtained from 
hot stage microscopy. The melting points of the starting materials, gabapentin and oxalic 
acid are 161°C and 101°C respectively. The plot also indicates that the melting of the 
crystalline substance is the only phase transition which takes place.  
 
5.4.8 Discussion and Conclusion 
 
Through visual examination of these crystals as well as the recording of an X-ray powder 
diffraction pattern, the crystalline substance which formed at pH 4 was found to be 
different from the starting materials and other gabapentin polymorphs, therefore 
indicating that a different crystalline phase had been formed. X-ray single crystal 
diffraction indicated that the crystalline phase is in fact the gabapentin-oxalic acid co-
crystal. For these co-crystals gabapentin is protonated while oxalic acid is in the 
carboxylate dianion form. 
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The unit cell representation indicates the presence of four gabapentin molecules and two 
oxalic acid dianion molecules. Therefore, a 2:1 co-crystal of gabapentin-oxalic acid has 
formed. Again, as in the case of the GABA-oxalic acid co-crystal, the presence of the 
oxalate dianion clearly has an effect on the conformation of the gabapentin molecule as it 
has a very different conformation from all other gabapentin polymorphs and analogues. 
The hydrogen bonding network for this structure is also very extensive, indicated by a 
range of different graph sets. It is made up of gabapentin chains extended along the b-axis 
and linked together in different ways by the oxalate dianions. 
 
The Cambridge Structural Database was searched in attempts to find out whether the 2:1 
gabapentin-oxalic acid co-crystals had been previously reported. The structure of this co-
crystal was not found and it has not yet been published and is therefore novel*. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* However, it is noted that after a private communication from Prof. J. Bernstein to Prof. D.C. Levendis, it 
appears that Wenger M. & Bernstein J. have recently submitted a paper on the same structure. 
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Chapter 5.5 Co-crystals of β-alanine and Oxalic acid 
 
5.5.1 Introduction  
 
β-alanine is the only beta amino acid which occurs naturally. It is a non-essential amino 
acid which can be found naturally in the body as well as in protein foods. The structure of 
β-alanine is closely related to the structure of the neurotransmitter GABA, where it 
simply contains one less carbon atom in the backbone.  
 
The protonation constants of β-alanine are approximately 3.55 and 10.19 
(www.research.chem.psu.edu/brpgroup/pka_compilation.pdf, 07/10/2007) and it can 
therefore exist in three different ionization states. A plot of the calculated molar fractions 
of β-alanine (determined from the protonation constants) against the pH, indicates the 
regions in which the different ionization states occur (figure 5.5.1). 
Figure 5.5.1 Speciation diagram of β-alanine. 
 
At a pH of 3, β-alanine can exist as a mixture of zwitterionic and protonated species 
while oxalic acid exists in the semi-carboxylate anion form. For a pH of 6, β-alanine is a 
zwitterion and oxalic acid is in the carboxylate dianion form. At a pH of 12, β-alanine 
exists as an anion and oxalic acid again has the carboxylate dianion form.  
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5.5.2 Experimental 
 
Equimolar amounts of β-alanine (Sigma Aldrich) and oxalic acid were dissolved in 
deionised water at room temperature. The solution was then adjusted to the desired pH 
using 1M hydrochloric acid and 2M sodium hydroxide solutions. Solutions of the 
compounds were adjusted to pH values of approximately 3, 6 and 12. The pH values were 
estimated using indicator paper. The solutions were then placed into vials and left in a 
fume hood in order for open-air evaporation to take place. For the solutions at pH 6 and 
12, no suitable crystals were formed for X-ray single crystal diffraction analysis. In the 
pH 3 solution, block shaped crystals were obtained. 
 
5.5.3 Microscopic analysis of the crystals formed 
 
The crystals, which were formed at pH 3, were visually analyzed using an optical Micro 
Met Scientific microscope at a magnification of 45x. The images are shown in figure 
5.5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.2 Optical microscope images of the crystals formed at pH 3 using a 45x magnification. 
 
These images indicate that the crystals obtained are large blocks and suitable for X-ray 
single crystal diffraction analysis. 
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5.5.4 X-ray Powder diffraction 
 
X-ray powder diffraction patterns for the three samples obtained at the pH values of 3, 6 
and 12 were recorded in order to test for the presence of different crystalline phases when 
compared with the β-alanine and oxalic acid starting materials. Figure 5.5.3 shows the 
overlap of the powder diffraction patterns using Winplotr (Roisnel et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.3 X-ray powder diffraction pattern comparison of the products obtained at the pH values of 3, 6 
and 12 with the patterns of the starting materials, β-alanine and oxalic acid. 
 
This comparison shows that the substances produced at pH 6 and 12 and the β-alanine 
powder diffraction patterns are all similar. However, the powder pattern of the pH 3 
product is different from the other patterns. This indicates the presence of a different 
crystalline phase which can be further characterised by X-ray single crystal diffraction. 
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5.5.5 X-ray Single Crystal Diffraction 
The block shaped crystals formed at pH 3, were examined by X-ray single crystal 
diffraction at 25°C on the Bruker, SMART 1K CCD area detector diffractometer. The 
crystallographic data is presented in table 5.5.1. 
Table 5.5.1: Crystallographic data for the β-alanine-oxalic acid-water co-crystal. 
Formula (C3 H8 N O2),(C2 O4 H),(H2O) 
Formula Weight 376.28g/mol 
Temperature 298(2)K 
Crystal System Monoclinic 
Space Group C2/c 
Description Colourless, blocks 
Unit cell dimensions a= 22.419(5) 
 b = 5.6992(11) 
 c = 14.036(3) 
 α = 90 
 β =115.394(4) 
 γ = 90 
Volume V = 1620.1(6)A3 
Z 4 
Density 1.543g/cm-3 
Absorption coefficient 0.145mm-1 
Θ range for data col. 2.0-27.0° 
Reflections collected 4882 
Independent reflect. 1769 
Final R indices 0.045 
The molecular conformational diagram obtained through X-ray single crystal diffraction 
as well as the numbering scheme for this structure, is presented in figure 5.5.4. 
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Figure 5.5.4 Ortep diagram of the molecular conformation of the β-alanine-oxalic acid-water structure with 
displacement ellipsoids at a 50% probability level. 
It is evident from figure 5.5.4 that the crystals obtained at pH 3 are co-crystals of β-
alanine, oxalic acid and water. By a comparison with other β-alanine conformations, it is 
evident that the molecular conformation of the β-alanine molecule is greatly affected by 
the presence of the oxalic acid and water molecules within this co-crystal. This would be 
due to the extensive hydrogen bonding interactions which are present between the three 
molecules. The β-alanine molecules in this case exist in a cationic form with the carboxyl 
group being neutral and the amino group positively charged. The oxalic acid molecule is 
a semi-oxalate anion. 
 
The unit cell of the β-alanine-oxalic acid-water co-crystal is shown in figure 5.5.5. 
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Figure 5.5.5 Unit cell of the β-alanine-oxalic acid-water co-crystal. 
 
There are 8 β-alanine molecules, ((8 x 0.5) + 4) = 8 semi-oxalate anions and ((4 x 0.5)+2) 
= 4 water molecules. Therefore, this is a 2:2:1 β-alanine-oxalic acid-water co-crystal with 
the formula 2(C3 H8 N O2), 2(C2 H O4), H2O. 
 
5.5.6 Hydrogen bonding 
 
The co-crystal of β-alanine-oxalic acid-water has an extensive hydrogen bonding network 
due to the presence of the NH3
+ and COOH groups on the β-alanine molecules and the 
COO- and COOH groups of the semi-oxalate anion as well as the H2O molecule. The 
numbering scheme of the hydrogen atoms present on the molecules in the β-alanine-
oxalic acid-water co-crystal is given in figure 5.5.6. 
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Figure 5.5.6 Numbering scheme for the hydrogen atoms present on the molecules within the β-alanine-
oxalic acid-water co-crystal. 
 
Each NH3
+ group is involved in four hydrogen bonding interactions, where three of the 
interactions are with neighbouring oxalate dianion molecules and one of the interactions 
is with a neighbouring water molecule. Atom H1 acts as a bifurcated hydrogen bond 
donor and interacts with both the O4 and O6 atoms on a single neighbouring semi-oxalate 
anion ie. H1---O4 = 2.65Å and H1---O6 = 2.02Å. These two hydrogen bonding 
interactions are relatively weak. Atom H3 acts as a single hydrogen bond donor and 
interacts with an O7 atom on a neighbouring water molecule. The hydrogen bond length 
for the interaction is H3---O7 = 1.90Å (O7 has two different H3 atoms from different 
molecules interacting with it).  Atom H2 acts as a single hydrogen bond donor and 
interacts with O5 on a neighouring semi-oxalate anion. The hydrogen bond length is H2--
-O5 = 2.06Å. 
 
Atom H8, which is part of the OH group on the β-alanine molecule, interacts with O2 on 
a neighbouring β-alanine molecule. This interaction forms a dimer which is shown in 
figure 5.5.7. 
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Figure 5.5.7 Hydrogen bonding interaction O1-H8---O2 forming a dimer. 
 
The hydrogen bonding interaction has a length of H8---O2= 1.73Å, which is a relatively 
strong hydrogen bond. Atom H9 which is part of the OH group on the oxalate anion 
interacts with O6 on a neighbouring semi-oxalate anion (the same anion with which H1 
interacted). The hydrogen bonding interaction has a length of H9---O6= 1.62Å and is 
very strong. Finally, atom H10, attached to the water molecule, interacts with O5 on a 
neighbouring semi-oxalate anion and has a bond length of H10---O5= 1.86Å. 
 
A summary of the hydrogen bonding is presented in table 5.5.2. 
 
Table 5.5.2: Hydrogen bonding parameters of the β-alanine-oxalic acid-water co-
crystal(Å, °). 
  
 
 
 
 
 
 
 
D-H---A D-H H---A D---A D-H---A 
N1-H1-O6 0.89 2.02 2.852(2) 156 
N1-H1-O4 0.89 2.65 3.274(2) 128 
N1-H2-O5 0.89 2.06 2.866(2) 151 
N1-H3-O7 0.89 1.90 2.790(2) 174 
O1-H8-O2 0.93 1.73 2.663(2) 175 
O3-H9-O6 0.98 1.62 2.584(2) 171 
O7-H10-O5 0.88 1.86 2.717(2) 166 
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Each β-alanine molecule interacts with two different oxalate anion molecules, one 
different neighbouring β-alanine molecule and one water molecule as shown in figure 
5.5.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.8 Hydrogen bonding interactions amongst the β-alanine, oxalic acid and water molecules. 
 
Each semi-oxalate anion interacts with two β-alanine, two semi-oxalate anions and one 
water molecule, while each water molecule interacts with two β-alanine molecules and 
two semi-oxalate anions. 
 
The hydrogen bonding network can be effectively characterised by examining the graph 
sets which are involved. The first and second level hydrogen bond motifs which are 
present for the seven hydrogen bonds were determined by RPLUTO (Motherwell et al., 
1999). A summary of the main graph sets is shown in matrix form in table 5.5.3 which 
corresponds to figure 5.5.9. 
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Table 5.5.3: Matrix of selected graph sets for the hydrogen bonding of the β-alanine-
oxalic acid-water co-crystal. 
 
 
 
 
 
 
 
 
 
Figure 5.5.9 The letters a – f refer to the six strongest individual hydrogen bonds which are present, where 
some of the first and second level graph set motifs resulting from these bonds are indicated in table 5.5.3.    
                                                        
Figure 5.5.9 shows the extensive hydrogen bonding present for the β-alanine-oxalic acid-
water co-crystal. There is also an additional weaker hydrogen bond (N1-H1-O4) which is 
not shown in this diagram, but is recorded in table 5.5.2.  Figure 5.5.9 also shows the 
different ways in which the β-alanine, semi carboxylate anion and water molecules are 
linked to each other. The large number and variety of graph sets for this structure would 
have the effect of increasing the stability of the compound.  
 
 
 
 a b c d e f 
a )8(22R  - - - - - 
b )15(
3
3D  )2(
1
1D  - - - - 
c )14(
2
3C  )5(
2
2D  )3(
1
2D  - - - 
d - )5(22D  )4(
2
2D  )2(
1
1D  - - 
e - )11(
3
3C  - )10(
3
3D  )5(
1
1C  - 
f - )6(22C  )5(
2
2D  - )8(
2
3D  )2(
1
1D  
  107 
5.5.7 Thermal analysis 
 
Again, for these β-alanine-oxalic acid-water co-crystals, the melting point was initially 
determined by hot stage microscopy. The value obtained was approximately 166°C. This 
value was verified by running a DSC scan. The DSC scan of these co-crystals produced 
the curve shown in figure 5.5.10. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.10 DSC scan of heat flow (mW) vs. temperature (°) for the 2:2:1 β-alanine-oxalic acid-water co-
crystals over the range 25-200°C. 
 
The curve in figure 5.5.10 indicates that the co-crystals melt at 168.4°C. This value is 
similar to the value obtained by hot stage microscopy. The melting points of the starting 
materials, β-alanine and oxalic acid are 196°C and 101°C respectively. Therefore, the 
melting point of the co-crystals is significantly different from that of the starting 
materials.  
 
The DSC scan also contains two other peaks at 108.1°C and 146.6° which are different 
from the starting materials. This indicates that there are possibly phase transitions at these 
points. These possible phase transitions were further investigated by observing the 
changes which a crystal undergoes as the temperature changes. This was done under a 
microscope and snapshot images were taken at various temperatures. Figures 5.5.11 
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indicates the visible changes which the crystal undergoes at the above mentioned 
temperatures. 
 
 
 
 
 
 
 
Figure 5.5.11 Images of the β-alanine-oxalic acid-water co-crystal: a.) Room temperature b.) 110°C c.) 
147°C. 
 
From figure 5.5.11(a) and (b), it is evident that the crystal undergoes a significant colour 
change from being clear to being darkened in colour. This could represent the first phase 
transition. When the temperature is increased further, the crystal appears to melt slightly 
and then re-crystallize to form a much darker black crystal as indicated in figure 
5.5.11(c). This could possibly represent the second phase transition. When the crystal is 
heated further, it finally melts at approximately 168.4°C. The visual changes in the 
crystal could be as a result of phase transitions. They could also be due to the loss of 
water from the crystal. Single crystals of the b and c phases could not be isolated for 
analysis. 
 
5.5.8 Discussion and Conclusion 
 
Crystals were obtained at a pH of 3. The crystals obtained were compared visually in 
order to determine whether they differ in appearance. They were also examined using X-
ray powder diffraction, comparing the powder patterns to those of the starting materials 
in order to investigate the presence of a different crystalline form. The visual differences 
and the difference in the powder pattern resulted in further characterisation being done. 
Through X-ray single crystal diffraction the crystals were identified as co-crystals of β-
alanine, oxalic acid and water. Within the co-crystals, the β-alanine is in the cationic form 
and oxalic acid in the semi-carboxylate anion form. 
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The unit cell representation indicates the presence of eight β-alanine molecules, eight 
semi-oxalate anions and four water molecules, resulting in a 2:2:1 co-crystal of β-alanine-
oxalic acid-water. The presence of the semi-oxalate anions and water molecules has a 
significant effect on the conformation of the β-alanine and this would be due to the 
extensive hydrogen bonding network which is present. 
 
Within the hydrogen bonding network, there is the formation of a dimer between the β-
alanine molecules. These dimers are linked together by forming hydrogen bonds with 
neighbouring semi-oxalate anions and water molecules. The complexity of the hydrogen 
bonding network can be seen by the large number of graph sets needed to represent the 
network. 
 
The thermal analysis of the co-crystal indicated that its melting point is very different 
from the starting materials. The DSC scan also indicated the presence of possible phase 
changes which were also verified visually. These could not be explored further as single 
crystals of these phases could not be isolated. 
 
The Cambridge Structural Database was again searched in attempts to find out whether 
the 2:2:1 β-alanine-oxalic acid-water co-crystal had previously been published. It was 
found that this structure had been published in an ACTA E paper by Krishnakumar and 
co-workers (Krishnakumar et al., 2002).  The unit cell parameters, conformation and 
hydrogen bonding networks of this structure were compared with the reported structure 
and they were found to be similar. Therefore, the co-crystals grown resemble the 
published structure of β-alaninium oxalate hemihydrate. 
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Chapter 6  
Conclusion 
 
6.1 Conclusion 
 
This research project, firstly allowed for the study of the neurotransmitter γ-aminobutyric 
acid (GABA). Through the experimental method of vapour diffusion, thin needle-like 
single crystals were formed which grew from the contact line of the solution. These could 
be analysed by X-ray powder and single crystal diffraction in order to compare this form 
with the two previously reported monoclinic and tetragonal polymorphs.  The single 
crystal analysis allowed for these needle-like crystals to be identified as a hexagonal 
GABA pseudo polymorph which contains two different GABA molecules and disordered 
solvent molecules in the asymmetric unit. One type of GABA molecule (molecule 1) 
forms hexagonal channels down the c-axis and the other type of GABA molecule 
(molecule 2) forms 3-fold axis chains which coincide with 3-fold screw axis.  It was 
discovered that this form resembles the dipeptide structures reported by Görbitz et al., 
(2007), which contain hexagonally symmetric pores. The disorder of the solvent 
molecules could not be properly resolved, however, 1H NMR allowed for the solvent to 
be identified as ethanol with a 1:10 ratio of EtOH : GABA molecules in the crystals. 
 
A significant feature of this structure was found to be the release of the ethanol and other 
gases from the channels at a temperature which is significantly higher than the boiling 
temperature of ethanol. This therefore indicates the high stability of the hexagonal 
channels. 
 
Thermal analysis was also carried out for all of the GABA polymorphs and it was found 
from the calculation of the enthalpy values that the hexagonal GABA solvate is 
significantly less thermodynamically stable than the two previously reported polymorphs. 
 
A search of the Cambridge Structural Database indicates that this GABA solvate is 
unique, as it is the first single amino acid to be crystallized in this form, where there are 
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hexagonal GABA crystals containing a solvent. Further studies can be done on these 
crystals in order to examine their potential as microporous organic crystals. 
 
The study of the neurotransmitter GABA was extended to the structurally related drug 
compound gabapentin. Through different experimental methods, two unreported 
gabapentin polymorphs were obtained and compared with an existing polymorph. The 
techniques of X-ray powder and single crystal diffraction allowed for a comparison of the 
three polymorphs. The conformations of the gabapentin polymorphs showed a number of 
differences, in particular with regard to the torsion angles related to the positioning of the 
NH3
+ and COO- groups in each structure. The hydrogen bonding networks also showed 
distinct differences which could be compared using graph set notation. β-gabapentin was 
the only polymorph which contained an intramolecular hydrogen bond. 
 
A comparison of the densities and packing efficiencies of the three gabapentin 
polymorphs showed that the molecules are most efficiently packed in α-gabapentin. This 
is also the polymorph which is most easily crystallized. It is therefore evident that α-
gabapentin is the most thermodynamically stable polymorph. Thermal analysis was 
carried our for these polymorphs and it was found that β-gabapentin had an additional 
endotherm at 87.5°C and γ-gabapentin had an additional exotherm at 89°C. Further X-ray 
single crystal diffraction experiments were carried out at temperatures below and above 
the endotherm and exotherm temperatures for β-gabapentin and γ-gabapentin 
respectively, in order to examine the possibility of phase transitions. However, there were 
no significant changes in the structures. It is possible that these peaks could represent the 
small changes which occur in the structures and hydrogen bonding networks. 
 
Therefore, it is evident that two unpublished gabapentin polymorphs have been obtained 
and comparisons show significant differences amongst the three gabapentin polymorphs.  
 
Further studies were carried out on the co-crystallization of neurotransmitter amino acids 
and analogues with oxalic acid. It was discovered that the conditions under which the 
experiments are carried out is significant due to the large number of crystalline forms 
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which can be produced for a particular substance. These different crystalline forms 
include polymorphs, salts, hydrates and solvates. 
 
 It was found that in order to produce co-crystals, the ionization states of the compounds 
at different pH values need to be examined. Experiments were set up at various pH values 
for each set of compounds, however, co-crystals were only formed for GABA-oxalic acid 
at pH 6, for gabapentin-oxalic acid at pH 4 and for β-alanine-oxalic acid-water at pH 3. In 
the GABA-oxalic acid co-crystal, GABA exists as a protonated species and oxalic acid as 
a carboxylate dianion. In the gabapentin-oxalic acid co-crystal, gabapentin is protonated 
while the oxalic acid is in the carboxylate dianion form. The β-alanine-oxalic acid-water 
co-crystal was formed with the β-alanine in a cationic form and oxalic acid in the semi-
carboxylate anion form. This shows that in order for co-crystals to form, the amino acid 
needs to have an NH3
+ group and the carboxylic acid must be in an anionic form where it 
is either a semi-carboxylate anion or a carboxylate dianion.  
 
The crystal structures of the GABA-oxalic acid and gabapentin-oxalic acid co-crystals 
both have the amino acid protonated and the carboxylic acid in the carboxylate dianion 
form. The GABA-oxalic acid and gabapentin-oxalic acid co-crystals are also both present 
in the ratio of 2:1 for the amino acid: carboxylic acid molecules. The β-alanine-oxalic 
acid-water co-crystal has the amino acid in the protonated form and the carboxylic acid as 
a semi-carboxylate anion. This co-crystal has a ratio of 2:2:1 for the amino acid: 
carboxylic acid: water molecules. It is therefore a possibility that the 2:1 co-crystal of β-
alanine-oxalic acid without the presence of water could be formed if the oxalic acid were 
in the carboxylate dianion form as was the case with the other two co-crystals.  
 
It is evident for all the structures, that the presence of the oxalic acid greatly influences 
the conformation of the amino acid within the co-crystal. This would be due to the 
extensive hydrogen bonding present for all three structures. 
 
The GABA-oxalic acid and gabapentin-oxalic acid structures have similarities in there 
hydrogen bonding networks. For both the structures, the amino acid molecules hydrogen 
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bond to form chains along the b-axis. These amino acid chains are then linked by forming 
hydrogen bonds in different ways with the oxalate dianions. The network of the β-
alanine-oxalic acid-water structure is different due to the presence of the additional water 
molecule.  
 
It is therefore evident that in order to obtain amino acid: carboxylic acid co-crystals, the 
ionization states of the involved compounds at specific pH values need to be examined in 
order to predict whether they will interact in a manner in which co-crystals will form.  
 
Therefore, this research project allowed for the structural analysis and co-crystallization 
of neurotransmitter analogues. 
 
6.2 Chapter 6 Reference 
 
Görbitz, C.H. (2007). Chem. Eur. J., 13, 1022-1031. 
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Appendix 
 
1.1 γ-aminobutyric acid 
 
1.1.1.) DSC monoclinic GABA 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1 DSC curve of heat flow (mW) vs. temperature (°C) for monoclinic GABA from 30 to 280°C. 
 
1.1.2) DSC Tetragonal GABA 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.2 DSC curve of heat flow (mW) vs. temperature (°C) for tetragonal GABA from 30 to 280°C. 
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1.1.3.) Additional Crystallographic Data- Hexagonal GABA Solvate 
 
Table A1.1.1: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters for the hexagonal GABA solvate (Å2). 
 
 x y z Uiso*/Ueq Occ. (<1) 
C1 0.2522 (3) 0.2905 (3) 0.8922 (5) 0.0312 (9)  
H4 0.2481 0.3477 0.9199 0.037*  
H5 0.1882 0.2340 0.9057 0.037*  
C2 0.2856 (3) 0.2967 (3) 0.7108 (4) 0.0316 (9)  
H6 0.3489 0.3543 0.6984 0.038*  
H7 0.2928 0.2409 0.6868 0.038*  
C1X 0.056 (3) 0.097 (3) 1.123 (8) 0.17 (2)* 0.36 (5) 
C3 0.2179 (3) 0.3005 (3) 0.5831 (5) 0.0359 (9)  
H8 0.2119 0.3572 0.6060 0.043*  
H9 0.1543 0.2437 0.5978 0.043*  
C2X 0.0000 0.0000 0.54 (2) 0.200* 0.24 (5) 
C4 0.2489 (3) 0.3045 (3) 0.4013 (4) 0.0316 (9)  
C3X −0.007 (4) 0.035 (4) 0.729 (10) 0.200* 0.34 (3) 
C5 0.5796 (3) 0.4242 (3) 0.4086 (4) 0.0332 (10)  
H13 0.6415 0.4281 0.4303 0.040*  
H14 0.5870 0.4875 0.4304 0.040*  
C6 0.5510 (3) 0.3965 (3) 0.2262 (5) 0.0335 (9)  
H15 0.5330 0.3290 0.2113 0.040*  
H16 0.4941 0.4019 0.2023 0.040*  
C5X 0.008 (5) −0.061 (5) 0.577 (13) 0.200* 0.28 (4) 
C7 0.6280 (3) 0.4563 (3) 0.0991 (5) 0.0408 (10)  
H17 0.6828 0.4466 0.1180 0.049*  
H18 0.6499 0.5241 0.1213 0.049*  
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C8 0.5999 (3) 0.4365 (3) −0.0850 (4) 0.0298 (8)  
N1 0.3213 (2) 0.2831 (2) 1.0076 (3) 0.0310 (8)  
H1 0.3817 0.3271 0.9786 0.046*  
H2 0.3140 0.2241 1.0000 0.046*  
H3 0.3099 0.2938 1.1138 0.046*  
N2 0.5050 (2) 0.3517 (2) 0.5234 (3) 0.0304 (7)  
H10 0.5161 0.3747 0.6290 0.046*  
H11 0.5075 0.2971 0.5201 0.046*  
H12 0.4466 0.3396 0.4902 0.046*  
O1 0.1916 (2) 0.2972 (2) 0.2850 (3) 0.0501 (8)  
O2 0.33175 (17) 0.31598 (19) 0.3682 (3) 0.0360 (7)  
O3 0.51131 (19) 0.3909 (2) −0.1237 (3) 0.0412 (7)  
O4 0.66632 (18) 0.46627 (19) −0.1932 (3) 0.0398 (7)  
O5 −0.067 (10) −0.027 (8) 0.639 (19) 0.200* 0.10 (2) 
Note: (1) Ueq = Equivalent isotropic atomic displacement parameter; (2) Atoms C1X, C2X, C3X, C5X and 
O5 are isotropic as they are part of the disordered solvent. 
 
Table A1.1.2: Atomic displacement parameters for the hexagonal GABA 
solvate(Å2). 
 
 U
11 U22 U33 U12 U13 U23 
C1 0.035 (2) 0.031 (2) 0.031 (2) 0.0193 (19) −0.0010 (17) −0.0013 (18) 
C2 0.037 (2) 0.041 (2) 0.023 (2) 0.0241 (19) 0.0015 (18) −0.0011 (18) 
C3 0.038 (2) 0.053 (2) 0.027 (2) 0.030 (2) 0.0027 (18) 0.0018 (19) 
C4 0.039 (2) 0.039 (2) 0.022 (2) 0.023 (2) −0.0010 (18) −0.0028 (18) 
C5 0.031 (2) 0.038 (2) 0.025 (2) 0.0137 (18) −0.0016 (18) 0.0014 (19) 
C6 0.037 (2) 0.036 (2) 0.025 (2) 0.0172 (19) 0.0011 (18) 0.0010 (18) 
C7 0.035 (2) 0.049 (2) 0.032 (2) 0.016 (2) 0.0013 (19) −0.003 (2) 
C8 0.039 (2) 0.034 (2) 0.0204 (19) 0.0207 (19) −0.0013 (19) −0.0001 (18) 
N1 0.0414 (19) 0.0357 (17) 0.0204 (16) 0.0226 (15) 0.0021 (15) −0.0005 (14) 
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N2 0.0335 (18) 0.0389 (17) 0.0235 (16) 0.0217 (15) −0.0024 (14) −0.0030 (16) 
O1 0.0440 (17) 0.092 (2) 0.0259 (15) 0.0423 (17) −0.0066 (14) −0.0043 (15) 
O2 0.0304 (14) 0.0570 (17) 0.0266 (13) 0.0262 (13) 0.0023 (12) −0.0015 (13) 
O3 0.0307 (16) 0.0583 (18) 0.0296 (15) 0.0185 (14) −0.0020 (12) −0.0023 (14) 
O4 0.0345 (15) 0.0564 (18) 0.0264 (15) 0.0212 (13) 0.0035 (12) 0.0007 (13) 
 
Table A1.1.3: Bond length parameters for the hexagonal GABA solvate (Å). 
 
C1—N1 1.476 (4) C3X—C1Xvi 1.42 (6) 
C1—C2 1.510 (5) C3X—O5v 1.44 (11) 
C1—H4 0.9700 C3X—C5Xii 1.68 (9) 
C1—H5 0.9700 C3X—C1Xvii 1.69 (6) 
C2—C3 1.498 (5) C5—N2 1.480 (4) 
C2—H6 0.9700 C5—C6 1.505 (5) 
C2—H7 0.9700 C5—H13 0.9700 
C1X—C5Xi 1.07 (8) C5—H14 0.9700 
C1X—O5ii 1.26 (13) C6—C7 1.497 (5) 
C1X—C3Xii 1.42 (6) C6—H15 0.9700 
C1X—C2Xi 1.50 (9) C6—H16 0.9700 
C1X—C3Xiii 1.69 (6) C5X—C1Xix 1.07 (8) 
C1X—O5iv 1.86 (12) C5X—C3Xv 1.27 (11) 
C3—C4 1.505 (5) C5X—O5v 1.34 (12) 
C3—H8 0.9700 C5X—O5 1.62 (14) 
C3—H9 0.9700 C5X—C3Xvi 1.68 (8) 
C2X—C5Xv 1.09 (7) C7—C8 1.503 (5) 
C2X—C5X 1.09 (7) C7—H17 0.9700 
C2X—O5v 1.21 (15) C7—H18 0.9700 
C2X—O5 1.21 (15) C8—O4 1.252 (4) 
C2X—C3Xvi 1.31 (13) C8—O3 1.259 (5) 
C2X—C3Xvii 1.31 (13) N1—H1 0.8900 
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C2X—C1Xviii 1.50 (9) N1—H2 0.8900 
C2X—C1Xix 1.50 (9) N1—H3 0.8900 
C2X—C3X 1.61 (15) N2—H10 0.8900 
C2X—C3Xv 1.61 (15) N2—H11 0.8900 
C4—O1 1.257 (4) N2—H12 0.8900 
C4—O2 1.265 (4) O5—C1Xvi 1.26 (13) 
C3X—O5 1.21 (11) O5—C5Xv 1.34 (12) 
C3X—C3Xv 1.26 (8) O5—C3Xv 1.44 (11) 
C3X—C5Xv 1.27 (11) O5—C1Xviii 1.86 (12) 
C3X—C2Xii 1.31 (13)   
 
Symmetry codes: (i) −y, x−y, z+2/3; (ii) −x+y, −x, z+1/3; (iii) x−y, x, z+1/3; (iv) y, −x+y, z+2/3; (v) −x, −y, 
z; (vi) −y, x−y, z−1/3; (vii) y, −x+y, z−1/3; (viii) x−y, x, z−2/3; (ix) −x+y, −x, z−2/3. 
 
Table A1.1.4: Bond angle parameters for the hexagonal GABA solvate (°). 
 
N1—C1—C2 109.6 (3) C5Xv—C3X—O5v 73 (6) 
N1—C1—H4 109.7 C2Xii—C3X—O5v 98 (7) 
C2—C1—H4 109.7 C1Xvi—C3X—O5v 127 (7) 
N1—C1—H5 109.7 O5—C3X—C2X 48 (7) 
C2—C1—H5 109.7 C3Xv—C3X—C2X 67 (2) 
H4—C1—H5 108.2 C5Xv—C3X—C2X 42 (4) 
C3—C2—C1 113.6 (3) C2Xii—C3X—C2X 128 (3) 
C3—C2—H6 108.8 C1Xvi—C3X—C2X 103 (4) 
C1—C2—H6 108.8 O5v—C3X—C2X 46 (6) 
C3—C2—H7 108.8 O5—C3X—C5Xii 96 (8) 
C1—C2—H7 108.8 C3Xv—C3X—C5Xii 88 (4) 
H6—C2—H7 107.7 C5Xv—C3X—C5Xii 147 (7) 
C5Xi—C1X—O5ii 136 (9) C2Xii—C3X—C5Xii 40 (3) 
C5Xi—C1X—C3Xii 83 (5) C1Xvi—C3X—C5Xii 39 (3) 
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O5ii—C1X—C3Xii 53 (6) O5v—C3X—C5Xii 136 (6) 
C5Xi—C1X—C2Xi 46 (6) C2X—C3X—C5Xii 140 (5) 
O5ii—C1X—C2Xi 97 (10) O5—C3X—C1Xvii 124 (7) 
C3Xii—C1X—C2Xi 53 (5) C3Xv—C3X—C1Xvii 55 (3) 
C5Xi—C1X—C3Xiii 94 (6) C5Xv—C3X—C1Xvii 115 (4) 
O5ii—C1X—C3Xiii 56 (6) C2Xii—C3X—C1Xvii 58 (4) 
C3Xii—C1X—C3Xiii 47 (3) C1Xvi—C3X—C1Xvii 120 (5) 
C2Xi—C1X—C3Xiii 48 (5) O5v—C3X—C1Xvii 46 (6) 
C5Xi—C1X—O5iv 45 (6) C2X—C3X—C1Xvii 92 (3) 
O5ii—C1X—O5iv 126 (8) C5Xii—C3X—C1Xvii 98 (5) 
C3Xii—C1X—O5iv 93 (6) N2—C5—C6 110.4 (3) 
C2Xi—C1X—O5iv 41 (5) N2—C5—H13 109.6 
C3Xiii—C1X—O5iv 70 (5) C6—C5—H13 109.6 
C2—C3—C4 114.4 (3) N2—C5—H14 109.6 
C2—C3—H8 108.7 C6—C5—H14 109.6 
C4—C3—H8 108.7 H13—C5—H14 108.1 
C2—C3—H9 108.7 C7—C6—C5 114.9 (3) 
C4—C3—H9 108.7 C7—C6—H15 108.6 
H8—C3—H9 107.6 C5—C6—H15 108.6 
C5Xv—C2X—C5X 150 (10) C7—C6—H16 108.6 
C5Xv—C2X—O5v 89 (10) C5—C6—H16 108.6 
C5X—C2X—O5v 71 (7) H15—C6—H16 107.5 
C5Xv—C2X—O5 71 (7) C1Xix—C5X—C2X 88 (10) 
C5X—C2X—O5 89 (10) C1Xix—C5X—C3Xv 154 (8) 
O5v—C2X—O5 101 (10) C2X—C5X—C3Xv 86 (10) 
C5Xv—C2X—C3Xvi 119 (10) C1Xix—C5X—O5v 100 (8) 
C5X—C2X—C3Xvi 89 (8) C2X—C5X—O5v 59 (7) 
O5v—C2X—C3Xvi 145 (10) C3Xv—C5X—O5v 55 (6) 
O5—C2X—C3Xvi 107 (6) C1Xix—C5X—O5 131 (9) 
C5Xv—C2X—C3Xvii 89 (8) C2X—C5X—O5 48 (8) 
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C5X—C2X—C3Xvii 119 (10) C3Xv—C5X—O5 59 (6) 
O5v—C2X—C3Xvii 107 (6) O5v—C5X—O5 78 (10) 
O5—C2X—C3Xvii 145 (10) C1Xix—C5X—C3Xvi 57 (5) 
C3Xvi—C2X—C3Xvii 58 (8) C2X—C5X—C3Xvi 51 (8) 
C5Xv—C2X—C1Xviii 45 (5) C3Xv—C5X—C3Xvi 133 (6) 
C5X—C2X—C1Xviii 159 (9) O5v—C5X—C3Xvi 105 (7) 
O5v—C2X—C1Xviii 130 (6) O5—C5X—C3Xvi 76 (6) 
O5—C2X—C1Xviii 86 (5) C6—C7—C8 116.7 (3) 
C3Xvi—C2X—C1Xviii 74 (8) C6—C7—H17 108.1 
C3Xvii—C2X—C1Xviii 60 (6) C8—C7—H17 108.1 
C5Xv—C2X—C1Xix 159 (9) C6—C7—H18 108.1 
C5X—C2X—C1Xix 45 (5) C8—C7—H18 108.1 
O5v—C2X—C1Xix 86 (5) H17—C7—H18 107.3 
O5—C2X—C1Xix 130 (6) O4—C8—O3 122.9 (3) 
C3Xvi—C2X—C1Xix 60 (6) O4—C8—C7 118.1 (3) 
C3Xvii—C2X—C1Xix 74 (8) O3—C8—C7 118.9 (3) 
C1Xviii—C2X—C1Xix 127 (10) C1—N1—H1 109.5 
C5Xv—C2X—C3X 52 (9) C1—N1—H2 109.5 
C5X—C2X—C3X 98 (10) H1—N1—H2 109.5 
O5v—C2X—C3X 60 (10) C1—N1—H3 109.5 
O5—C2X—C3X 48 (9) H1—N1—H3 109.5 
C3Xvi—C2X—C3X 154 (2) H2—N1—H3 109.5 
C3Xvii—C2X—C3X 135 (3) C5—N2—H10 109.5 
C1Xviii—C2X—C3X 94 (5) C5—N2—H11 109.5 
C1Xix—C2X—C3X 138 (8) H10—N2—H11 109.5 
C5Xv—C2X—C3Xv 98 (10) C5—N2—H12 109.5 
C5X—C2X—C3Xv 52 (9) H10—N2—H12 109.5 
O5v—C2X—C3Xv 48 (9) H11—N2—H12 109.5 
O5—C2X—C3Xv 60 (10) C3X—O5—C2X 84 (10) 
C3Xvi—C2X—C3Xv 135 (3) C3X—O5—C1Xvi 70 (8) 
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C3Xvii—C2X—C3Xv 154 (2) C2X—O5—C1Xvi 149 (10) 
C1Xviii—C2X—C3Xv 138 (8) C3X—O5—C5Xv 60 (7) 
C1Xix—C2X—C3Xv 94 (5) C2X—O5—C5Xv 50 (6) 
C3X—C2X—C3Xv 46 (5) C1Xvi—O5—C5Xv 123 (10) 
O1—C4—O2 121.3 (3) C3X—O5—C3Xv 56 (8) 
O1—C4—C3 118.9 (3) C2X—O5—C3Xv 74 (10) 
O2—C4—C3 119.9 (3) C1Xvi—O5—C3Xv 77 (7) 
O5—C3X—C3Xv 72 (7) C5Xv—O5—C3Xv 96 (10) 
O5—C3X—C5Xv 65 (7) C3X—O5—C5X 93 (9) 
C3Xv—C3X—C5Xv 109 (4) C2X—O5—C5X 42 (6) 
O5—C3X—C2Xii 111 (8) C1Xvi—O5—C5X 120 (9) 
C3Xv—C3X—C2Xii 61 (4) C5Xv—O5—C5X 90 (9) 
C5Xv—C3X—C2Xii 170 (6) C3Xv—O5—C5X 48 (5) 
O5—C3X—C1Xvi 56 (7) C3X—O5—C1Xviii 94 (8) 
C3Xv—C3X—C1Xvi 78 (5) C2X—O5—C1Xviii 54 (6) 
C5Xv—C3X—C1Xvi 115 (7) C1Xvi—O5—C1Xviii 142 (8) 
C2Xii—C3X—C1Xvi 67 (3) C5Xv—O5—C1Xviii 35 (5) 
O5—C3X—O5v 89 (10) C3Xv—O5—C1Xviii 123 (10) 
C3Xv—C3X—O5v 52 (4) C5X—O5—C1Xviii 94 (7) 
 
Symmetry codes: (i) −y, x−y, z+2/3; (ii) −x+y, −x, z+1/3; (iii) x−y, x, z+1/3; (iv) y, −x+y, z+2/3; (v) −x, −y, 
z; (vi) −y, x−y, z−1/3; (vii) y, −x+y, z−1/3; (viii) x−y, x, z−2/3; (ix) −x+y, −x, z−2/3. 
 
 
Table A1.1.5: Torsion angle parameters for the hexagonal GABA solvate (°). 
 
 
N1—C1—C2—C3 177.7 (3) C1Xvi—C3X—O5—C2X −163 (9) 
C1—C2—C3—C4 −178.7 (3) O5v—C3X—O5—C2X −25 (8) 
C2—C3—C4—O1 172.4 (3) C5Xii—C3X—O5—C2X −161 (4) 
C2—C3—C4—O2 −8.3 (5) C1Xvii—C3X—O5—C2X −57 (10) 
C5Xv—C2X—C3X—O5 99 (9) C3Xv—C3X—O5—C1Xvi 87 (5) 
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C5X—C2X—C3X—O5 −82 (8) C5Xv—C3X—O5—C1Xvi −150 (8) 
O5v—C2X—C3X—O5 −145 (10) C2Xii—C3X—O5—C1Xvi 40 (8) 
C3Xvi—C2X—C3X—O5 21 (10) O5v—C3X—O5—C1Xvi 138 (8) 
C3Xvii—C2X—C3X—O5 131 (11) C2X—C3X—O5—C1Xvi 163 (9) 
C1Xviii—C2X—C3X—O5 81 (8) C5Xii—C3X—O5—C1Xvi 1(6) 
C1Xix—C2X—C3X—O5 −107 (10) C1Xvii—C3X—O5—C1Xvi 105 (8) 
C3Xv—C2X—C3X—O5 −85 (9) C3Xv—C3X—O5—C5Xv −122 (7) 
C5Xv—C2X—C3X—C3Xv −176 (8) C2Xii—C3X—O5—C5Xv −170 (6) 
C5X—C2X—C3X—C3Xv 3(6) C1Xvi—C3X—O5—C5Xv 150 (8) 
O5v—C2X—C3X—C3Xv −59 (6) O5v—C3X—O5—C5Xv −72 (5) 
O5—C2X—C3X—C3Xv 85 (9) C2X—C3X—O5—C5Xv −47 (7) 
C3Xvi—C2X—C3X—C3Xv 106 (10) C5Xii—C3X—O5—C5Xv 152 (6) 
C3Xvii—C2X—C3X—C3Xv −143 (4) C1Xvii—C3X—O5—C5Xv −104 (7) 
C1Xviii—C2X—C3X—C3Xv 166 (4) C5Xv—C3X—O5—C3Xv 122 (7) 
C1Xix—C2X—C3X—C3Xv −21 (7) C2Xii—C3X—O5—C3Xv −47 (7) 
C5X—C2X—C3X—C5Xv 179.2 (18) C1Xvi—C3X—O5—C3Xv −87 (5) 
O5v—C2X—C3X—C5Xv 117 (8) O5v—C3X—O5—C3Xv 50 (7) 
O5—C2X—C3X—C5Xv −99 (9) C2X—C3X—O5—C3Xv 75 (7) 
C3Xvi—C2X—C3X—C5Xv −78 (13) C5Xii—C3X—O5—C3Xv −86 (4) 
C3Xvii—C2X—C3X—C5Xv 33 (8) C1Xvii—C3X—O5—C3Xv 18 (9) 
C1Xviii—C2X—C3X—C5Xv −18 (6) C3Xv—C3X—O5—C5X −34 (5) 
C1Xix—C2X—C3X—C5Xv 155 (5) C5Xv—C3X—O5—C5X 88 (8) 
C3Xv—C2X—C3X—C5Xv 176 (8) C2Xii—C3X—O5—C5X −81 (8) 
C5Xv—C2X—C3X—C2Xii −176 (8) C1Xvi—C3X—O5—C5X −121 (8) 
C5X—C2X—C3X—C2Xii 3(6) O5v—C3X—O5—C5X 16 (9) 
O5v—C2X—C3X—C2Xii −59 (6) C2X—C3X—O5—C5X 41 (6) 
O5—C2X—C3X—C2Xii 85 (9) C5Xii—C3X—O5—C5X −120 (5) 
C3Xvi—C2X—C3X—C2Xii 106 (10) C1Xvii—C3X—O5—C5X −16 (11) 
C3Xvii—C2X—C3X—C2Xii −143 (4) C3Xv—C3X—O5—C1Xviii −128 (7) 
C1Xviii—C2X—C3X—C2Xii 166 (4) C5Xv—C3X—O5—C1Xviii −6(4) 
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C1Xix—C2X—C3X—C2Xii −21 (7) C2Xii—C3X—O5—C1Xviii −176 (3) 
C3Xv—C2X—C3X—C2Xii 0.000 (17) C1Xvi—C3X—O5—C1Xviii 145 (8) 
C5Xv—C2X—C3X—C1Xvi 113 (6) O5v—C3X—O5—C1Xviii −78 (5) 
C5X—C2X—C3X—C1Xvi −67 (5) C2X—C3X—O5—C1Xviii −53 (5) 
O5v—C2X—C3X—C1Xvi −130 (8) C5Xii—C3X—O5—C1Xviii 146 (4) 
O5—C2X—C3X—C1Xvi 15 (8) C1Xvii—C3X—O5—C1Xviii −110 (7) 
C3Xvi—C2X—C3X—C1Xvi 36 (11) C5Xv—C2X—O5—C3X −55 (10) 
C3Xvii—C2X—C3X—C1Xvi 146 (6) C5X—C2X—O5—C3X 101 (8) 
C1Xviii—C2X—C3X—C1Xvi 95 (3) O5v—C2X—O5—C3X 30 (4) 
C1Xix—C2X—C3X—C1Xvi −92 (5) C3Xvi—C2X—O5—C3X −171 (4) 
C3Xv—C2X—C3X—C1Xvi −70 (4) C3Xvii—C2X—O5—C3X −112 (18) 
C5Xv—C2X—C3X—O5v −117 (8) C1Xviii—C2X—O5—C3X −99 (8) 
C5X—C2X—C3X—O5v 62 (7) C1Xix—C2X—O5—C3X 124 (13) 
O5—C2X—C3X—O5v 145 (10) C3Xv—C2X—O5—C3X 56 (7) 
C3Xvi—C2X—C3X—O5v 165 (14) C5Xv—C2X—O5—C1Xvi −88 (20) 
C3Xvii—C2X—C3X—O5v −84 (6) C5X—C2X—O5—C1Xvi 68 (17) 
C1Xviii—C2X—C3X—O5v −135 (8) O5v—C2X—O5—C1Xvi −3(14) 
C1Xix—C2X—C3X—O5v 38 (8) C3Xvi—C2X—O5—C1Xvi 156 (16) 
C3Xv—C2X—C3X—O5v 59 (6) C3Xvii—C2X—O5—C1Xvi −146 (19) 
C5Xv—C2X—C3X—C5Xii 129 (8) C1Xviii—C2X—O5—C1Xvi −132 (19) 
C5X—C2X—C3X—C5Xii −52 (7) C1Xix—C2X—O5—C1Xvi 91 (23) 
O5v—C2X—C3X—C5Xii −114 (8) C3X—C2X—O5—C1Xvi −33 (15) 
O5—C2X—C3X—C5Xii 30 (8) C3Xv—C2X—O5—C1Xvi 23 (15) 
C3Xvi—C2X—C3X—C5Xii 51 (11) C5X—C2X—O5—C5Xv 156 (15) 
C3Xvii—C2X—C3X—C5Xii 162 (6) O5v—C2X—O5—C5Xv 86 (9) 
C1Xviii—C2X—C3X—C5Xii 111 (6) C3Xvi—C2X—O5—C5Xv −115 (11) 
C1Xix—C2X—C3X—C5Xii −76 (8) C3Xvii—C2X—O5—C5Xv −57 (14) 
C3Xv—C2X—C3X—C5Xii −55 (5) C1Xviii—C2X—O5—C5Xv −44 (5) 
C5Xv—C2X—C3X—C1Xvii −126 (6) C1Xix—C2X—O5—C5Xv 179 (20) 
C5X—C2X—C3X—C1Xvii 54 (4) C3X—C2X—O5—C5Xv 55 (10) 
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O5v—C2X—C3X—C1Xvii −9(7) C3Xv—C2X—O5—C5Xv 112 (10) 
O5—C2X—C3X—C1Xvii 136 (9) C5Xv—C2X—O5—C3Xv −112 (10) 
C3Xvi—C2X—C3X—C1Xvii 157 (11) C5X—C2X—O5—C3Xv 45 (8) 
C3Xvii—C2X—C3X—C1Xvii −93 (5) O5v—C2X—O5—C3Xv −26 (3) 
C1Xviii—C2X—C3X—C1Xvii −144 (2) C3Xvi—C2X—O5—C3Xv 133 (5) 
C1Xix—C2X—C3X—C1Xvii 29 (4) C3Xvii—C2X—O5—C3Xv −169 (14) 
C3Xv—C2X—C3X—C1Xvii 51 (4) C1Xviii—C2X—O5—C3Xv −156 (6) 
N2—C5—C6—C7 −171.1 (3) C1Xix—C2X—O5—C3Xv 67 (16) 
C5Xv—C2X—C5X—C1Xix −156 (5) C3X—C2X—O5—C3Xv −56 (7) 
O5v—C2X—C5X—C1Xix −103 (10) C5Xv—C2X—O5—C5X −156 (15) 
O5—C2X—C5X—C1Xix 155 (11) O5v—C2X—O5—C5X −70 (8) 
C3Xvi—C2X—C5X—C1Xix 48 (6) C3Xvi—C2X—O5—C5X 88 (5) 
C3Xvii—C2X—C5X—C1Xix −3(9) C3Xvii—C2X—O5—C5X 147 (21) 
C1Xviii—C2X—C5X—C1Xix 79 (41) C1Xviii—C2X—O5—C5X 160 (12) 
C3X—C2X—C5X—C1Xix −157 (4) C1Xix—C2X—O5—C5X 23 (10) 
C3Xv—C2X—C5X—C1Xix −154 (7) C3X—C2X—O5—C5X −101 (8) 
C5Xv—C2X—C5X—C3Xv −2(3) C3Xv—C2X—O5—C5X −45 (8) 
O5v—C2X—C5X—C3Xv 51 (9) C5Xv—C2X—O5—C1Xviii 44 (5) 
O5—C2X—C5X—C3Xv −50 (10) C5X—C2X—O5—C1Xviii −160 (12) 
C3Xvi—C2X—C5X—C3Xv −158 (6) O5v—C2X—O5—C1Xviii 130 (6) 
C3Xvii—C2X—C5X—C3Xv 151 (7) C3Xvi—C2X—O5—C1Xviii −71 (8) 
C1Xviii—C2X—C5X—C3Xv −127 (39) C3Xvii—C2X—O5—C1Xviii −13 (13) 
C1Xix—C2X—C5X—C3Xv 154 (7) C1Xix—C2X—O5—C1Xviii −137 (18) 
C3X—C2X—C5X—C3Xv −3(6) C3X—C2X—O5—C1Xviii 99 (8) 
C5Xv—C2X—C5X—O5v −53 (9) C3Xv—C2X—O5—C1Xviii 156 (6) 
O5—C2X—C5X—O5v −101 (18) C1Xix—C5X—O5—C3X −111 (10) 
C3Xvi—C2X—C5X—O5v 151 (12) C2X—C5X—O5—C3X −78 (12) 
C3Xvii—C2X—C5X—O5v 100 (6) C3Xv—C5X—O5—C3X 38 (7) 
C1Xviii—C2X—C5X—O5v −178 (45) O5v—C5X—O5—C3X −18 (11) 
C1Xix—C2X—C5X—O5v 103 (10) C3Xvi—C5X—O5—C3X −128 (7) 
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C3X—C2X—C5X—O5v −54 (9) C1Xix—C5X—O5—C2X −34 (14) 
C3Xv—C2X—C5X—O5v −51 (9) C3Xv—C5X—O5—C2X 116 (13) 
C5Xv—C2X—C5X—O5 49 (9) O5v—C5X—O5—C2X 59 (13) 
O5v—C2X—C5X—O5 101 (18) C3Xvi—C5X—O5—C2X −50 (10) 
C3Xvi—C2X—C5X—O5 −107 (7) C1Xix—C5X—O5—C1Xvi 180 (8) 
C3Xvii—C2X—C5X—O5 −159 (15) C2X—C5X—O5—C1Xvi −146 (18) 
C1Xviii—C2X—C5X—O5 −76 (34) C3Xv—C5X—O5—C1Xvi −31 (8) 
C1Xix—C2X—C5X—O5 −155 (11) O5v—C5X—O5—C1Xvi −87 (9) 
C3X—C2X—C5X—O5 47 (9) C3Xvi—C5X—O5—C1Xvi 164 (11) 
C3Xv—C2X—C5X—O5 50 (10) C1Xix—C5X—O5—C5Xv −52 (13) 
C5Xv—C2X—C5X—C3Xvi 156 (4) C2X—C5X—O5—C5Xv −18 (12) 
O5v—C2X—C5X—C3Xvi −151 (12) C3Xv—C5X—O5—C5Xv 98 (10) 
O5—C2X—C5X—C3Xvi 107 (7) O5v—C5X—O5—C5Xv 41 (13) 
C3Xvii—C2X—C5X—C3Xvi −51 (10) C3Xvi—C5X—O5—C5Xv −68 (6) 
C1Xviii—C2X—C5X—C3Xvi 31 (38) C1Xix—C5X—O5—C3Xv −150 (10) 
C1Xix—C2X—C5X—C3Xvi −48 (6) C2X—C5X—O5—C3Xv −116 (13) 
C3X—C2X—C5X—C3Xvi 155 (3) O5v—C5X—O5—C3Xv −56 (6) 
C3Xv—C2X—C5X—C3Xvi 158(6) C3Xvi—C5X—O5—C3Xv −166 (7) 
C5—C6—C7—C8 −175.2 (3) C1Xix—C5X—O5—C1Xviii −18 (13) 
C6—C7—C8—O4 −162.5 (3) C2X—C5X—O5—C1Xviii 16 (10) 
C6—C7—C8—O3 17.4 (6) C3Xv—C5X—O5—C1Xviii 132 (8) 
C3Xv—C3X—O5—C2X −75 (7) O5v—C5X—O5—C1Xviii 76 (10) 
C5Xv—C3X—O5—C2X 47 (7) C3Xvi—C5X—O5—C1Xviii −34 (4) 
C2Xii—C3X—O5—C2X −123 (4)   
 
Symmetry codes: (i) −y, x−y, z+2/3; (ii) −x+y, −x, z+1/3; (iii) x−y, x, z+1/3; (iv) y, −x+y, z+2/3; (v) −x, −y, 
z; (vi) −y, x−y, z−1/3; (vii) y, −x+y, z−1/3; (viii) x−y, x, z−2/3; (ix) −x+y, −x, z−2/3. 
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Table A1.1.6: Hydrogen bonding parameters for the hexagonal GABA solvate (Å,°). 
 
 
D—H···A D—H H···A D···A D—H···A 
N1—H2···O1iv 0.89 1.81 2.690 (4) 172 
N1—H3···O2x 0.89 2.03 2.878 (3) 158 
N1—H3···O1x 0.89 2.34 3.091 (4) 142 
N1—H1···O3x 0.89 1.96 2.823 (4) 163 
N2—H10···O3x 0.89 1.97 2.840 (4) 165 
N2—H10···O4x 0.89 2.51 3.197 (4) 134 
N2—H11···O4xi 0.89 1.83 2.701 (4) 166 
N2—H12···O2 0.89 1.93 2.803 (4) 167 
 
Symmetry codes: (iv) y, −x+y, z+2/3; (x) x, y, z+1; (xi) −y+1, x−y, z+2/3. 
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1.2 Gabapentin 
 
1.2.1) DSC α-gabapentin 
 
 
Figure A1.3: DSC curve of heat flow (mW) vs. temperature (°C) for α-gabapentin from 30 to 300°C. 
 
1.2.2 Additional Crystallographic Data: β- and γ-gabapentin 
 
1.2.2A β-gabapentin  
 
Table A1.2.1: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters for β-gabapentin (Å2). 
 
 x y z Uiso*/Ueq 
C2 0.10437 (13) 0.2698 (3) 0.47078 (19) 0.0237 (4) 
C3 0.17104 (12) 0.1189 (3) 0.56450 (18) 0.0210 (4) 
H1 0.1329 0.0230 0.6039 0.025* 
H2 0.2148 0.1912 0.6446 0.025* 
C4 0.16677 (12) −0.0743 (3) 0.34216 (18) 0.0233 (4) 
H3 0.1456 0.0435 0.2796 0.028* 
H4 0.2053 −0.1615 0.2971 0.028* 
C1 0.23067 (12) 0.0001 (3) 0.48329 (18) 0.0191 (4) 
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C5 0.28098 (12) −0.1785 (3) 0.57268 (18) 0.0227 (4) 
H7 0.2325 −0.2632 0.5990 0.027* 
H8 0.3124 −0.2621 0.5150 0.027* 
C7 0.35531 (13) −0.1127 (3) 0.70615 (19) 0.0276 (5) 
H9 0.3237 −0.0369 0.7675 0.033* 
H10 0.3861 −0.2331 0.7588 0.033* 
C8 0.43075 (13) 0.0192 (3) 0.6708 (2) 0.0365 (5) 
H11 0.4678 −0.0620 0.6198 0.044* 
H12 0.4755 0.0685 0.7595 0.044* 
C9 0.38609 (12) 0.1983 (3) 0.5799 (2) 0.0318 (5) 
H13 0.4365 0.2720 0.5501 0.038* 
H14 0.3585 0.2915 0.6369 0.038* 
C6 0.30796 (12) 0.1340 (3) 0.44909 (19) 0.0256 (4) 
H5 0.3377 0.0596 0.3848 0.031* 
H6 0.2771 0.2561 0.3987 0.031* 
N1 0.08083 (10) −0.1887 (2) 0.35151 (15) 0.0231 (4) 
H15 0.0438 −0.1090 0.3904 0.035* 
H16 0.0994 −0.2998 0.4065 0.035* 
H17 0.0467 −0.2274 0.2633 0.035* 
O1 0.01899 (8) 0.21326 (19) 0.41666 (13) 0.0272 (3) 
O2 0.13809 (10) 0.4345 (2) 0.44863 (17) 0.0460 (4) 
 
Table A1.2.2: Atomic displacement parameters for β-gabapentin (Å2). 
 
 
 U11 U22 U33 U12 U13 U23 
C2 0.0269 (10) 0.0189 (11) 0.0256 (10) 0.0027 (9) 0.0076 (9) −0.0044 (9) 
C3 0.0203 (9) 0.0222 (10) 0.0199 (9) −0.0010 (8) 0.0042 (8) −0.0024 (8) 
C4 0.0236 (9) 0.0254 (11) 0.0221 (10) −0.0021 (8) 0.0080 (9) −0.0004 (9) 
C1 0.0204 (9) 0.0184 (10) 0.0187 (9) −0.0006 (8) 0.0056 (8) 0.0014 (8) 
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C5 0.0228 (9) 0.0210 (11) 0.0250 (10) 0.0011 (8) 0.0075 (8) 0.0027 (9) 
C7 0.0232 (9) 0.0288 (12) 0.0285 (11) 0.0020 (8) 0.0030 (9) 0.0054 (9) 
C8 0.0238 (10) 0.0419 (14) 0.0393 (13) −0.0034 (10) 0.0010 (10) 0.0051 (11) 
C9 0.0261 (10) 0.0347 (13) 0.0341 (11) −0.0093 (9) 0.0071 (10) 0.0037 (10) 
C6 0.0241 (10) 0.0275 (11) 0.0266 (10) −0.0017 (8) 0.0093 (9) 0.0034 (9) 
N1 0.0223 (8) 0.0224 (9) 0.0238 (8) −0.0001 (7) 0.0048 (7) −0.0028 (7) 
O1 0.0211 (6) 0.0296 (8) 0.0282 (7) 0.0020 (6) 0.0023 (6) 0.0032 (6) 
O2 0.0380 (8) 0.0197 (8) 0.0761 (12) −0.0020 (7) 0.0085 (8) 0.0084 (8) 
 
Table A1.2.3: Bond lengths of β-gabapentin (Å). 
 
 
C2—O2 1.241 (2) C7—C8 1.516 (2) 
C2—O1 1.266 (2) C7—H9 0.9900 
C2—C3 1.517 (2) C7—H10 0.9900 
C3—C1 1.546 (2) C8—C9 1.521 (3) 
C3—H1 0.9900 C8—H11 0.9900 
C3—H2 0.9900 C8—H12 0.9900 
C4—N1 1.486 (2) C9—C6 1.525 (2) 
C4—C1 1.525 (2) C9—H13 0.9900 
C4—H3 0.9900 C9—H14 0.9900 
C4—H4 0.9900 C6—H5 0.9900 
C1—C5 1.536 (2) C6—H6 0.9900 
C1—C6 1.540 (2) N1—H15 0.9100 
C5—C7 1.518 (2) N1—H16 0.9100 
C5—H7 0.9900 N1—H17 0.9100 
C5—H8 0.9900   
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Table A1.2.4: Bond angles of β-gabapentin (°). 
 
O2—C2—O1 125.16 (17) C5—C7—H9 109.5 
O2—C2—C3 118.05 (16) C8—C7—H10 109.5 
O1—C2—C3 116.72 (16) C5—C7—H10 109.5 
C2—C3—C1 112.20 (14) H9—C7—H10 108.1 
C2—C3—H1 109.2 C7—C8—C9 111.49 (15) 
C1—C3—H1 109.2 C7—C8—H11 109.3 
C2—C3—H2 109.2 C9—C8—H11 109.3 
C1—C3—H2 109.2 C7—C8—H12 109.3 
H1—C3—H2 107.9 C9—C8—H12 109.3 
N1—C4—C1 114.93 (13) H11—C8—H12 108.0 
N1—C4—H3 108.5 C8—C9—C6 112.13 (16) 
C1—C4—H3 108.5 C8—C9—H13 109.2 
N1—C4—H4 108.5 C6—C9—H13 109.2 
C1—C4—H4 108.5 C8—C9—H14 109.2 
H3—C4—H4 107.5 C6—C9—H14 109.2 
C4—C1—C5 110.30 (15) H13—C9—H14 107.9 
C4—C1—C6 106.66 (13) C9—C6—C1 113.34 (15) 
C5—C1—C6 107.97 (14) C9—C6—H5 108.9 
C4—C1—C3 110.32 (14) C1—C6—H5 108.9 
C5—C1—C3 110.13 (14) C9—C6—H6 108.9 
C6—C1—C3 111.38 (15) C1—C6—H6 108.9 
C7—C5—C1 112.80 (15) H5—C6—H6 107.7 
C7—C5—H7 109.0 C4—N1—H15 109.5 
C1—C5—H7 109.0 C4—N1—H16 109.5 
C7—C5—H8 109.0 H15—N1—H16 109.5 
C1—C5—H8 109.0 C4—N1—H17 109.5 
H7—C5—H8 107.8 H15—N1—H17 109.5 
C8—C7—C5 110.86 (15) H16—N1—H17 109.5 
C8—C7—H9 109.5   
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Table A1.2.5: Torsion angles of β-gabapentin (°). 
 
 
O2—C2—C3—C1 −81.3 (2) C6—C1—C5—C7 56.37 (18) 
O1—C2—C3—C1 95.97 (18) C3—C1—C5—C7 −65.44 (18) 
N1—C4—C1—C5 69.42 (18) C1—C5—C7—C8 −58.3 (2) 
N1—C4—C1—C6 −173.57 (14) C5—C7—C8—C9 54.7 (2) 
N1—C4—C1—C3 −52.5 (2) C7—C8—C9—C6 −52.5 (2) 
C2—C3—C1—C4 −46.4 (2) C8—C9—C6—C1 53.3 (2) 
C2—C3—C1—C5 −168.37 (14) C4—C1—C6—C9 −172.22 (15) 
C2—C3—C1—C6 71.87 (18) C5—C1—C6—C9 −53.7 (2) 
C4—C1—C5—C7 172.56 (13) C3—C1—C6—C9 67.35 (19) 
 
 
Table A1.2.6: Hydrogen bonding parameters of β-gabapentin (Å, °). 
 
 
D—H···A D—H H···A D···A D—H···A 
N1—H15···O1 0.91 2.19 2.9398 (19) 139 
N1—H15···O1i 0.91 2.42 3.0242 (18) 124 
N1—H16···O2ii 0.91 1.86 2.723 (2) 157 
N1—H17···O1iii 0.91 1.81 2.7174 (19) 176 
 
Symmetry codes: (i) −x, −y, −z+1; (ii) x, y−1, z; (iii) −x, y−1/2, −z+1/2 
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1.2.2B : γ-gabapentin  
 
Table A1.2.7: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters for γ-gabapentin (Å2). 
 
 
 x y z Uiso*/Ueq 
C1 0.36190 (5) 0.2176 (3) 0.72157 (14) 0.0310 (3) 
C2 0.30226 (5) 0.2639 (3) 0.48949 (14) 0.0311 (3) 
C3 0.32851 (6) 0.1096 (3) 0.59961 (14) 0.0334 (4) 
H3 0.3463 0.0014 0.5648 0.040* 
H4 0.3056 0.0210 0.6265 0.040* 
C4 0.33683 (5) 0.3708 (3) 0.79133 (15) 0.0331 (4) 
H1 0.3587 0.4123 0.8767 0.040* 
H2 0.3279 0.5115 0.7406 0.040* 
C5 0.39772 (6) 0.3621 (3) 0.68455 (18) 0.0433 (4) 
H5 0.4101 0.2736 0.6257 0.052* 
H6 0.3821 0.4966 0.6365 0.052* 
C6 0.38743 (6) 0.0247 (3) 0.81054 (16) 0.0389 (4) 
H13 0.3651 −0.0573 0.8432 0.047* 
H14 0.3991 −0.0827 0.7586 0.047* 
C7 0.43791 (7) 0.4397 (4) 0.8004 (2) 0.0576 (5) 
H7 0.4604 0.5230 0.7691 0.069* 
H8 0.4263 0.5439 0.8542 0.069* 
C8 0.46176 (7) 0.2409 (4) 0.8823 (2) 0.0649 (6) 
H9 0.4763 0.1451 0.8314 0.078* 
H10 0.4864 0.2968 0.9592 0.078* 
C9 0.42760 (7) 0.1015 (4) 0.92549 (18) 0.0530 (5) 
H11 0.4157 0.1925 0.9845 0.064* 
H12 0.4435 −0.0322 0.9739 0.064* 
N1 0.29507 (4) 0.2717 (2) 0.81185 (12) 0.0332 (3) 
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H15 0.2711 0.2793 0.7369 0.050* 
H16 0.2879 0.3501 0.8748 0.050* 
H17 0.3006 0.1249 0.8364 0.050* 
O1 0.29105 (4) 0.1805 (2) 0.37705 (10) 0.0381 (3) 
O2 0.29272 (4) 0.4596 (2) 0.51366 (11) 0.0418 (3) 
 
 
Table A1.2.8: Atomic displacement parameters for γ-gabapentin (Å2). 
 
 U11 U22 U33 U12 U13 U23 
C1 0.0362 (8) 0.0254 (7) 0.0307 (7) 0.0041 (6) 0.0093 (6) 0.0027 (6) 
C2 0.0329 (8) 0.0308 (8) 0.0302 (7) 0.0003 (6) 0.0108 (6) 0.0034 (6) 
C3 0.0449 (9) 0.0270 (8) 0.0289 (8) 0.0046 (6) 0.0122 (7) 0.0005 (6) 
C4 0.0383 (8) 0.0261 (8) 0.0332 (8) 0.0011 (6) 0.0087 (6) −0.0032 (6) 
C5 0.0442 (9) 0.0379 (9) 0.0499 (10) 0.0016 (7) 0.0180 (8) 0.0069 (8) 
C6 0.0438 (9) 0.0322 (8) 0.0385 (9) 0.0086 (7) 0.0099 (7) 0.0056 (7) 
C7 0.0399 (10) 0.0500 (12) 0.0771 (14) −0.0055 (9) 0.0102 (9) 0.0043 (11) 
C8 0.0391 (10) 0.0626 (14) 0.0783 (15) 0.0056 (9) −0.0026 (10) 0.0015 (12) 
C9 0.0513 (11) 0.0503 (11) 0.0461 (11) 0.0142 (9) −0.0006 (8) 0.0079 (9) 
N1 0.0364 (7) 0.0308 (7) 0.0295 (6) 0.0048 (5) 0.0061 (5) −0.0038 (5) 
O1 0.0444 (7) 0.0380 (6) 0.0287 (6) 0.0000 (5) 0.0071 (5) 0.0001 (5) 
O2 0.0570 (7) 0.0319 (6) 0.0369 (6) 0.0118 (5) 0.0154 (5) 0.0056 (5) 
 
 
Table A1.2.9: Bond lengths of γ-gabapentin (Å). 
 
C1—C4 1.534 (2) C6—C9 1.521 (2) 
C1—C3 1.537 (2) C6—H13 0.9900 
C1—C5 1.539 (2) C6—H14 0.9900 
C1—C6 1.542 (2) C7—C8 1.518 (3) 
C2—O2 1.2440 (19) C7—H7 0.9900 
C2—O1 1.2632 (19) C7—H8 0.9900 
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C2—C3 1.520 (2) C8—C9 1.517 (3) 
C3—H3 0.9900 C8—H9 0.9900 
C3—H4 0.9900 C8—H10 0.9900 
C4—N1 1.484 (2) C9—H11 0.9900 
C4—H1 0.9900 C9—H12 0.9900 
C4—H2 0.9900 N1—H15 0.9100 
C5—C7 1.528 (3) N1—H16 0.9100 
C5—H5 0.9900 N1—H17 0.9100 
C5—H6 0.9900   
 
 
Table A1.2.10: Bond angles of γ-gabapentin (°). 
 
 
C4—C1—C3 112.05 (12) C1—C6—H13 108.7 
C4—C1—C5 107.87 (13) C9—C6—H14 108.7 
C3—C1—C5 109.82 (13) C1—C6—H14 108.7 
C4—C1—C6 111.14 (13) H13—C6—H14 107.6 
C3—C1—C6 107.51 (13) C8—C7—C5 111.32 (17) 
C5—C1—C6 108.42 (13) C8—C7—H7 109.4 
O2—C2—O1 124.01 (14) C5—C7—H7 109.4 
O2—C2—C3 119.65 (13) C8—C7—H8 109.4 
O1—C2—C3 116.34 (13) C5—C7—H8 109.4 
C2—C3—C1 118.21 (13) H7—C7—H8 108.0 
C2—C3—H3 107.8 C9—C8—C7 110.78 (16) 
C1—C3—H3 107.8 C9—C8—H9 109.5 
C2—C3—H4 107.8 C7—C8—H9 109.5 
C1—C3—H4 107.8 C9—C8—H10 109.5 
H3—C3—H4 107.1 C7—C8—H10 109.5 
N1—C4—C1 115.27 (13) H9—C8—H10 108.1 
N1—C4—H1 108.5 C8—C9—C6 111.33 (16) 
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C1—C4—H1 108.5 C8—C9—H11 109.4 
N1—C4—H2 108.5 C6—C9—H11 109.4 
C1—C4—H2 108.5 C8—C9—H12 109.4 
H1—C4—H2 107.5 C6—C9—H12 109.4 
C7—C5—C1 113.85 (15) H11—C9—H12 108.0 
C7—C5—H5 108.8 C4—N1—H15 109.5 
C1—C5—H5 108.8 C4—N1—H16 109.5 
C7—C5—H6 108.8 H15—N1—H16 109.5 
C1—C5—H6 108.8 C4—N1—H17 109.5 
H5—C5—H6 107.7 H15—N1—H17 109.5 
C9—C6—C1 114.37 (14) H16—N1—H17 109.5 
C9—C6—H13 108.7   
 
 
Table A1.2.11: Torsion angles of γ-gabapentin (°). 
 
 
O2—C2—C3—C1 −29.1 (2) C3—C1—C5—C7 −168.79 (15) 
O1—C2—C3—C1 151.56 (14) C6—C1—C5—C7 −51.60 (19) 
C4—C1—C3—C2 63.47 (18) C4—C1—C6—C9 −66.85 (19) 
C5—C1—C3—C2 −56.38 (18) C3—C1—C6—C9 170.20 (14) 
C6—C1—C3—C2 −174.14 (14) C5—C1—C6—C9 51.54 (19) 
C3—C1—C4—N1 47.74 (17) C1—C5—C7—C8 55.5 (2) 
C5—C1—C4—N1 168.72 (13) C5—C7—C8—C9 −55.8 (3) 
C6—C1—C4—N1 −72.56 (17) C7—C8—C9—C6 55.4 (2) 
C4—C1—C5—C7 68.85 (18) C1—C6—C9—C8 −55.0 (2) 
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Table A1.2.12: Hydrogen bonding parameters of γ-gabapentin (Å, °). 
 
 
D—H···A D—H H···A D···A D—H···A 
N1—H15···O1i 0.91 1.93 2.7980 (16) 159 
N1—H16···O2ii 0.91 1.85 2.7324 (17) 161 
N1—H17···O1iii 0.91 1.91 2.7851 (18) 161 
 
Symmetry codes: (i) −x+1/2, −y+1/2, −z+1; (ii) x, −y+1, z+1/2; (iii) x, −y, z+1/2 
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1.3 Co-crystals 
 
1.3.1 GABA-oxalic acid co-crystal 
 
Table A1.3.1: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters of the GABA-oxalic acid co-crystal (Å2). 
 
 
 x y z Uiso*/Ueq 
C1 0.4548 (2) 0.76480 (15) 0.82536 (14) 0.0381 (3) 
H4 0.5155 0.6807 0.8485 0.046* 
H5 0.4626 0.8080 0.9149 0.046* 
C2 0.5580 (2) 0.84471 (16) 0.74493 (14) 0.0414 (4) 
H6 0.4963 0.9283 0.7208 0.050* 
H7 0.5515 0.8010 0.6559 0.050* 
C3 0.7653 (2) 0.86581 (17) 0.83354 (15) 0.0430 (4) 
H8 0.8275 0.7823 0.8566 0.052* 
H9 0.8276 0.9143 0.7768 0.052* 
C4 0.78433 (18) 0.93869 (15) 0.97092 (14) 0.0342 (3) 
N1 0.25376 (16) 0.74599 (12) 0.73996 (12) 0.0377 (3) 
H1 0.1974 0.8229 0.7197 0.057* 
H2 0.1970 0.6990 0.7904 0.057* 
H3 0.2463 0.7048 0.6586 0.057* 
O1 0.84502 (16) 0.86745 (10) 1.08670 (10) 0.0479 (3) 
H10 0.8524 0.9121 1.1575 0.072* 
O2 0.74580 (19) 1.05242 (12) 0.97406 (12) 0.0551 (3) 
C5 0.9950 (2) 0.46330 (13) 1.06826 (13) 0.0321 (3) 
O3 0.87406 (17) 0.37922 (11) 1.05383 (11) 0.0498 (3) 
O4 1.11624 (17) 0.49738 (11) 1.18478 (10) 0.0497 (3) 
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Table A1.3.2: Atomic displacement parameters of the GABA-oxalic acid co-crystal 
(Å2). 
 
 U11 U22 U33 U12 U13 U23 
C1 0.0406 (8) 0.0404 (8) 0.0299 (7) −0.0014 (6) 0.0060 (6) 0.0008 (6) 
C2 0.0428 (8) 0.0557 (9) 0.0250 (6) −0.0062 (7) 0.0097 (6) −0.0022 (6) 
C3 0.0370 (8) 0.0626 (10) 0.0314 (7) −0.0026 (7) 0.0135 (6) −0.0094 (7) 
C4 0.0301 (6) 0.0429 (8) 0.0291 (6) −0.0040 (6) 0.0087 (5) −0.0028 (6) 
N1 0.0406 (7) 0.0397 (7) 0.0311 (6) −0.0068 (5) 0.0091 (5) 0.0017 (5) 
O1 0.0670 (8) 0.0447 (6) 0.0285 (5) 0.0070 (5) 0.0103 (5) −0.0027 (4) 
O2 0.0807 (9) 0.0439 (7) 0.0427 (6) 0.0094 (6) 0.0222 (6) 0.0047 (5) 
C5 0.0395 (7) 0.0336 (7) 0.0237 (6) −0.0004 (6) 0.0110 (5) 0.0011 (5) 
O3 0.0589 (7) 0.0568 (7) 0.0324 (5) −0.0227 (6) 0.0125 (5) 0.0049 (5) 
O4 0.0631 (7) 0.0557 (7) 0.0225 (5) −0.0179 (6) 0.0026 (5) 0.0043 (4) 
 
Table A1.3.3: Bond lengths of the GABA-oxalic acid co-crystal (Å). 
 
C1—N1 1.4835 (17) C4—O2 1.2087 (18) 
C1—C2 1.510 (2) C4—O1 1.3068 (17) 
C1—H4 0.9700 N1—H1 0.8900 
C1—H5 0.9700 N1—H2 0.8900 
C2—C3 1.533 (2) N1—H3 0.8900 
C2—H6 0.9700 O1—H10 0.8200 
C2—H7 0.9700 C5—O3 1.2272 (17) 
C3—C4 1.5097 (19) C5—O4 1.2629 (16) 
C3—H8 0.9700 C5—C5i 1.560 (2) 
C3—H9 0.9700   
 
                                           Symmetry codes: (i) −x+2, −y+1, −z+2. 
 
 
 
 
  141 
Table A1.3.4: Bond angles of the GABA-oxalic acid co-crystal (°). 
 
 
N1—C1—C2 111.71 (11) C2—C3—H9 109.3 
N1—C1—H4 109.3 H8—C3—H9 107.9 
C2—C1—H4 109.3 O2—C4—O1 122.80 (13) 
N1—C1—H5 109.3 O2—C4—C3 123.27 (13) 
C2—C1—H5 109.3 O1—C4—C3 113.93 (13) 
H4—C1—H5 107.9 C1—N1—H1 109.5 
C1—C2—C3 111.88 (12) C1—N1—H2 109.5 
C1—C2—H6 109.2 H1—N1—H2 109.5 
C3—C2—H6 109.2 C1—N1—H3 109.5 
C1—C2—H7 109.2 H1—N1—H3 109.5 
C3—C2—H7 109.2 H2—N1—H3 109.5 
H6—C2—H7 107.9 C4—O1—H10 109.5 
C4—C3—C2 111.66 (11) O3—C5—O4 126.27 (12) 
C4—C3—H8 109.3 O3—C5—C5i 118.47 (14) 
C2—C3—H8 109.3 O4—C5—C5i 115.26 (15) 
C4—C3—H9 109.3   
 
                                   Symmetry codes: (i) −x+2, −y+1, −z+2. 
 
 
Table A1.3.5: Torsion angles of the GABA-oxalic acid co-crystal (°). 
 
 
N1—C1—C2—C3 179.30 (12) C2—C3—C4—O2 −70.69 (19) 
C1—C2—C3—C4 −61.31 (18) C2—C3—C4—O1 108.80 (15) 
 
 
 
 
 
 
 
 
  142 
Table A1.3.6: Hydrogen bonding parameters of the GABA-oxalic acid co-crystal 
(Å,°). 
 
D—H···A D—H H···A D···A D—H···A 
N1—H1···O4ii 0.89 1.94 2.8250 (17) 171 
N1—H1···O3iii 0.89 2.63 3.0592 (16) 111 
N1—H2···O3iv 0.89 1.94 2.8096 (16) 164 
N1—H3···O2v 0.89 2.05 2.8961 (17) 158 
O1—H10···O4vi 0.82 1.73 2.5474 (14) 175 
 
Symmetry codes: (ii) x−1, −y+3/2, z−1/2; (iii) −x+1, y+1/2, −z+3/2; (iv) −x+1, −y+1, −z+2; (v) −x+1, y−1/2, 
−z+3/2; (vi) −x+2, y+1/2, −z+5/2. 
 
1.3.2 Gabapentin-oxalic acid co-crystal 
 
Table A1.3.7: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters of the gabapentin-oxalic acid co-crystal(Å2). 
 
 x y z Uiso*/Ueq 
C1 0.53866 (15) 0.33665 (11) 0.34173 (4) 0.01608 (19) 
C2 0.55374 (17) 0.35792 (12) 0.22119 (4) 0.0195 (2) 
C3 0.48751 (18) 0.25931 (13) 0.27636 (4) 0.0219 (2) 
H2 0.5626 0.1523 0.2758 0.026* 
H3 0.3272 0.2386 0.2706 0.026* 
C4 0.43706 (16) 0.22436 (11) 0.38927 (4) 0.0171 (2) 
H14 0.4606 0.2740 0.4314 0.020* 
H15 0.2763 0.2185 0.3787 0.020* 
C5 0.42340 (18) 0.50372 (12) 0.34443 (5) 0.0226 (2) 
H12 0.4708 0.5733 0.3101 0.027* 
H13 0.2624 0.4877 0.3374 0.027* 
C6 0.78643 (16) 0.36136 (13) 0.35730 (5) 0.0211 (2) 
H4 0.8606 0.2539 0.3581 0.025* 
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H5 0.8466 0.4273 0.3238 0.025* 
C7 0.4734 (2) 0.59204 (13) 0.40700 (6) 0.0314 (3) 
H10 0.4045 0.7014 0.4049 0.038* 
H11 0.4089 0.5300 0.4408 0.038* 
C8 0.7204 (2) 0.60985 (15) 0.42232 (6) 0.0363 (3) 
H8 0.7812 0.6851 0.3918 0.044* 
H9 0.7476 0.6581 0.4646 0.044* 
C9 0.83818 (19) 0.44632 (15) 0.42036 (5) 0.0298 (3) 
H6 0.7916 0.3757 0.4545 0.036* 
H7 0.9989 0.4637 0.4272 0.036* 
C10 0.42935 (15) 0.48529 (11) 0.02839 (4) 0.01434 (18) 
N1 0.52690 (13) 0.05509 (10) 0.39208 (4) 0.01588 (17) 
H16 0.6720 0.0580 0.4056 0.024* 
H17 0.5115 0.0094 0.3532 0.024* 
H18 0.4520 −0.0055 0.4191 0.024* 
O1 0.74308 (13) 0.38932 (11) 0.21192 (3) 0.0292 (2) 
O2 0.38491 (12) 0.40120 (11) 0.18245 (3) 0.0291 (2) 
H1 0.4302 0.4555 0.1527 0.044* 
O3 0.23776 (11) 0.43727 (9) 0.01761 (3) 0.02081 (17) 
O4 0.52499 (11) 0.51447 (9) 0.08163 (3) 0.02048 (17) 
 
 
Table A1.3.8: Atomic displacement parameters of the gabapentin-oxalic acid co-
crystal (Å2). 
 
 
 U11 U22 U33 U12 U13 U23 
C1 0.0177 (4) 0.0176 (4) 0.0132 (4) −0.0012 (3) 0.0024 (3) 0.0019 (3) 
C2 0.0245 (5) 0.0209 (5) 0.0132 (4) −0.0020 (4) 0.0030 (4) −0.0009 (3) 
C3 0.0291 (5) 0.0226 (5) 0.0143 (4) −0.0069 (4) 0.0026 (4) 0.0012 (4) 
C4 0.0178 (4) 0.0177 (4) 0.0163 (4) 0.0006 (3) 0.0051 (3) 0.0019 (3) 
C5 0.0254 (5) 0.0196 (5) 0.0230 (5) 0.0026 (4) 0.0037 (4) 0.0037 (4) 
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C6 0.0182 (5) 0.0263 (5) 0.0189 (5) −0.0032 (4) 0.0024 (4) 0.0035 (4) 
C7 0.0489 (7) 0.0188 (5) 0.0278 (6) 0.0012 (5) 0.0109 (5) −0.0017 (4) 
C8 0.0560 (8) 0.0306 (6) 0.0226 (5) −0.0190 (5) 0.0045 (5) −0.0051 (4) 
C9 0.0267 (6) 0.0426 (7) 0.0196 (5) −0.0128 (5) −0.0021 (4) 0.0027 (4) 
C10 0.0164 (4) 0.0144 (4) 0.0126 (4) 0.0022 (3) 0.0032 (3) 0.0004 (3) 
N1 0.0166 (4) 0.0182 (4) 0.0130 (4) −0.0001 (3) 0.0021 (3) 0.0023 (3) 
O1 0.0247 (4) 0.0440 (5) 0.0190 (4) −0.0053 (3) 0.0030 (3) 0.0066 (3) 
O2 0.0230 (4) 0.0468 (5) 0.0177 (4) −0.0005 (3) 0.0036 (3) 0.0113 (3) 
O3 0.0165 (3) 0.0304 (4) 0.0160 (3) −0.0033 (3) 0.0040 (3) −0.0028 (3) 
O4 0.0194 (3) 0.0310 (4) 0.0112 (3) −0.0033 (3) 0.0022 (3) −0.0004 (3) 
 
Table A1.3.9: Bond lengths of the gabapentin-oxalic acid co-crystal (Å). 
 
C1—C6 1.5351 (13) C6—H5 0.9900 
C1—C4 1.5361 (12) C7—C8 1.5230 (19) 
C1—C5 1.5425 (13) C7—H10 0.9900 
C1—C3 1.5458 (13) C7—H11 0.9900 
C2—O1 1.2130 (13) C8—C9 1.5230 (19) 
C2—O2 1.3205 (13) C8—H8 0.9900 
C2—C3 1.5104 (13) C8—H9 0.9900 
C3—H2 0.9900 C9—H6 0.9900 
C3—H3 0.9900 C9—H7 0.9900 
C4—N1 1.4915 (12) C10—O3 1.2373 (12) 
C4—H14 0.9900 C10—O4 1.2628 (11) 
C4—H15 0.9900 C10—C10i 1.5594 (17) 
C5—C7 1.5324 (15) N1—H16 0.9100 
C5—H12 0.9900 N1—H17 0.9100 
C5—H13 0.9900 N1—H18 0.9100 
C6—C9 1.5301 (15) O2—H1 0.8400 
C6—H4 0.9900   
                                          
                                             Symmetry codes: (i) −x+1, −y+1, −z. 
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Table A1.3.10: Bond angles of the gabapentin-oxalic acid co-crystal (°). 
 
C6—C1—C4 111.97 (8) C1—C6—H5 109.1 
C6—C1—C5 108.54 (8) H4—C6—H5 107.8 
C4—C1—C5 107.47 (8) C8—C7—C5 111.24 (9) 
C6—C1—C3 112.27 (8) C8—C7—H10 109.4 
C4—C1—C3 106.80 (8) C5—C7—H10 109.4 
C5—C1—C3 109.67 (8) C8—C7—H11 109.4 
O1—C2—O2 123.12 (9) C5—C7—H11 109.4 
O1—C2—C3 123.68 (9) H10—C7—H11 108.0 
O2—C2—C3 113.15 (9) C9—C8—C7 111.71 (9) 
C2—C3—C1 116.09 (8) C9—C8—H8 109.3 
C2—C3—H2 108.3 C7—C8—H8 109.3 
C1—C3—H2 108.3 C9—C8—H9 109.3 
C2—C3—H3 108.3 C7—C8—H9 109.3 
C1—C3—H3 108.3 H8—C8—H9 107.9 
H2—C3—H3 107.4 C8—C9—C6 111.02 (9) 
N1—C4—C1 114.81 (7) C8—C9—H6 109.4 
N1—C4—H14 108.6 C6—C9—H6 109.4 
C1—C4—H14 108.6 C8—C9—H7 109.4 
N1—C4—H15 108.6 C6—C9—H7 109.4 
C1—C4—H15 108.6 H6—C9—H7 108.0 
H14—C4—H15 107.5 O3—C10—O4 126.42 (8) 
C7—C5—C1 113.02 (9) O3—C10—C10i 118.20 (10) 
C7—C5—H12 109.0 O4—C10—C10i 115.38 (10) 
C1—C5—H12 109.0 C4—N1—H16 109.5 
C7—C5—H13 109.0 C4—N1—H17 109.5 
C1—C5—H13 109.0 H16—N1—H17 109.5 
H12—C5—H13 107.8 C4—N1—H18 109.5 
C9—C6—C1 112.70 (8) H16—N1—H18 109.5 
C9—C6—H4 109.1 H17—N1—H18 109.5 
C1—C6—H4 109.1 C2—O2—H1 109.5 
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C9—C6—H5 109.1   
 
                                Symmetry codes: (i) −x+1, −y+1, −z. 
 
Table A1.3.11: Torsion angles of the gabapentin-oxalic acid co-crystal (°). 
 
 
O1—C2—C3—C1 65.25 (14) C4—C1—C5—C7 66.60 (11) 
O2—C2—C3—C1 −117.36 (10) C3—C1—C5—C7 −177.66 (8) 
C6—C1—C3—C2 −62.50 (12) C4—C1—C6—C9 −63.00 (11) 
C4—C1—C3—C2 174.41 (8) C5—C1—C6—C9 55.48 (11) 
C5—C1—C3—C2 58.24 (11) C3—C1—C6—C9 176.88 (8) 
C6—C1—C4—N1 −62.02 (10) C1—C5—C7—C8 54.86 (12) 
C5—C1—C4—N1 178.88 (8) C5—C7—C8—C9 −53.86 (12) 
C3—C1—C4—N1 61.25 (10) C7—C8—C9—C6 54.69 (12) 
C6—C1—C5—C7 −54.68 (11) C1—C6—C9—C8 −56.58 (12) 
 
Table A1.3.12: Hydrogen bonding parameters of the gabapentin-oxalic acid co-
crystal (Å,°). 
 
D—H···A D—H H···A D···A D—H···A 
N1—H16···O4ii 0.91 1.88 2.7668 (11) 164 
N1—H16···O3iii 0.91 2.40 2.8898 (11) 114 
N1—H17···O1ii 0.91 2.34 3.0380 (11) 134 
N1—H17···O2iv 0.91 2.63 3.1358 (11) 116 
N1—H18···O3iv 0.91 1.90 2.7810 (10) 161 
O2—H1···O4 0.84 1.74 2.5533 (10) 164 
 
Symmetry codes: (ii) −x+3/2, y−1/2, −z+1/2; (iii) x+1/2, −y+1/2, z+1/2; (iv) −x+1/2, y−1/2, −z+1/2. 
 
 
 
 
 
 
 
 
  147 
1.3.3 β-alanine-oxalic acid-water co-crystal 
 
Table A1.3.13: Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters of the β-alanine-oxalic acid-water co-crystal (Å2). 
 
 x y z Uiso*/Ueq 
C1 0.27443 (9) −0.0044 (4) 0.60455 (15) 0.0354 (5) 
C2 0.29133 (10) 0.1804 (4) 0.68747 (17) 0.0418 (5) 
H6 0.3042 0.1039 0.7552 0.050* 
H7 0.2519 0.2716 0.6735 0.050* 
C3 0.34573 (10) 0.3462 (4) 0.69565 (16) 0.0392 (5) 
H4 0.3375 0.4007 0.6256 0.047* 
H5 0.3453 0.4817 0.7371 0.047* 
C4 0.41515 (9) 0.7971 (3) 0.96368 (14) 0.0306 (4) 
C5 0.42914 (9) 1.0422 (3) 1.01543 (14) 0.0284 (4) 
N1 0.41161 (8) 0.2348 (3) 0.74478 (13) 0.0379 (4) 
H1 0.4197 0.1872 0.8096 0.057* 
H2 0.4422 0.3382 0.7481 0.057* 
H3 0.4126 0.1121 0.7063 0.057* 
O1 0.23235 (9) −0.1580 (3) 0.60741 (13) 0.0604 (5) 
O2 0.29607 (8) −0.0082 (3) 0.53827 (12) 0.0535 (5) 
O3 0.42921 (8) 0.6255 (2) 1.03091 (11) 0.0465 (4) 
O4 0.39377 (10) 0.7744 (3) 0.86972 (12) 0.0631 (5) 
O5 0.44872 (8) 1.0548 (2) 1.11208 (10) 0.0461 (4) 
O6 0.41960 (8) 1.2091 (2) 0.95282 (11) 0.0446 (4) 
O7 0.5000 1.4153 (3) 1.2500 0.0357 (5) 
H8 0.2213 (13) −0.269 (5) 0.554 (2) 0.069 (8)* 
H9 0.4251 (14) 0.475 (6) 0.995 (2) 0.089 (10)* 
H10 0.4811 (12) 1.317 (5) 1.1973 (18) 0.061 (8)* 
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Table A1.3.14: Atomic displacement parameters of the β-alanine-oxalic acid-water 
co-crystal (Å2). 
 
 U11 U22 U33 U12 U13 U23 
C1 0.0346 (10) 0.0400 (11) 0.0309 (10) −0.0034 (9) 0.0133 (8) −0.0026 (8) 
C2 0.0440 (12) 0.0485 (13) 0.0344 (11) −0.0032 (9) 0.0181 (9) −0.0106 (9) 
C3 0.0512 (12) 0.0300 (10) 0.0324 (10) −0.0009 (9) 0.0140 (9) −0.0072 (8) 
C4 0.0432 (11) 0.0212 (9) 0.0267 (10) −0.0033 (7) 0.0143 (8) −0.0021 (7) 
C5 0.0369 (9) 0.0212 (9) 0.0282 (9) −0.0032 (7) 0.0150 (8) −0.0034 (7) 
N1 0.0440 (10) 0.0400 (9) 0.0295 (9) −0.0067 (8) 0.0155 (7) −0.0046 (7) 
O1 0.0784 (12) 0.0665 (11) 0.0541 (11) −0.0393 (10) 0.0452 (10) −0.0249 (9) 
O2 0.0672 (10) 0.0557 (10) 0.0527 (10) −0.0278 (8) 0.0401 (9) −0.0241 (8) 
O3 0.0858 (12) 0.0195 (7) 0.0316 (8) 0.0001 (7) 0.0227 (7) 0.0001 (6) 
O4 0.1184 (15) 0.0296 (8) 0.0257 (8) −0.0073 (9) 0.0162 (9) −0.0058 (6) 
O5 0.0780 (11) 0.0303 (7) 0.0277 (8) −0.0135 (7) 0.0205 (7) −0.0061 (6) 
O6 0.0814 (11) 0.0201 (7) 0.0337 (8) −0.0012 (6) 0.0262 (8) 0.0004 (6) 
O7 0.0492 (12) 0.0242 (10) 0.0264 (10) 0.000 0.0092 (9) 0.000 
 
Table A1.3.15: Bond lengths of the β-alanine-oxalic acid-water co-crystal (Å). 
 
 
C1—O2 1.220 (2) C4—O3 1.301 (2) 
C1—O1 1.300 (2) C4—C5 1.543 (2) 
C1—C2 1.493 (3) C5—O5 1.236 (2) 
C2—C3 1.508 (3) C5—O6 1.249 (2) 
C2—H6 0.9700 N1—H1 0.8900 
C2—H7 0.9700 N1—H2 0.8900 
C3—N1 1.479 (3) N1—H3 0.8900 
C3—H4 0.9700 O1—H8 0.93 (3) 
C3—H5 0.9700 O3—H9 0.98 (3) 
C4—O4 1.202 (2) O7—H10 0.88 (2) 
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Table A1.3.16: Bond angles of the β-alanine-oxalic acid-water co-crystal (°). 
 
 
O2—C1—O1 122.86 (18) O4—C4—O3 125.02 (17) 
O2—C1—C2 123.79 (18) O4—C4—C5 121.25 (16) 
O1—C1—C2 113.31 (17) O3—C4—C5 113.72 (15) 
C1—C2—C3 115.34 (17) O5—C5—O6 126.93 (17) 
C1—C2—H6 108.4 O5—C5—C4 118.28 (16) 
C3—C2—H6 108.4 O6—C5—C4 114.78 (15) 
C1—C2—H7 108.4 C3—N1—H1 109.5 
C3—C2—H7 108.4 C3—N1—H2 109.5 
H6—C2—H7 107.5 H1—N1—H2 109.5 
N1—C3—C2 112.34 (17) C3—N1—H3 109.5 
N1—C3—H4 109.1 H1—N1—H3 109.5 
C2—C3—H4 109.1 H2—N1—H3 109.5 
N1—C3—H5 109.1 C1—O1—H8 112.1 (17) 
C2—C3—H5 109.1 C4—O3—H9 110.3 (18) 
H4—C3—H5 107.9   
 
 
Table A1.3.17: Torsion angles of the β-alanine-oxalic acid-water co-crystal (°). 
 
 
O2—C1—C2—C3 −9.0 (3) O3—C4—C5—O5 −3.3 (3) 
O1—C1—C2—C3 173.20 (19) O4—C4—C5—O6 −3.3 (3) 
C1—C2—C3—N1 −73.8 (2) O3—C4—C5—O6 176.04 (17) 
O4—C4—C5—O5 177.3 (2)   
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Table A1.3.18: Hydrogen bonding parameters of the β-alanine-oxalic acid-water co-
crystal (Å,°). 
 
D—H···A D—H H···A D···A D—H···A 
N1—H1···O6i 0.89 2.02 2.852 (2) 156 
N1—H1···O4i 0.89 2.65 3.274 (2) 128 
N1—H3···O5ii 0.89 2.06 2.866 (2) 151 
N1—H2···O7iii 0.89 1.90 2.790 (2) 174 
O1—H8···O2iv 0.93  1.73  2.663 (2) 175  
O3—H9···O6i 0.98  1.62  2.584 (2) 171  
O7—H10···O5 0.88  1.86  2.717 (2) 166  
 
Symmetry codes: (i) x, y−1, z; (ii) x, −y+1, z−1/2; (iii) −x+1, −y+2, −z+2; (iv) −x+1/2, −y−1/2, −z+1. 
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1.4 Additional Experimental Work Performed 
 
Experiments were set up in order to attempt the co-crystallization of different amino 
acids. Initially, attempts were made to reproduce the co-crystals grown by Görbitz et al., 
(1999) which include the co-crystallization of hydrophobic D- and L-amino acids. Some 
of the crystals which have been produced by Görbitz et al., (1999) include the co-crystals 
of L-isoleucine with the D-amino acids D-valine, D-leucine, D-alanine, D-methionine 
and D-norleucine.  
 
In order to reproduce these crystals, the same experimental method was followed 
(Görbitz et al., 1999) which involves gel diffusion. Crystals were formed in the gel for L-
isoleucine and D-norleucine using 96% ethanol as the diffusion solvent. The crystals 
however, were too small and flat to obtain the unit cell and collect data. Therefore, they 
could not be characterised. The remaining co-crystallization attempts using this same 
method did not produce crystals.    
 
Various methods were attempted to produce co-crystals of GABA and gabapentin with 
the amino acids D-valine, β-alanine, L-aspartic acid, L-glutamic acid, L-serine, L-
glycine. The gel diffusion method was again attempted; however, no crystals were 
obtained. Equimolar amounts of each amino acid were then also dissolved in various 
solvents including water, ethanol, methanol and 2-propanol and left under open-air 
evaporation. In this case, only crystals of the starting materials were produced. 
Crystallizations were also attempted at 60°C and 100°C, again not producing co-crystals. 
Refluxing of the solutions was also carried out, but this did not aid in the formation of co-
crystals.   
 
In order to test for the possible co-crystallization of further amino acids such as L-valine, 
D-norleucine, L-isoleucine and D-methionine, the method of solvent grinding was used 
and X-ray powder diffraction patterns of the ground products and starting materials were 
recorded. These patterns again did not indicate the presence of any different crystalline 
phases. 
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